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ABSTRACT

Cell-surface plasminogen activation (PA) occurs by virtue of the presence o

specific receptors for plasminogen (pig) and urokinase or tissue plasminoge
activator (uPA and tPA respectively). Receptor binding of pig induces a
conformational change in the molecule, which makes it more susceptible to
activation by uPA/tPA. Plasmin (plm) generated on the cell-surface in this
manner is protected from fast acting inhibitors and can subsequently

participate in various extracellular proteolytic events such as cell migrat
(e.g angiogenesis, tumour cell invasion, inflammation, wound healing,
bacterial invasion), ovulation, tissue remodelling and the activation of

other protease classes and growth factors. Evidence is also emerging that PA
plays as yet undefined roles in cell death either as a cytoprotective or
cytotoxic agent.

125

I-plg binding studies on the human monocytic leukemic cell line U937,

the breast carcinoma cell lines MCF-7 and MDA-MB-231, and the colon

carcinoma cell line HCT116 indicated that the presence of plg-Rs (i.e. spec
pig binding) was highly variable on both U937 and MDA-MB-231 cells. This
suggested that

125

I-plg binding assays might not be suitable for measuring pi

binding on all cell types and/or that plg-R expression is a variable
phenomenon. Pig-binding proteins of 40-43kDa and 48-50kDa were
consistently isolated from the plasma membranes of HCT116 cells using pigaffinity chromatography. The low concentrations of these proteins and the

apparent loss of their pig-binding ability following isolation made if diff
to proceed with any further studies. Collectively these observations
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indicated that it w a s essential to develop alternative

techniques for

measuring pig binding.

A flow cytometric pig binding assay was developed, using fluorescein
isothyocyanate-labelled pig (FITC-plg), to enable the measurement of plg-Rs
(i.e specific pig binding) on various cell types (e.g adherent and nonadherent cells) and on specific subpopulations of cells (e.g viable and nonviable). A direct relationship was found to exist between cell viability
[propidium iodide (PI) uptake] and the magnitude of lysine-dependent pig
binding with non-viable subpopulations of cells binding up to 100-fold more
pig than viable cells. This relationship was observed on numerous cell lines

and indicated that the presence of non-viable cells could artifactually elev
the measurement of pig binding using non-cytometric assays, and more
importantly, that plg-Rs (i.e specific pig binding) might play a role during
cell death.

U937 cells that had been induced to undergo apoptosis with the protein
synthesis inhibitor cycloheximide (CHX) were also shown to have highly
elevated levels of plg-Rs (i.e specific pig binding) in addition to a large
transient increase in cell-surface uPA. This increase in plg-Rs was a late
apoptotic event, coincident with PI uptake and internucleosomal DNA
fragmentation but occurring after elevations in phosphatidylserine (PS)
exposure. Pig was also observed to dramatically increase the rate of CHXinduced apoptosis. These observations suggested that plg-Rs play a role
during the degradative phase of apoptosis.

V

In order to ascertain whether apoptotic cells could activate pig, a novel flow
cytometric PA assay was developed utilising fluorescein isothyocyanatelabelled aprotinin (FITC-aprotinin), to detect cell-surface plm. PA was found
to be highly increased on apoptotic cells, which supports the observations
that both plg-Rs and uPA are increased during apoptosis.

In summary, evidence is provided that plg-Rs (i.e-specific pig binding) are
dramatically increased during cell death. The presence of both plg-Rs (i.e
cell-surface pig) and uPA is critical for cell surface PA to proceed and this
predominantly restricted to apoptotic U937 cells which displayed highly
elevated levels of PA. These novel observations support the important role
of flow cytometry in cellular pig binding and activation studies and strongly

implicate the PA cascade in apoptosis, particularly on those cells that expres
uPA.
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ICE = interleukin -16-converting enzyme
IFNy = interferon gamma
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Kl, K2 ... = kringle 1, kringle 2 ...
Kd = dissociation constant
LBS = lysine binding site
LRP = low density lipoprotein receptor-related protein
Mr = molecular weight
NTP = N-terminal peptide
PA = plasminogen activation
PAI-1 = plasminogen activator inhibitor type 1
PAI-2 = plasminogen activator inhibitor type 2
PBS = phosphate buffered saline
PEG = polyethylene glycol
PI = propidium iodide
Pig = plasminogen
Plm = plasmin
PMA = phorbol 12-myristate 13 acetate
PMSF = phenylmethylsulfonyl fluoride
PS = phosphatidylserine
PVDF = polyvinylidene difluoride
rpm = revolutions per minute
RT = room temperature
SDS = sodium dodecyl sulphate
SDS-PAGE = sodium dodecyl sulphate polyacrylamide gel electrophoresis
serpin = serine protease inhibitor
7-AAD = 7-aminoactinomycin D
SSC = side scatter
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STA = staphylokinase
SK = streptokinase
TA = tranexamic acid
TGFfi = transforming growth factor beta
TNFa = tumour necrosis factor alpha
TSP = thrombospondin
tPA = tissue plasminogen activator
sctPA = single chain tissue plasminogen activator
tctPA = twin chain tissue plasminogen activator
tPAR = tissue plasminogen activator receptor
uPA = urokinase plasminogen activator
scuPA = single chain urokinase plasminogen activator
tcuPA = twin chain urokinase plasminogen activator
uPAR = urokinase plasminogen activator receptor
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VEGF = vascular endothelial growth factor
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Chapter 1

The Biology of Plasminogen
Activation - Literature Review

2

1.1 Plasminogen activation - an overview
Plasminogen activation (PA) is the proteolytic conversion of plasminogen
(pig) to the serine protease plasmin (plm). The predominant function of PA
is the removal of fibrin blood clots from the circulature (fibrinolysis) but
also involved in numerous other processes which involve the degradation
of extracellular matrix (ECM) or basement membrane (BM) components
such as cell migration (tumour cell invasion and metastasis, inflammation,
angiogenesis, bacterial invasion, wound healing), tissue remodelling
(embryogenesis) and ovulation. Additionally PA is important for activating
certain hormones, growth factors and other protease classes.

Although plm is considered to be a broad range serine protease, a number of
key regulatory mechanisms ensure that PA is directed to specific sites within
the body. It is the fine interplay between these mechanisms that determines
the specific role that PA plays at any one time. PA occurs by the action of
either of two plasminogen activators, urokinase-type plasminogen activator
(uPA) or tissue-type plasminogen activator (tPA) which are both secreted as
zymogens that need to be converted to their proteolytically active forms.
The activity of uPA and tPA is regulated by the presence of plasminogen
activator inhibitors such as plasminogen activator inhibitor type 1 (PAI-1)
and plasminogen activator inhibitor type 2 (PAI-2). The proteolytic activity
of plm is modulated by plm inhibitors such as oc2-antiplasmin (oc2AP) and cc2macroglobulin (cc2MG). The presence of specific binding sites for pig and pig
activators on cells, fibrin and ECM also regulate PA by localising plg/plg
activators to specific extracellular sites, and, inducing conformational

3

changes to pig which m a k e its activation kinetically more favourable. T h e
nature of the binding event also protects cell- and fibrin-bound plm from

inactivation by oc2-AP and a2-MG. It is thus the levels of bound pig, receptor
associated uPA/tPA, serpin expression, cellular receptors and substrate
binding sites that determines the location and ultimately the function of PA

at any given time. Figure 1.1 illustrates the key features of PA including it
various components, regulatory mechanisms and physiological outcomes.

Another important feature of PA is that it operates as a positive feedback
loop whereby an initial small amount of plm, that was generated by the

action of uPA/tPA, can activate more pig. In this way a proteolytic cascade i
spawned which significantly and quickly amplifies the generation of plm.
PA is also functionally linked to other proteolytic systems as plm can
activate other protease classes (e.g metalloproteases). In this manner the

role of PA can be either direct (i.e via plm) or indirect (i.e via the activa
of other protease classes) and indicates that plm can work in unison with
other proteases during extracellular proteolytic events.

In summary, the key features of PA include: (1) the generation of the serine
protease plm; (2) a number of regulatory mechanisms which can quickly
switch PA on and off; (3) a positive feedback loop which amplifies PA; (4)
linking with other proteolytic pathways; (5) is involved in numerous
biological and pathobiological processes.

pro-uPA/tPA
uPA-R
tPA-R

plg-R

•

release of 8kDa
N-terminal
pro-activation
peptide

uPA/tPA

PAI-1, PAI-2

lys-plg

positive feedback loop

0C2-AP

a2-MG

fibrin

E C M , B M components

t

t
fibrinolysis

prohormones
proteases

cell migration
metastasis
tissue remodelling

Fig 1.1: O v e r v i e w of plasminogen activation.

hormone and
protease activation
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1. 2 Components of the P A system

1.2.1 Plasminogen
Pig is a single chain glycoprotein of 791 amino acid residues and has a
molecular weight of 92kDa. Native pig has a glutamic acid residue at its
amino terminus and is consequently referred to as glu-plg. Although pig

can be activated by uPA or tPA, plm can also activate pig by hydrolysing t
peptide bond at Lys^-Lys77 causing the release of a 76 amino acid (~8kDa)

preactivation peptide and the formation of lys-plg (Castellino, 1984). Lys
is not found in the circulation and is considered to be a short-lived
intermediate in the activation pathway (Hajjar & Nachman, 1988). There
are two different glycoforms of pig that possess identical amino acid

sequences but differ in their glycosylation sites (Lijnen et al 1981): typ

glycosylated at Asn289and Thr346; type II pig is glycosylated only at Thr346.

kinetics of activation of each glycoform is slightly different (Collen et

Hall et al 1990) in addition to their binding to cells (Gonzalez-Gronow et

1989; Hall et al 1990), a2-AP, fibrin and lysine analogues (Lijnen et al 1

A schematic representation of native glu-plg is given in Fig 1.2. The pig
molecule consists a short N-terminal peptide (NTP), 5 kringle domains

consisting of approximately 80 amino acids (Sottrup-Jensen et al, 1978) an
serine protease domain. The N-terminal peptide is thought to be important
for regulating the conformation and activation of glu-plg (Ponting et al

1992). Kringles are a common structural motif in serum proteins associated
with blood coagulation and fibrinolysis and are found in proteins such as
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u P A , tPA, coagulation factor XII, prothrombin and hepatocyte growth factor
(Donate et al 1994).

Protease Domain

Fig 1.2: Schematic representation of pig (adapted from Castellino 1984).
Cleavage at residues 77/78 releases the N-terrninal peptide that liberates
Subsequent cleavage at residues 561/562 liberates lys-plm. An N-linked

polysaccharide is linked to residue 289 with an O-linked glycan found at po

Of the five kringles, kringle 1, 4 and 5 (K 1, 4 and 5 respectively) contain
preformed lysine binding sites (LBS) (Wu et al, 1991) which enable pig to
interact with a variety of lysine-containing molecules (Wiman et al 1979;

Thorsen et al 1981; Knudson et al 1986; Silverstein et al 1985; Plow et al 1
Strong LBS are located in Kl and K4, however the LBS in K4 is thought to be
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hidden in the intact molecule (Vali & Patthy 1981). The primary role of the

strong LBS in Kl is to mediate the interaction with a2-AP (Wiman et al 19

Christensen 1984) however other evidence suggests it is important for pi
binding to cells (Plow et al 1986), ECM (knudsen et al 1986) and fibrin
(Thorsen et al 1981). K5 contains the weak LBS which is also termed the

AH-site as it binds to the aminohexyl group of lysine (Christensen 1984;

Thewes et al 1990). K5 also contains a weak binding site for benzamidine
(Thewes et al 1987). K2 and 3 have been reported to possess weak LBS
(Matsuka et al 1990).

Native glu-plg possesses a closed, right-handed spiral conformation (Pon
et al 1992) due to the lysine-dependent interaction between the NTP and
(Christensen 1984). Upon binding to lysine residues, such as E-ACA or TA,

pig undergoes a large conformational change (Markus et al 1978; Mangel e

al 1990; Christensen 1991) which appears to involve two weak LBS in K4 a
K5 (Christensen & Molgaard 1992). This open conformation can also be

induced via plm-hydrolysis of the NTP that yields lys-plg (Violand et al
1975). The difference between the closed and open conformation is

apparently due to changes in the interactions of the various pig domains
(Vuk-Pavlovic et al 1979).

Pig is synthesised in the liver and is present in serum and extracellula

tissue spaces at concentrations of approximately 2|J.M (Castellino 1984)

Recent evidence has shown that retinoic acid enhances the secretion of p
from rat microglia (Nakajima et al 1992). The gene for human pig has
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recently been characterised and found to be 52.5kb (Petersen et al 1990) and
mapped to chromosome 6q26-6q27 (Murray et
probably evolved from a c o m m o n

al 1987).

The pig gene

ancestral gene consisting of an N -

terminal preactivation domain, three copies of the kringle domain and a
serine proteinase domain (Donate et al 1994). This gene also gave rise to
hepatocyte

growth

factor/scatter

factor, hepatocyte

growth

factor-

like/macrophage stimulating protein and lipoprotein (a) (Donate et al 1994)
(Fig 1.3).
uPA
factor XII
hepatocyte growth factor/ scatter factor-activation protein
prothrombin
hepatocyte growth factor like/'
macrophage stimulating factor

. . hepatocyte growth factor/scatter factor

plasminogen

Fig 1.3: Phylogenetic relationship of pig to other kringle-containing and
serine proteinase domain-containing proteins (adapted from Donate et al
1994).

1.2.2 Plasmin
Hydrolysis of the Arg560-Val561 bond in pig by u P A or tPA yields the
disulphide-linked heterodimer of plm (Castellino 1984). The heavy chain of
plm contains the five pig kringles that are important for binding to fibrin,
E C M components or cellular receptors. The light chain contains the active
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site which consists of the catalytic triad of His603, Asp 6 4 6 and Ser741 which is

characteristic of the serine protease family which also includes trypsin and
elastase (Castellino 1995). The light and heavy plm chains are covalently
linked by two disulphide bonds between Cys548 of the heavy chain and Cys666

of the light chain, and Cys558 of the heavy chain and Cys566 of the light chai
(Castellino 1995). The secondary structure of the light chain consists of a
barrel (Ponting et al 1992).

Plm hydrolyses peptide bonds on the C-terminal side of lysine and arginine

residues (Ponting et al 1992) and for this reason it is generally considered
have broad substrate specificity. However the physiological targets of plm
are very specific due to regulatory mechanisms that ensures PA occurs at
specific sites within the body. The main target of plm is fibrin but it can
hydrolyse several ECM components such as laminin (Moser et al, 1993),
fibronectin (Moser et al, 1993; Wang et al, 1994), type IV collagen (Mackay

al 1990) in addition to the protein core of proteoglycans (Richardson et al,

1988). This targeting of plm to the ECM implicates it in processes requiring
ECM degradation such as cell migration (e.g. angiogenesis, inflammation,
tumor cell invasion) and tissue remodelling. The role of plm in ECM
dissolution is augmented by the fact that plm can activate both ECM
metalloproteinases (He et al 1989; Murphy et al, 1992) and cell-surface
gelatinases (Mazzieri et al 1997).

An interesting by-product of plm-catalysed ECM degradation is the release of
bound growth factors, such as TGF-fi (Taipale et al, 1992). Plm also causes
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the release of basic fibroblasts growth factor (bFGF) and TGF-6 from

macrophages and endothelial cells respectively (Falcone et al, 1993 & 1994)
Plm has several other substrates including van Willebrand factor (Hamilton

et al 1985), glycoprotein Ilia (Pasche et al 1994), insulin-like growth fac
(Campbell et al 1992), interferon y (Gonias et al 1989) and the thrombin

receptor (Turner et al 1994). Plm can also cleave adhesion proteins such as
vitronectin (Kost et al 1996).

1.2.3 Plasminogen activators
There are two classes of plasminogen activators. Firstly there are serine
proteases such as tPA and uPA that proteolytically activate pig to plm via
cleavage of a single peptide bond. Secondly there are bacterial activators
such as streptokinase (SK) and staphylokinase (STA) which induce
conformational activation.

1.2.3.1 uPA
Single chain uPA (scuPA) is a ~55kDa proenzyme which is converted to
twin chain uPA (tcuPA) via the cleavage of Lys158-lle159 by plm. Conversion

of scuPA to tcuPA can also occur via plasma kallikrein (Ichinose et al 1986

thrombin (Lijnen et al 1987), cathepsin B (Kobayashi et al 1991), cathepsin
(Goretzki 1992) and nerve growth factor-y (Wolf et al 1993). Plm can also
generate an active low molecular weight 33kDa form of uPA by hydrolysing
Lys135-Lys136 (Stump et al 1986). Thrombin cleavage of the Arg156-Phe157
yields inactive tcuPA (Duffy 1993). The two polypeptide chains of tcuPA (Mr
= 20 and 34kDa) are held together by a single disulphide bridge.
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Phosphorylated and non-phosphorylated variants of u P A exist which are
functionally identical but differ in their sensitivity to PAI-1 with
phosphorylated uPA more than a magnitude less sensitive to PAI-1 than
non-phosphorylated uPA (Franco et al 1992). Although scuPA is a zymogen

it has been found to possess some pig activating ability (Ellis et al 1987)

can interact with glu and lys-plg via a high affinity site (Longstaff et al

In some circumstances uPA can be activated indirectly via the activation of
cathepsin C after thrombin stimulation (Lenich et al 1997). A single copy
gene for uPA is found on chromosome 10 (Rajput et al 1985).

uPA consists of a growth factor domain that contains the uPAR binding site
(Appella et al 1987), a single kringle and a protease domain that contains
catalytic triad of His204, Asp255 and Ser356 (Pennica et al 1983; Verde et al
The kringle domain contains a high-affinity PAI-1 binding site that
facilitates the reversible interaction with PAI-1 (Mimuro et al 1992). The
protease domain may also contain a second reversible PAI-1 binding site
(Mimuro et al 1992). The predominant substrate for uPA is pig however
there is evidence that uPA can directly cleave fibronectin at high

concentrations of uPA (Gold et al 1989). uPA has also been found to activat

collagenase IV (Reith et al 1992). uPA-induced PA occurs on a variety of ce
types including thrombin stimulated platelets (Lenich et al 1997). uPA is
also found associated with strands of vinculin on the undersurface of
human fibroblasts (Hebert & Baker 1988). This suggests a role for uPAcatalysed PA during cellular detachment and adhesion.

3 0009 03254527 4
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u P A is synthesised by a variety of cells including endothelial cells (Levin et
al 1982), monocytes/macrophages (Vassalli et al 1984); keratinocytes

(Hashimoto et al 1988) and leukemic cells (Wilson et al 1983). uPA synthesi
and/or secretion is increased by various growth factors such as estradiol

(Ryan et al 1984), FSH (Lacroix & Fritz 1982), EGF (Laiho et al 1986; (Boyd

Brattain 1989), TGFa (Laiho et al 1986), TGF-fi (Hamilton et al 1991; Falco

et al 1995), hepatocyte growth factor (HGF) (Pepper et al 1992), basic fibro
growth factor (bFGF) (Montesano et al 1986), IL-1 (Hamilton et al 1991),
TNFa (Niedbala & Stein 1990) and LPS (Schwartz & Bradshaw 1992;
Chapman & Stone 1985). The significance of this mode of uPA regulation is

that growth factor-mediated processes (such as angiogenesis, cell migration
and ovulation) can seconder the input of uPA.

1.2.3.2 tPA
tPA is a ~68kDa glycoprotein that is predominantly synthesised by vascular
endothelial cells as a single-chain proteolyticly active form (Levin &

Loskutoff 1982). tPA is also produced by cerebellar cells (Verrall and Seed

leukemic cells (Wilson et al 1983) and monocytes (Hart et al 1989). Plm can

cleave single-chain tPA (sctPA) to twin-chain tPA (tctPA) with only a minor

increase in activity (Madison et al 1993). There are two glycoforms of tPA:

type I has N-linked oligosaccharides at sites 117, 184 and 448 while type H
glycosylated only at sites 117 and 448. Both glycoforms have an O-linked

fucose residues at Thr61 (Harris et al 1991). Type II tPA has a 2-fold high
activity than type I (Mori et al 1995).
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tPA consists of a finger domain, a growth factor-like domain, two kringles

and a serine protease domain that contains the catalytic triad of His322, As
and Ser478 (Pennica et al 1983; Verde et al 1984). PAI-1 binding sites are
located in the finger domain (Wittwer & Sanzo 1990; Kaneko et al 1992),

kringle 2 domain (Knaeko et al 1991) and the catalytic domain (Madison et a

1990, Bennett et al 1991) and mediate the reversible interaction between tP
and PAI-1.

A single copy gene for tPA is located on chromosome 8 (Rajput et al 1985).
Dexamethasone causes an increase in tPA production in mammary

epithelial cells due to a direct effect on tPA gene expression (Bussi et al

tPA production by monocytes is increased by LPS and IL-4 (Hart et al 1989).

tPA is responsible for activating pig on fibrin blood clots and is consequ
important for fibrinolysis. The predominant substrate for tPA is pig
however there is evidence that tPA can directly cleave fibrinogen at high
tPA concentrations (Weitz et al 1988).

1.2.3.3 Bacterial activators
Streptokinase (SK) is a 414 amino acid, 48kDa protein that is secreted by
group A, C and G streptococci and is able to bind and activate human pig
(Bennsar et al 1994). Unlike uPA and tPA that are serine proteases, SK has

no intrinsic proteolytic activity. The process of SK-induced PA begins by t
initial formation of a series of stoichiometric plg:SK complexes. SK binds
rapidly and with high affinity to the pig light chain (Summaria & Robbins
1976; Cederholm-Williams et al 1979). This binding event is mediated by a
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17kDa region spanning Val43-Lys293 in S K (Rodriguez 1994). Lysine residues

in SK are important for the binding of pig (Lin et al, 1996). The formation
the 'activator complex' induces a conformational change in pig which
exposes the pig active site (McClintock & Bell 1971; Reddy & Markus 1972;
Summaria et al 1982). The resulting complex is then capable of activating
pig - that is the plg:SK complex is a pig activator. Plg:SK has been shown

bind to hepatocytes and endothelial cells which may help to localise PA nea

the cell surface (Humphries et al 1993). This process is mediated by the LB
in the pig kringles which become exposed upon formation of plg:SK and

also enable binding to fibrin (Fears 1989). Recent evidence suggests SK can
bind to receptor-bound pig on the bacterial surface (Rigdahl et al 1998).

Staphylokinase (STA) is a pig activator produced by various strains of

Staphylococcus aureus. It is a single chain protein of 136 amino acids (Sak

& Tsuchida 1983) and binds to glu and lys-plg with similar affinity and via

similar sites to SK (Lijnen et al 1994) to form a 1:1 stoichiometric comple

(Lijnen et al 1993). Plm generation is essential for exposure of the active
in plg:STA complexes (Collen et al 1993). Neither the protease domain nor

kringles 1-4 of pig are involved in STA binding (Lijnen et al 1994). The LB

in pig kringles 1-4 have been proposed to play a role in the interaction wi
STA (Arai et al 1998). a2-AP is able to rapidly inhibit pmr.STA complexes
which causes dissociation of active STA which can subsequently bind to
other pig molecules (Silence et al 1993).
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1.2.4 Plasminogen activator inhibitors
The proteolytic activity of both uPA and tPA is modulated predominantly by
PAI-1 and PAI-2 that belong to the serpin family of protease inhibitors
(serine protein inhibitors). Serpins undergo a large conformational change
upon complex formation with proteases which is essential for their
inhibitory properties (Gettins et al 1993). PAI-/PAI-2 form 1:1 molar
complexes with uPA/tPA via a reactive centre loop that interacts with the
catalytic site of the serine protease. Complexes are then cleared from the
circulation or from the cell surface via receptor mediated endocytosis.

1.2.4.1 PAI-1

PAI-1 is a single chain glycoprotein of ~54kDa and is the major extracellul

inhibitor of both uPA and tPA. For this reason PAI-1 is a regulator of both
fibrinolysis and cell-surface proteolysis. PAI-1 has also been found to

inactivate a-thrombin (Naski et al 1993). PAI-1 is synthesised by a variety
cells including endothelial cells (Kruithof et al 1984) and
monocytes/macrophages (Wohlwend et al 1987a & b) and is found in
plasma at about 0.4nm (Booth et al 1988; Declerck et al 1988) and on the
surface of platelets (Booth et al 1988). Although platelet-bound PAI-1

accounts for the majority of circulating PAI-1, it possesses a lower specif
activity than free PAI-1 (Booth et al 1988; Declerck et al 1988).

The interaction between PAI-1 and tPA is a two step mechanism involving
an initial rapid, reversible interaction, followed by a slow irreversible
reaction (Heckman & Loskutoff 1988). In contrast the interaction between
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u P A and PAI-1 is a single step interaction between the active site of u P A and
the reactive centre of PAI-1 (Heckman & Loskutoff 1988). PAI-1 can also
bind to uPAR-bound uPA (Cubellis et al 1989; Ellis et al 1990) and the
resulting complex binds to the a2-MG/lipoprotein receptor protein which
causes the endocytic clearance of PAI-1/uPA/uPAR from the cell surface

(Cubellis et al 1990; Conease et al 1995). gp330 is also responsible for cl
uPA:PAI-l complexes from renal proximal tubules (Moestrup et al 1993).
Evidence suggests that in addition to their involvement in extracellular
proteolysis PAI-1/uPA/uPAR complexes may be involved in cell fusion by
acting as a bridge between cells and ECM (Bonavaud et al 1997). Free tPA
and tPA:PAI-l complexes are also cleared and degraded from the surface of
endothelial cells (Grobmyer et al 1993), fibroblasts (Willnow et al 1992)

hepatoma cells (Owensby et al 1988; Owensby et al 1989; Morton et al 1990;
Owensby et al 1991; Bu et al 1993) via a2-MGR.

Vitronectin serves as a co-factor for PAI-1 and acts as a PAI-1 binding
protein, allowing the accumulation of PAI-1 at sites of tissue damage
(Declerck et al 1988; Podor et al 1992). This association of PAI-1 with

vitronectin apparently stabilises PAI-1 in its active conformation without

interfering with its inhibitory activity (Seiffert et al 1990). Vitronectim
complexes are able to inhibit both uPA and tPA (Salonen et al 1989). This
tight complex between PAI-1 and vitronectin has been found to accelerate
the inactivation of human cc-thrombin (Naski et al 1993). PAI-1 can also
interact with heparin which enhances its reactivity towards thrombin
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(Ehrlich et al 1991). PAI-1 is a major component of the E C M of cultured
human fibroblasts and sarcoma cells (Pollanen et al 1987). The
incorporation of PAI-1 into the ECM has been proposed to protect ECM

components from the proteolytic activity on the surface of migrating cells

(Seiffert et al 1990). PAI-1 released from endothelial cells is also incor
into developing fibrin clots which similarly may be a mechanism of
regulating tPA-catalysed fibrinolysis (Handt et al 1994).

A variety of growth factors have been shown to increase the synthesis and
secretion of PAI-1 such as IL-1 (Bevilacqua et al 1986), thrombin (van

Hinsbergh et al 1987), bFGF (Gospodarowicz et al 1987), TNFa (Schleef et a

1987; Handt et al 1994), TGF-fix (Lund et al 1987; Albo et al 1994; Pepper
1990; Handt et al 1994), TSP (Albo et al 1994) and LPS (Chapman & Stone
1985; Schwartz & Bradshaw 1992). These observations suggest that growth
factor driven processes, such as cell migration, angiogenesis and
inflammation, can utilise PAI-1.

1.2.4.2 PAI-2
PAI-2 is a protein which exists as a 46kDa non-glycosylated intracellular
form and a 60kDa glycosylated extracellular form (Astedt et al 1987;

Wohlwend et al 1987; Wun et al 1987.). Glycosylated tPA has three N-linked
glycosylation sites at Asn75, Asn115 and Asn339 (Ye et al 1988). Both forms
PAI-2 are encoded by a single mRNA (Belin et al 1989). The gene for PAI-2
located on chromosome 18q21-23 and is the closest mammalian homologue

to ovalbumin (Ye et al 1989). The reactive centre of PAI-2 is located at A
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Thr 381 (Kiso et al 1988). PAI-2 can inactivate both u P A and tctPA but less
effectively than PAI-1 (Kruithof 1988). uPA:PAI-2 complexes are rapidly
cleared from the surface of monocytes (Estreicher et al 1990).

PAI-2 was originally isolated from human placenta and is sharply increased

during the third trimester of pregnancy (Kruithof et al 1987). PAI-2 is fou
intracellularly in a variety of cells including monocytes /macrophages

(Wohlwend et al 1987a & b), fibroblasts (Hamilton et al 1992; Pytel et al 1

syncytiotrophoblasts (Astedt et al 1986), keratinocytes (Hashimoto et al 19
vascular smooth muscle cells (Laug et al 1989), endothelial cells (Webb et

1987), granulosa cells (Piquette et al 1993) and various cells of the brain

including mesothelial cells (van Hinsbergh et al 1990; Idell et al 1992) an
microglia (Akiyama et al 1993).

PAI-2 synthesis /secretion may be cell cycle-dependent (Wick et al 1994) as
well as being modulated by a variety of factors. LPS increases PAI-2
expression on monocytes/macrophages (Chapman & Stone 1985; Schwartz
& Bradshaw 1992). PMA is a strong inducer of PAI-2 in endothelial cells
(Scarpati & Sadler 1989) monocytes/macrophage-like cells (Vassalli et al

1984; Kruithof et al 1986;) and a number of cancer cells (Johnson & Baglion
1990; Medcalf 1992). Okadaic acid stimulates PAI-2 synthesis in U937 and
HT1080 cells (Medcalf 1992). TNF stimulates PAI-2 synthesis in monocytic

cells (Medcalf 1992), fibroblasts (Pytel et 1990), endothelial cells (Scarpa

Sadler 1989; Zoellner et al 1993), mesothelial cells (van Hinsbergh et al 1
Idell et al 1992) and melanoma cells (Johnson & Baglioni 1990; Pytel et al
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1990). IL-1 increases PAI-2 expression in monocytes (Gyetko et al 1993),
endothelial cells (Zoellner et al 1993), synovial fibroblasts (Hamilton et

1992; Hamilton et al 1993), bone marrow stromal cells (Hannocks et al 1992)
and granulosa cells (Piquette et al 1994). PAI-2 expression in
monocytes/macrophages is also increased by IL-2 (Gyetko et al 1993), IFNy
(Gyetko et al 1992), macrophage and granulocyte-macrophage colony
stimulating factors (Wohlwend et al 1987; Hamilton et al 1993). EGF also
increases PAI-2 expression in epidermoid carcinoma (George et al 1990) and
granulosa cells (Piquette et al 1993).

PAI-2 expression in macrophages/monocytes is decreased by TGFfi
(Hamilton et al 1993) and glucocorticoids such as dexamethasone
(Wohlwend et al 1987; Medcalf et al 1988). Non-glycosylated PAI-2 is

released by U937 cells after prolonged exposure to PMA (Kruithof et al 1986
Cell death has been proposed to be another way in which non-glycosylated
PAI-2 might me released from cells (Kruithof et al 1995).

1.2.5 Plasmin inhibitors
There are a number of serpins which function to inactivate plm by forming
irreversible enzyme-inhibitor complexes. Some of these inhibitors are
specific for plm, for example a2-antiplasmin (a2-AP) while others are able
inhibit a variety of serine proteases, for example a2-macroglobulin and
protease nexin 1. Plm can also complex with other serpins such as
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antithrombin IE, arantitrypsin and Cl inhibitor (Levi et al 1993), however
the main physiological plm inhibitor is a2-AP followed by a2-MG.

1.2.5.1 a2-antiplasmin
a2-AP is a single chain glycoprotein of 65-70kDa (452 amino acids) and is

main physiological plasmin inhibitor. Under certain in vitro conditions a

AP can also inhibit factor XII, plasma kallikrein, activated factor XI an
thrombin (Saito et al 1979). It is found in mammalian plasma at a
concentration of luM (Wiman & Collen 1977) and a small amount (-0.5%)

is found on the surface of platelets (Plow & Collen 1981). a2-AP exists as

either a pig binding or non-pig binding form. The pig binding form inhibi

plm, reversibly interacts with pig and covalently attaches to fibrin duri
coagulation. The non-pig binding form inhibits plm more slowly and does

not bind to pig or fibrin (Tamaki & Aoki 1982; Kluft et al 1984). The pig
binding form of a2-AP is produced by the liver while the non-pig binding
form is formed in the circulation (Kluft et al 1986).

a2-AP consists of a plg/plm binding site, a reactive site (which binds to

active site of plm) at Arg364-Met365 and a fibrin binding site (which binds
the a-chain of fibrin) (Wiman et al 1989). The binding of plm to a2-AP is

rapid with the rate limiting step being the interaction between the LBS i
and a C-terminal lysine residue in a2-AP (Wiman & Collen 1978; Wiman

1981; Sasaki et al 1986). This facilitates the interaction between the act
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of plm and the reactive site peptide in a2-AP to form a stable enzyme
inhibitor complex (Wiman & Collen 1979; Nilsson & Wiman 1982). The
major sites of a2-AP production are the liver and the kidney (Menoud et
1996) however cultured monocytes (Kloczko et al 1990) and glioblastoma
organ cultures (Keohane et al 1990) can release a2-AP. Numerous studies

have shown that a2-AP can not inhibit cell- (Ellis et al 1991) or fibrinplm (Anonick & Gonias 1991).

1.2.5.2 a2-macroglobulin

a2-MG is a 726kDa protein consisting of four identical 185kDa subunits t

are non-covalently associated via two disulphide bonded pairs of subunits

In addition to plm, a2-MG is capable of inhibiting trypsin, chymotrypsin

neutrophil elastase and fibroblast collagenase. Only when the inhibitory
capacity of a2-AP is exceeded by high plasma concentrations of plm does
MG come into play (Saito 1988). a2-MG is produced by monocytes and

macrophages (Ganter et al 1989) and tumour cells (Bizik et al 1986). a2-M

found at relatively high concentrations in plasma and lymph, pleural and

amniotic fluids (Starkey & Barrett 1977). The interaction of plm with a2does not depend on the LBS in Kl (Steiner et al 1987). Studies have

demonstrated that fibrin-bound plm is protected from inhibition by a2-MG
(Anonick & Gonias 1991).
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a 2 -MG:plm complexes bind to the a 2 - M G / L R P receptor (a 2 -MGR) which is
present on a range of cell types including hepatocytes, macrophages,
fibroblasts and neurons (Moestrup et al 1992). PAI-l:uPA/tPA complexes
can also bind to the a2-MGR but bind to a site distinct from a2-MG:plm
(Nykjaer et al 1992). Once bound to the cell surface a2-MG:plm is cleared
receptor mediated endocytosis.

1.2.6 Cellular Receptors

Another critical component of the PA cascade is binding sites for uPA, tPA

and pig. There are two general classes of binding sites: (1) cellular rece
and (2) receptors/binding determinates on fibrin/ECM components.
Binding of pig, tPA or uPA serves to localise PA to the cell surface, ECM
fibrin clot thereby focussing proteolytic activity at these regions.
Additionally, immobilised plm is protected from fast-acting plasma

inhibitors such as a2-AP and a2-MG (Lottenberg et al 1987; Hall et al 1991;
Fuchs et al 1994). In this manner cellular receptors are an important
regulatory element of the PA system.

1.2.6.1 uPAR (CD87)

uPA (both sc and tc-uPA) is able to specifically interact with a variety o
(Table 1.1) via a ~55kDa single glycosylphosphoinositol (GPI)-anchored
membrane glycoprotein which consists of three homologous domains

(Cubellis et al 1986; Ploug et al 1991). uPA can also interact with ganglio
on U937 cells (Miles et al 1989). uPAR possesses an N-linked carbohydrate
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which appears to be important for its cellular transport and maturation
(Moller et al 1993) and also contributes to the affinity for uPA (Behrendt

1991; Moller et al 1993). There is outstanding evidence that the N-terminal
growth factor domain of uPA is responsible for mediating the high affinity

binding to uPAR (Stopelli et al 1985; Appella et al 1987; Goretzki et al 19

Quax et al 1999). Recent evidence indicates that intracellular stores of uP
occur in some cells that do not express cell-surface uPAR suggesting that

translocation may occur if necessary (Jardi et al 1996). A truncated form o
uPAR, lacking the uPA binding domain, has been found on normal and
tumour thyroid cells (Ragno et al 1998). Studies have also revealed that
unoccupied uPAR is relatively mobile (Myohanen et al 1993).

T A B L E 1.1: Characteristics of cellular u P A binding
Cell Type

N o receptors/cell

U937 (monocytoid)
5.0 ± 2.9 x 107cell

Kd

Reference

0.5nm

Cubellis et al 1986

2.0 ±1.6nm

Plow et al 1986

1.8±0.3xl04/cell

Felez et al 1990

GM1380 (fibroblast)

2.6±0.8xl05/cell

0.8 ±0.5nm

Plow et al 1986

Endothelial cells

2.9±2.9xl05/cell

2.1 ±1.5nM

Miles et al 1988

Granulocytes

5.6 ±3.1x107 cell

Miles et al 1987

Monocytes

5.7 ±1.6x107 cell

Miles et al 1987

Lymphocytes

l±0.2xl07cell

Miles et al 1987

Platelets

< 70/cell

Miles et al 1987

RBC

< 70/cell

Miles et al 1987

THP-1 (monocytoid)

2.1 ±0.1x107 cell

Felez et al 1990

HL-60 (monocytoid)

1.3 ±0.3x107 cell

Felez et al 1990
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vascular smooth muscle cells

2nM

DU-145 cells (prostate cancer) 10.3 ± 1.6 x 107cell

0.4

Ellis & Whawell 1997
±

Yoshida et al 1997

0.17nM
mouse spermatozoa

Zhou & Vassalli 1997

Vitronectin can also bind with high affinity to u P A R (Hoyer-Hansen et al
1992) at a site different from uPA. This co-localisation of vitronectin and
uPA on uPAR contributes to cell adhesion and migration (Kanse et al 1996;
Chapman 1997). Recent evidence indicates the existence of a soluble uPAR
(suPAR) which is secreted by human endothelial and monocytic cells and is
increased by PMA stimulation (Chavakis et al 1998). Vitronectin mediates
the binding of uPA/suPAR to cell surfaces and ECM (Chavakis et al 1998)
presumably via binding to suPAR. uPAR is found in close association with

fi2-intergrins on leukocytes where it is required for leukocyte-endothelial
interactions and migration to inflamed areas (May et al 1998).

uPAR is expressed on a variety of cell types including leukemic cells and

peripheral blood cells (Jardi et al 1996), keratinocytes (Reinartz et al 199
human thyroid cells (Ragno et al 1998), and mouse spermatozoa (Zhou &
Vassalli 1997). uPAR expression on leukemic cells appears to be confined to
more differentiated cells along the myelo-monocytic pathway (Jardi et al
1996). This is supported by a previous observation that uPAR expression
increases during the differentiation of mouse erythroleukemic cells (Del
Rosso et al 1987). As with other components of the PA system, uPAR
expression is increased by a variety of growth factors such as phorbol 12-

myristate 13 acetate (PMA) (Stopelli et al 1985; Estreicher et al 1989; Pic
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al 1989; Lund et al 1991; W a n g et al 1994; Jardi et al 1996), H G F (Pepper et al

1992), IFNy (Kirchheimer et al 1988; Lu et al 1988), TNFa (Kirchheimer et a
1988; Lu et al 1988; Wang et al 1994), TGF-Ga (Falcone et al 1995) and
thrombin (Yoshida et al 1997). These results suggest that the increase in
uPAR expression during processes such as cell migration and inflammation
can be attributed to the effect of growth factors.

The obvious role of uPA binding to uPAR is to localise PA to the cell

surface. The enzymic activity of scuPA is increased 100-fold upon binding t
uPAR on monocytes (Manchandra & Schwartz 1991). Unlike cell-surface

plm which is relatively resistant to inactivation by its circulating inhib

receptor-bound uPA is efficiently inactivated by both PAI-1 and PAI-2 (Elli
et al 1990; Pollanen et al 1990). Another outcome of uPA binding is the

initiation of signal transduction pathways that can cause phosphorylation o
protein kinases (Dumler 1993; Busso 1994; Bohuslav 1995; Resnati 1996;

Dumler et al 1998) and intracellular calcium mobilisation (Cao et al 1995).
Recent evidence (Dumler et al 1998) has shown that uPA/uPAR signalling
utilises a direct Jak/Stat cascade and a second pathway utilising Src-like
protein-tyrosine kinases. Although the Jak/Stat pathway appears to be

involved in cell migration, the role of the Src-like protein-tyrosine kinas
pathway remains to be elucidated. Evidence also suggests that uPA binding

can actually transactivate the PAI-2 gene promoter in HT-1080 cells (Dear e
al 1997). The mechanism of uPA/uPAR signal transduction is thought to be
via related transmembrane integrins (Petty & Todd 1996) as uPAR does not
contain any transmembrane or cytomplasmic domains (May et al 1998).
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Infact u P A R is found associated with various integrins in focal contacts

(Pollanen et al 1991) where it appears to be involved in cell migration (Bu
et al 1994; Gyetko et al 1994).

Additionally uPA can bind to several ECM components such as heparin,
laminin and nidogen (Stephens et al 1992a & b). uPA binds weakly to
fibronectin (Salonen et al 1985).

1.2.6.2 tPAR
tPA can bind to a variety of cells (Table 1.2) via two mechanisms. One
mechanism is mediated by PAI-1 which binds (and hence inactivates)
functionally active tPA (Cheng et al 1992). The resulting tPA:PAI-l
complexes bind to a2-MGR, low density lipoprotein receptor-related protein

(LRP) or the mannose receptor on the surface of liver parenchymal cells (Bu
et al 1993; Smedsrod & Einarsson 1990) and endothelial cells (Einarsson et
1988; Smedsrod & Einarsson 1990) and are then cleared by receptor mediated
endocytosis. The second mechanism involves tPA binding directly to
specific membrane receptors and does not involve the protease (Cheng et al
1992) or EGF domain of tPA (Verrall & Seeds 1989). This second mechanism
also results in the internalisation and degradation of tPA (Nguyen et al
1992).

tPA has a unique receptor on some bacteria (Ullberg et al 1994) and vascula
smooth muscle cells (Ellis & Whawell 1997), however both tPA and pig

share a common set of binding sites on nucleated cells (Felez et al, 1996).
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tPA can bind to several plg-R candidates such as a-enolase, gangliosides
(Felez et al 1993) annexin II (Hajjar et al 1994), a 45kDa protein on

endothelial cells (Dudani et al 1994) and E. Coli Fimbriae (Parkkinen et al
1991). tPA can also bind to the mannose receptor via its high mannose-type

T A B L E 1.2: Characteristics of cellular tPA binding
Kd

Cell Type

N o receptors/cell

U937

1.6 ±0.1x107cell

Felez et al 1993

THP-1

2.3 ± 1.2 x 107cell

Felez et al 1993

K562 (leukemic)

3.2 ± 0.2 x 107cell

Felez et al 1993

Raji (lymphoma)

4.0 ±0.3x107 cell

Felez et al 1993

leukemic)

1.3 ±0.1x107 cell

Felez et al 1993

endothelial cells

1.2 x 107cell

4.2 x 10'6M

Beebe 1987

3.7 ±0.3x107 cell

28.7 ± 10.8pM

Hajjar et al 1987

8.15 ± 1.46 x 107cell

18.1 ± 3.8 n M

Hajjar et al 1987

Nalm-6

Reference

(pre-B

8 x 107cell

Cheng et al 1992

1.4±0.8xl07cell

Felez et al 1993

Chang (liver)

0.3 ±0.1x107 cell

Felez et al 1993

Rat

5.4 x 107cell

Novikoff

12mM

Nguyen et al 1992

hepatoma cells
Bu et al 1993

HepG2 (liver)
A431 (epidermoid)

Felez et al 1993

1.4 ±0.1x107 cell

50pM

mouse cerebellar cells

Felez et al 1993

HT1080 (fibrosarcoma) 3.2 ± 1.0 x 107cell
Neisseria
meningitidis (Mo 52)

8.5 x 107cell

Verral & Seeds 1989

70nM

Ullberg et al 1994
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1 x lOVcell

Haemophilus

20nM

Ullberg et al 1994

25nM

Ellis & Whawell 1997

influenzae (HI23354)
vascular
muscle cells

smooth

300nM

oligosaccharide (Otter et al 1991) however other studies have shown that the

carbohydrate moiety of tPA is not important for cellular binding (Verral
Seeds 1989). The clearance of tPA from the surface of Novikoff hepatoma
cells does not involve the mannose receptor (Nguyen et al 1992).

tPA has been shown to bind to ECM produced by both smooth muscle and

endothelial cells (Stack et al 1994). tPA can interact with laminin (Salone
al 1984) and to heparan sulphate- and chondroitin sulphate-containing

proteoglycans produced by human endothelial cells (Bohm et al 1996). tPA
can also bind to heparin which stimulates fibrin-dependent PA (AndradeGordon & Strickland 1986; Paques et al 1986; Stein et al 1989). tPA can

bind to fibronectin via a 55kDa amino terminal fragment (Salonen et al 1

Moser et al 1993). Binding of tPA (and pig) to intact fibronectin does n
enhance PA, however, proteolytic fragments of fibronectin are potent
stimulators of PA (Stack and Pizzo 1993). tPA (and pig) binds with high
affinity to thrombospondin which results in a 40-fold increase in the
efficiency of PA (Silverstein et al 1985). tPA binds with high affinity to

fibrin and fibrin fragments which enhances tPA-catalysed PA (Hoylaerts et a

1982) but has a lower affinity for fibrin than pig (Fleury et al 1993). Fibr
bound tPA appears to be protected from inhibition by PAI-2 (Leung et al

1987). Antimicrobial peptides called defensins have been shown to inhibi
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tPA binding to endothelial cells and fibrin and consequently inhibit P A
(Higazi et al 1996).

Although the main physiological outcome of tPA binding to its receptor/s is
an enhancement of tPA-dependent PA (Parkkinen et al 1991; Hajjar et al
1994) there is some evidence that tPA binding may initiate a signal

transduction pathway. The binding of tPA to its receptor/s appears to induce
endothelial cell proliferation which is independent of plm activity but
apparently dependent on protein kinase A activity (Welling et al 1996).

1.2.6.3 Plg-Rs
Plg-Rs are a heterogenous group of molecules that are characterised by the

presence of terminal lysine residues that serve as a binding site for pig vi
the LBSs (Winram &Lottemberg 1998). C-terminal lysine residues appear to

be the defining feature of plg-Rs however, recent evidence indicates that Nterminal lysine residues are also important in pig binding to a-enolase on
pathogenic streptococci (Pancholi & Fischetti 1988). Although cellular pig
binding is a widespread phenomena most plg-R candidates are restricted to

specific cell types (Table 1.3) and are generally proteins, however some non
proteinacious molecules, such as gangliosides, function as plg-Rs on U937

cells (Miles et al, 1989). The general consensus is that several different p

Rs are responsible for the total pig binding potential of cells. For example
although glyceraldehyde-3-phosphate functions as a bacterial plg-R it does

not account for all the pig-binding ability of cells as bacterial strains wi
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mutated plg-R genes can still bind the same level of pig as wild type strains
(Winram & Lottenberg, 1998).

Pig has also been found to share some cellular binding sites with tPA
(Parkkinen & Rauvala 1991; Felez et al 1993; Cesarman et al 1994).
Lipoprotein(a) can compete with pig for cellular binding sites due to the

ability of Lp(a) to bind to plg-Rs on U937 cells and endothelial cells (Mi
1988)

T A B L E 1.3: Candidate plg-Rs
MWt

Cell Type/s

Receptor Candidate

Miles et al 1986; Adelman et a 1

platelets

GPIIb/IIIa

Reference

1988
Type I Fimbrae

Salmonella enterica

G Fimbrae

Escherichia coli

Kukkonen et al 1998

S Fimbrae

Escherichia coli

Parkkinen & Korhonen 1989

Gangliosides

Endothelial

Miles et al 1989

cells,

granulaocytes, platelets,
U937s
Annexin II

Endothelial cells

40kDa

Hajjar et al 1994

45kDa protein

Rat neocortical neurons

45kDa

Nakajima et al 1993

Thrombospondin/

platelets

450kDa

Silverstein et al 1985

U937s

54kDa

Miles et al 1991; Redlitz et a 1

Histidine-rich
glycoprotein
ce-enolase

/

enolase-relatedmolecule

oc-

1995; Arza et al 1997

3 1

MCF-7

55-

Lopez-alemany et al 1994

60kDa
streptococci
Cytokeratin 8

45kDa

hepatocytes; HepG2 cells

Pancholi & Fischetti 1998
Hembrough et al 1995

(hepatocellular
carcinoma);
MCF-7

BT20

cells

&

(breast

carcinoma)
45kDa protein

endothelial cells

45kDa

Dudani et al 1993

Actin

endothelial cells

45kDa

Dudani et al 1996

50-60kDa protein

rat colon carcinoma cells

50-

Durliat et al 1992

60kDa

PAM

Streptococcus pyogenes

43kDa

Berge & Sjobring 1993; Wistedt
et al, 1995

Flagella

E. Coli LE393

97kDa protein

Rheumatoid

arthritis

human

synovial

Lahteenmaki et al 1993
97kDa

Gonzalez-Gronow et al 1994

30kDa

Parkkinen & Rauvala 1991

76kDa

Kanalas & Makker 1991

fibroblasts
amphoterin
Rat

heymann

rat kidney cells

nephritis
autoantigen gp330
cell-surface

Fuchs et al 1994

Borrelia Burgdorferi

lipoprotein A
corneal fibroblasts

55kDa

Lopez-Alemany et al 1995

glyceraldehyde-3-

Streptococcus equisimilis

~41kDa

Broder et al 1991; Gase et al

phosphate

H46A

55kDa protein
Tetranectin

dehydrogenase

1996
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surface protein A

Borrelia Burgdorferi

70kDa protein

Borrelia Burgdorferi

Tissue factor

C H O (transfected)

Fan et al 1998

Complement protein

endothelial cells

Christiansen et al 1997

H u et al 1997
70kDa

H u et al 1997

C9
Aspartase

Haemophilus influenzae

55kDa

Sjostrom et al 1997

al 1995). The basis for this competition is that Lp(a) contains kringles
(analogous to pig kringle 4) which have lysine binding ability.

The regulation of plg-R expression is another important mechanism
whereby cellular PA can be modulated. A variety of pig binding
experiments have been performed (without identification of an actual plg-R)
which indicate that plg-R expression can be modulated by a variety of
growth factors. Interferon y and vitamin D3 have been shown to increase

plg-R expression on U937 cells (Lu et al 1988 & 89). Plg-Rs are decreased by
glucocorticoids on HT-1080 fibrosarcoma cells (Pollanen, 1989) and thrombin
on endothelial cells (Miles et al 1988) which contrasts with thrombin

stimulated platelets which express more plg-Rs (Miles et al, 1986). Plg-Rs a
also upregulated following fil-intergrin-dependent cellular adherence (Kim
et al 1996). PMA has also been shown to increase plg-R expression on
monocytoid cells (Felez et al 1990). Plg-R expression is not modulated by

TGF-fi,. on THP-1 cells (Falcone et al 1995). Some candidate plg-Rs have als
been suggested to be important for cell viability (Winram & Lottenberg
1998).
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1.2.6.4 Characteristics of cellular pig binding
Plasminogen binding has been reported on a variety of both prokaryotic

(Table 1.4) and eukaryotic cells (Table 1.5). The main features of cellular p

binding are: (1) it is specific - it can be inhibited with an excess of unlab
pig, and lysine analogues such as 1-lysine, e-amino caproic acid (e-ACA) and
tranexamic acid (TA) and partially by the arginine analogue benzamidine;_(2)

it is saturable - there are a finite number of cellular binding sites ranging
from IO2 on some bacteria (Kuusela & Saksela 1990) up to IO7 on some
eukaryotic cells (Miles et al 1988) and (3) it is a relatively low affinity
interaction with dissociation constants (Kd) on eukaryotes of up to 2.6fiM.
Generally, pig binding to prokaryotes is a much higher affinity interaction
than binding to eukaryotes.

T A B L E 1.4: Characteristics of pig binding to prokaryotic cells
Cell Type

N o of

Affinity

Receptors

(Kd)

Reference

Ringner et al 1994; Khin et

Helicobacter pylori

al 1996; Pantzar et al 1998
Neisseria meningitidis

3-6 x lOVcell

50nm

1-2 x lOVcell

200nm

Ullberg et al 1992
Eberhard et al 1995

Neisseria gonorrhoeae

Ullberg et al 1992

Group A streptococcus

Lottenberg et al 1987; W a n g
et al 1994; Eberhard et al
1995

Staphylococcus aureus

780/cell

1.7nm

Kuusela & Saksela 1990
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Gram-negative bacteria

2-2.5

Haemophilus influenzae
Branhamella catarrhalis

x

6-8nm

Ullberg et al 1990; Eberhard

lOVcell

50-80nm

et al 1995

9 x lOVcell

60nm

8 x lOVcell
Group C & G streptococci

Ben-Nasr

et

al

1994;

Eberhard et al 1995
Borrelia burgdorferi

106±14/cell

24 ± 12pm

2,683 ± 36/cell 20±4nm

Coleman et al 1995; Fuchs et
al 1994

Streptococcus pneumoniae

Eberhard et al 1995

Proteus mirabilis

Eberhard et al 1995

Salmonella enterica

Lahteenmaki et al 1995

Table 1.5: Characteristics of pig binding to eukaryotic cells
Cell Type
THP-1 (monocytoid)

N o of Receptors

Affinity (Kd)

Reference

0.3 ±0.1 x lOVcell

Felez et al 1990

1.6 ±.0.2 xlO6/cell

Felez et al 1993

THP-1 macrophage

1.4 ± 0.3 x lOVcell

15.8±6.2nM

Falcone et al 1994

platelets (resting)

3.7±lx lOVcell

1.9-2.6-uM

Miles &

Plow 1985;

Miles et al 1986
platelets

(thrombin-

1.9 ± 0.45 xlOVcell

1.9-2.6uM

Miles &
Miles

stimulated)

et

Plow 1985;
al

1986;

Adelman et al 1988
U937 (monocytoid)

1.6 ± 1.4 x lOVcell
0.4 ±0.1 x lOVcell

0.8 ±0.5 u M

Plow et al 1986
Felez et al 1990
Edelberg et al 1990
Gonzalez-Gronow et a 1
1991

2.0 ± 0.7 x lOVcell

Felez et al 1993
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GM1380 (fibroblast)

3.1±0.4xl07/cell

0.9±0.4uM

Plow et al 1986

SW1116 tumor cells

1.5 x lOVcell

1.5 x IO'7

C o m a c h o et al 1989

Endothelial cells

1.4 ± 1 x lOVcell

310±235nM

Hajjar et al 1986

1.8 ± 1.3 x lOVcell

2.1 ± 1.3 uM

Miles et al 1988

0.8 ± 0.5 x lOVcell
SW1116

Felez et al 1993

5xlO"6M

(colonic

Burtin &
1988

adenocarcinoma)
PROb

Fondaneche

(rat

colon

0.9 x lOVcell

10"7M

Durliat et al 1992

colon

3.6 x lOVcell

5.10"7 M

Durliat et al 1992

6 x lOVcell (plm)

5.4 x 10-9

carcinoma)
REGb

(rat

carcinoma)
HT-1080

(fibrosarcoma

M

Pollanen 1989

(plm)

cells)
rat hepatocytes

9.4 + 0.8 x lOVcell

3.2 ± 0.2

9.8 + 1.3 x lOVcell

(pig 1)

1.9 ± 0.1

Hall et al 1990

uM

(pig 2)
rat C6 glioma cells

2.8 + 0.6 x lOVcell

2.2 ±0.1

3.7 + 0.9 x lOVcell

(pig D
1.5 ±

[M

Hall et al 1990

0.2uM

(pig 2)
Humphries et al 1993
mammary

Burtin et al 1993

carcinoma

cells
MCF-7

cells

Correc et al 1990

(breast

carcinoma cells)
HL-60 (monocytoid)

0.5 ±0.2 x lOVcell

Osteosarcoma cells

-7.5 x lOVcell

K562 (leukemic)

3.1 ± 0.2 x lOVcell

Felez et al 1990
~ 0.6uM

Campbell et al 1994
Felez et al 1993
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Raji (lymphoma)

3.4 ± 0.1 x lOVcell

Felez et al 1993

leukemic)

1.2 ± 0.2 x lOVcell

Felez et al 1993

Chang (liver)

0.5 ± 0.1 x lOVcell

Felez et al 1993

A431 (epidermoid)

1.6 ± 0.1 x lOVcell

Felez et al 1993

2.4 ± 1.9 x lOVcell

Felez et al 1993

Nalm-6

(pre-B-

HT1080 (fibrosarcoma)

corneal fibroblasts
WEHI-38

murine

Lopez-Alemany 1995

4 x lOVcell

0.38uM

Leukemic cells

Martinez

&

Santibanez 1994

rat hepatocytes

1.41 ± 1.1 x lOVcell

0.59±0.16uM

Gonias et al 1989

human keratinocytes

1.3 x lOVcell

0.8uM

Reinartz et al 1993

Various proteins can mediate the binding of pig to cells including
complement protein C5B-9 which has been found to increase pig binding
and activation on human endothelial cells (Christiansen et al 1997). Pig
binding to U937 cells is also enhanced by complestatin which is a small
peptide-like metabolite from streptomyces (Tachikawa et al 1997).
Additionally, antimicrobial peptides called defensins have been shown to
modulate the binding of both pig and tPA to endothelial cells (Higazi et al
1996). Pig binding to endothelial cells has been inhibited with
hypertriglyceridemic VLDL (Li et al 1996).

Proteolytic treatment of cells with plm has been shown to increase the
number of pig binding sites on platelets (Ouimet et al 1994) tumor cells

(Comacho et al 1989) and bacteria (Gase et al 1996). Limited plm treatment o
the candidate plg-R G3PDH, has been shown to enhance its binding capacity
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for pig (Gase et al 1996). The mechanism of this observation is that p l m
enhances pig binding by exposing new C-terminal lysine residues.

LBS in the pig molecule have been repeatedly shown to mediate cellular pig
binding, however there is some evidence that the carbohydrates of pig also

contribute to cellular binding. Edelberg et al (1990) determined that neon

pig, that differs in carbohydrate composition to adult pig, interacts diff

with cells. Hall et al (1990) also found that pig type 2 had a slightly hig

affinity for rat C6 glioma cells than pig type 1. A recent study on the rea
time binding of pig to immobilised 1-lysine (mimicking fibrin, ECM or plg-

Rs) also indicated that pig binding is very complex and may not be entirely
mediated by pig kringles (Warkentin et al 1998).

The main physiological outcome of pig binding to cells is the generation of

cell-surface plm which then participates in various extracellular proteoly
events. There is some evidence that pig binding followed by PA may be
involved in other cellular processes. uPA-catalysed PA on human
rheumatoid arthritis synovial fibroblasts stimulates an increase in
intracellular calcium which is not evident in normal cells (GonzalezGronow et al 1993). K4 and the Thr245-linked carbohydrate are involved in
mediating this increase in calcium (Gonzalez-Gronow et al 1993). On

platelets, plm can indirectly induce calcium mobilisation by proteolytical
modifying adhesive receptors (Winters et al 1990). Plm has been shown to
induce receptor-mediated arachidonate release which is coupled with G
proteins in endothelial cells (Chang et al 1993). The early phase of this
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release involved the LBS and active site of plm, and was mediated by the
calcium-dependent activation of phospholipase A2 via a GTP-binding
protein (Chang et al 1993). The late phase of this release was calcium
independent and involved the active site of plm (Chang et al 1993).

1.2.7 Pig binding to extracellular protiens
C-terminal lysine residues also serve as binding sites for pig on ECM and
fibrin. Just as with cells, pig binding to ECM/fibrin serves to direct the
proteolytic activity of plm against ECM and fibrin which is crucial for
processes like cell migration, tissue remodelling and fibrinolysis. Pig
binding to ECM and fibrin also induces suitable conformational changes in
pig which make it more susceptible to activation by uPA/tPA.

1.2.7.1 Pig binding to ECM
Pig has been shown to bind to intact ECM (Knudson et al 1986; Stack et al

1994; Lopez-Alemany 1995; Pekelharing et al 1996) in addition to individual
ECM components such as type 1 collagen (Martinez & Santibanez 1994), type

IV collagen (Stack et al 1992), heparin (Stack & Pizzo 1993), laminin (Salo

et al 1984; Moser et al 1993) and fibronectin (Moser et al 1993). Pig has a
relatively high affinity for ECM components such as type 1 collagen
(Martinez & Santibanez 1994), thrombospondin (35nM) (Silverstein et al
1985), fibronectin (91nM) (Salonen et al 1985) and type IV collagen (12nM)

(Stack et al 1992) which suggests that pig would preferentially bind to ECM
rather than cells in vivo.
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The binding of pig to E C M , like binding to fibrin or cells, results in m o r e
efficient activation and serves to direct PA to the extracellular tissue
environment. For example, pig binding to type IV collagen enhances the
rate of tPA-catalysed PA (Stack et al 1990). The binding of pig to ECM
components also establishes a reservoir of pig, which when activated,
degrades ECM (Martinez and Santibanez 199) either directly with plm or via
the activation of matrix metalloproteases. Additionally, the degradation of
ECM by plm also causes the release of matrix-bound growth factors such as
TGF-fi (Taipale et al, 1992). Lp (A) and LDL have both been shown to
compete with pig for binding sites on ECM thereby inhibiting PA
(Pekelharing et al 1996).

1.2.7.2 Pig binding to Fibrin

Both glu- and lys-plg can bind to fibrin with lys-plg having a higher affini
(Kd = 0.32|iM) for both noncross-linked and crosslinked fibrin than glu-plg

(Kd = 38^M) (Lucas et al 1983). These binding sites for pig pre-exist in int

fibrin and are not modified by the presence of tPA (Fleury et al 1993). More
glu- and lys-plg can bind to non-crosslinked fibrin compared to crosslinked
fibrin (Sakata et al 1984). This difference is apparently due to structural

changes in the fibrin a-chain which reduces either the affinity or number of
binding sites (Sakata et al 1984).

Initial plm digestion of fibrin generates new high affinity binding sites (C

terminal lysine residues) for glu-plg (Kd = 0.3uM) (Trang-Thang et al (1986)
which accelerates PA and hence fibrinolysis. (Bok & Mangel 1985; Harpel et
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al 1985; Fluery et al 1993). Pig binding to fibrin is mediated by two fibrin-

binding domains: a high affinity site in K5 and a lower affinity site in Kl-3
(Wu et al 1990). It is however the binding via K5 which is thought to be
essential for tPA-catalysed PA to proceed (Wu et al 1990).

Pig binding to fibrin can be both enhanced and dampened by several
proteins. The mechanism by which plg-Rs and fibrin fragments enhance pig
binding and activation is similar but not identical (Felez et al 1996). Pig
binding and subsequent activation on fibrin is enhanced by staplabin due to
a conformational change in pig which is different from that induced by
lysine analogues (Takayasu et al 1997). Pig binding to fibrin and subsequent
fibrinolysis is enhanced by chloropeptin I (Tachikawa et al, 1997a) and
complestatin (Tachikawa et al, 1997b).

Pig binding to plm-modified fibrin is inhibited by apolipoprotein(a) [apo (a)

by the formation of solution phase plg:apo(a) complexes (Sangrar et al 1997).
Apo(a) can also bind to C-terminal lysine residues on the surface of fibrin
and this binding increases following treatment with plm which blocks pig
binding (Angles-Cano et al 1994). This suggests that apo(a) binding may
impair fibrinolysis (Angles-Cano et al 1994). The mechanism for this
inhibition is due to the strong homology between pig and apo(a) (AnglesCano 1994). Additionally, small antimicrobial peptides called defensins can
compete with pig for binding to fibrin due to defensin having close
structural similarity to pig kringles (Higazi et al, 1995). This caused the
inhibition of tPA-catalysed fibrinolysis.
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1.2.7.3 Pig binding to other proteins
Pig can specifically bind to several other proteins including histidineproline-rich glycoprotein (Leung, 1986) which is has been suggested to play
physiological role in fibrinolysis considering that approximately 50% of
serum pig is bound to HPRG (Lijnen et al 1980). Like binding to other
proteins, pig binding to HPRG stimulates tPA-induced activation (Borza &
Morgan 1997). Pig can bind, in a lysine-dependent, manner to apolipoprotein
(A) in a 1:1 stoichiometry (Sangrar et al 1997). Complement component C7
is a plasminogen-binding protein and is mediated by the LBS of pig
(Reinartz et al 1995). Pig can bind, with relatively high affinity to the
multifunctional platelet a-granule thrombospondin (TSP) via the LBS
(Silverstein et al 1984). uPA and tPA have been shown to increase pig
binding to TSP via the generation of cryptic C-terminal lysine residues by

small amounts of plm (Silverstein et al 1986). Once again this is an example

of the positive feedback loop in the PA system. Plm generated on TSP is also
protected from a2-AP (Silverstein et al 1985). Pig can bind to tissue factor
which is mediated by the LBS in Kl and 3 (Fan et al 1998). Pig has been
shown to bind to vitronectin following plm modification due to the
liberation of C-terminal lysine residues (Kost et al 1996).

1.3 The mechanism of plasminogen activation

The first step in the activation pathway is the binding of pig to a C-termin
lysine residue on either a plg-R, fibrin or ECM component. This binding

event induces a reversible structural transition from the closed to the open
conformation, which exposes the Arg561-VaP2 activation bond thus
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stimulating activation by u P A (Peltz et al 1982) or tPA Hoylaerts et al 1982).
The overall mechanism for the conversion of glu-plg to lys-plm is
illustrated in Fig 1.4.

uPA/tPA
Glu-plm

Glu-plg

Plm

Plm

uPA/tPA
Lys-plg

\

Lys-plm

Fig 1.4: Overall pathway of activation of glu-plg to lys-plm (Adapted from
Castellino 1995).

Initially t P A / u P A cleaves glu-plg at the Arg561-Val562 peptide bond which
generates a small amount of glu-plm. This glu-plm then cleaves a 77 amino
acid peptide from the amino terminus of glu-plm to generate lys-plm, or
from the amino terminus of glu-plg to yield lys-plg. Lys-plg is then
converted to lys-plm via the activity of uPA/tPA. The key feature of this
pathway is that the end product (i.e plm) is able to feed back and activate
more pig. In this manner PA can be accelerated quickly to generate large
quantities of plm.
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A s P A proceeds plm degrades fibrin or E C M components which generates
additional lysine residues thus facilitating the binding and activation of
more glu-plg. Cellular pig binding has been shown to increase when cells
are pretreated with plm (Comacho et al 1989; Ouimet et al 1994; Gase et al
1996). Plm bound to the surface of macrophages is also capable of
autoproteolysis which has been proposed to be another mechanism for

regulating membrane-bound plm activity (Falcone et al 1994). Pig binding is
also increased on fibrin that has been partially degraded with plm (Bok &
Mangel 1985).

1.4 Roles of plasminogen activation

The main physiological role of PA is fibrinolysis but it also contributes t
processes of cell migration (e.g angiogenesis, metastasis, inflammation,
wound healing, bacterial invasion), tissue remodelling and development,
ovulation and the activation of growth factors and other protease classes.
Although a myriad of in vitro studies have supported these diverse roles,
the development of pig 'knockout' mice have proven a vital model to
ascertain the in vivo role/s of PA.

Pig-deficient mice exhibit impaired thrombolysis which leads to
spontaneous fibrin deposition in various organs including the liver, lungs

and stomach (Ploplis et al 1995). The thrombolytic activity of these mice c
be restored by the bolus administration of pig (Lijnen et al 1996). Pig-

deficient mice also suffer from reduced fertility and retarded growth (Plo
et al 1995), and are protected from tPA-induced neuronal degeneration

44

(Tsirka et al 1997a & b). The role of P A in metastasis is supported by
'knockout' mouse studies showing that PA contributes to the morbidity and
mortality of lewis lung carcinoma (Bugge et al 1997) and metastasis of
polyoma virus middle T antigen-induced mammary cancer (Bugge et al
1998). A role for PA in wound healing is supported by studies showing that
pig-deficient mice exhibit defects in corneal epithelial healing (Kao et al
1998). Future knockout mouse studies will confirm/refute the other
proposed roles of PA in addition to the potential discovery of other roles.

1.4.1 Fibrinolysis
The predominant role of PA (i.e plm) is the proteolytic degradation of fibrin
clots (fibrinolysis). The formation of a fibrin clot is a complex process
involving the cleavage of fibrinogen (340kDa) initially by thrombin, and
then by Factor XIII and plm. The process of fibrin formation and clot
dissolution is summarised in Figure 1.5. Plm is responsible for degrading
fibrin I and cross-linked fibrin H polymers that yields fragment X polymers
which are inturn degraded to yield fibrin fragments D and E.

Fibrin and fibrinogen possess binding sites (C-terminal lysine residues) for
pig and tPA which facilitate the binding of both to the clot and the
progression of tPA-induced' PA. As plm degrades the clot, new C-terminal
lysine residues are exposed which allow more pig to bind and be activated,

thereby accelerating PA. In this way polymerised fibrin acts as both a catalyst
and substrate for PA (Fluery et al 1993). Plm is also able to 'feedback' and
activate both tPA and pig. a2-AP is also incorporated into the fibrin clot by
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Figure 1.5: Hypothesised model of fibrin formation and dissolution by plm
(adapted from Mullertz 1987)

cross-linking with the a-chain of fibrin (Aoki et al 1983). The rate of
fibrinolysis appears to be determined by the initial amount of

(Aoki et al 1983). PAI-1 secreted by endothelial cells is also i

the developing fibrin clot (Handt et al 1994). This ensures that
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is degraded there is a ready supply of a 2 -AP and PAI-1 to inhibit the free p l m
and tPA. Additionally serum a2-AP or a2-MG can also switch off released
plm.

1.4.2 Cell migration
Considerable evidence implicates the involvement of PA in various types of
cell migration such as tumour metastasis (Ossowski & Reich 1983; Carroll &
Binder 1999), bacterial invasion (Korhonen et al 1993; Coleman et al 1995;

Virkola et al 1996; Pantzar et al 1998; Li et al 1999), inflammation (Unkele
et al 1974; Wohlwend et al 1987), trophoblast invasion (Sappino et al 1989;
Salamonsen 1999; Floridin et al 1999), keratinocyte migration during wound

healing (Morioka et al 1991; Reinartz et al 1994) and angiogenesis (Gross et
1983; Pepper et al 1993). In all cases PA causes the degradation of BM/ECM
which enables cells to either penetrate a tissue barrier or to detach from
other cells or ECM/BM.

1.4.2.1 Cancer invasion and metastasis
The complex process of tumour cell invasion and metastasis involves a
cascade of events including the detachment of neoplastic cells from a
primary tumour mass, dissolution of the BM/ECM, migration of the
neoplastic cell into (intravasation) and then out (extravasation) of the

capillary endothelial lumen and finally the establishment of a metastatic fo

at a distant site (Blood and Zetter 1990). Angiogenesis also plays a key rol
this process by providing new blood vessels to the primary tumour mass.
These newly generated blood vessels provide nourishment to the expanding
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metastatic foci and also serve as pathways for tumour cell entry into the
circulation (Liotta and Stetler-Stevenson 1991). The ECM/BM is the major

barrier to tumour cell invasion and is thus the target for any cell-surface
proteolytic activity. This proteolytic activity breaks celhcell and
cell:ECM/BM attachments and facilitates cell migration not unlike other
normal processes of cell migration such as angiogenesis and monocyte
migration.

Strong evidence supports the involvement of various proteases in
metastasis including metalloproteases, plasminogen activators,
heparitinases, cathepsins and elastases (Blood and Zetter 1990). These
proteases either directly attack the ECM or activate other proteases which
turn degrade ECM. For example, a proteolytic cascade involving both
uPA/plm and collagenase IV is necessary for the invasion of basement

membranes by metastatic cells (Reich et al 1988). Most proteases operate at
very localised sites near the cell:ECM/BM boundary where the amount of

active protease outbalances its inhibitor/s (Brown et al 1990). Although th

ability of cancer cells to metastasise may be related to an increase in pro
production/secretion it may also be related to a decrease in inhibitor
concentration (Mignatti & Rifkin 1993).

Numerous studies have shown that various components of the PA system

are increased during certain types of cancer. There is an increased presenc
of components of the PA system in lymph node metastasis (Burtin et al

1987) and on a range of large lung cancer cell lines (Pappot & Brunner 1995
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u P A and u P A R production is elevated in ovarian carcinoma cells (Moser et
al 1994) and malignant ovarian tumours (Pujade-Lauraine et al 1993). uPA
is produced by malignant squamous cell carcinoma but not by basal cell
carcinoma (Sappino et al 1991). High levels of tPA are produced by
melanoma cells (Quax et al 1991). Several studies have shown that uPA and
uPAR are expressed at invading foci in colon (Pyke et al 1991) and lung
cancer (Brodt et al 1992). uPA and tPA are also secreted by leukemic cells

(Wilson et al 1983). Invasive prostate cancer cell lines have been shown to

express 10-fold more uPA than their benign counterparts (Hollas et al 1992)

Various studies have indicated that uPA is important for ECM/BM
degradation and invasion. Antibodies against uPA have been shown to
inhibit or prevent metastasis of human carcinoma Hep3 in a chick embryo
model (Ossowski & Reich 1983). Indirect evidence (Ossowski 1988)
implicates uPA as playing an essential role in tumour cell intravasation.
The metastatic potential of melanoma cells has been correlated with uPA
secretion (Yu & Schultz 1990). uPA expression on the surface of melanoma

cells is crucial for their ability to degrade fibronectin (Hearing et al 19
uPA and tPA-catalysed PA are essential for in vitro invasion of human
melanoma cells (Meissauer et al 1991). The presence of active uPA is

essential for in vitro invasion of tumour cells through BM (Kobayashi et al
1993).

Experimental evidence also suggests an important role for uPAR and
subsequently uPA binding to uPAR in cancer invasion and metastasis.

49

u P A R expression on osteosarcoma cells has been shown to facilitate matrix

degradation and invasion (Kariko et a, 1991) via the binding and activatio
of uPA. Overexpression of uPAR in a human osteosarcoma cell line has
been shown to increase ECM invasion (Kariko et al 1993. uPA binding to
uPAR has also been shown to be vital for the in vitro metastasis of lewis
lung carcinoma (Brodt et al 1992; Kobayashi et al 1994). Malignancy of
human fibroblasts is also correlated with increased receptor-bound uPA
activity (Jankun et al 1991).

Experimental evidence also points to a role for PAI-1 in tumour cell
invasion and metastasis. PAI-1 apparently inhibits uPA-induced tissue
degradation in murine Lewis Lung carcinoma while it is absent from areas
where tissue destruction is evident (Kristensen et al 1990). This has
generated the hypothesis that PAI-1 may protect the ECM in tumour tissue

against uPA-induced dissolution (Pyke et al 1991). Several lines of eviden

also indicate that cancer cells secrete and thus may utilise PAI-1 to prot
themselves from uPA-mediated tissue degradation (Skriver et al 1984;
Kristensen et al 1990; Sappino et al 1991). Additionally lung carcinomas

with the worst clinical prognosis no longer express PAI-1 (Gris et al 1993
which may permit cancer spread.

Convincing clinical evidence for the involvement of PA in cancer is
provided by studies showing that uPA and PAI-1 levels are independent and

significant prognostic indicators of survival in breast cancer patients (D

et al 1990; Janicke et al 1991; Foekens et al 1992; Grondahl-Hansen et al 19
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PAI-2 has also been shown to have some prognostic value in breast cancer
(Bouchet et al 1994). PAI-1 and uPA have also been demonstrated to have

prognostic significance in gastric (Nekarda et al 1994), colorectal (Gane

1994; Mulcahy et al 1994) and bladder cancer (Hasui et al 1994). Evidence
suggests that PAI-2 may be a marker for certain types of myelomocytic
leukemia (Scherrer et al 1991; Wada et al 1993).

The main contribution of PA to metastasis is ECM degradation which

enables cells to move, however, evidence is emerging that PA is important

for releasing certain growth/angiogeneic factors (e.g. bFGF and TGF-fij)
the ECM that contribute to the metastatic process. Thrombospondin (TSP)
and TGFfi promote PAI-1 production in human lung carcinoma cells which

facilitates tumor cell attachment (Albo et al 1994). Retraction of endoth

cells which is an important step in the extravasation of blood and metas

cells has been shown to be due to PA (Conforti et al 1994). Oncogenes and
growth factors associated with cancer have been shown to increase
uPA/uPAR production or secretion. For example, ras-oncogene

transformed malignant fibroblasts exhibit significantly higher levels of
receptor-bound tPA than their untransformed counterparts (Jankun et al
1991). uPA gene expression has also been shown to be induced by the src
oncogene product and tumour promoters (Bell et al 1990).

The logical mechanism of uPA-mediated metastasis is via the activation of
plm which in turn degrades ECM/BM components or activates other
protease classes. An alternate mechanism is via the direct action of uPA
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which has been shown to directly hydrolyse fibronectin (Gold et al 1989) and
activate collagenase IV (Reith et al 1992). Vitronectin-dependent carcinoma
cell migration, mediated by integrin avfi5, is also dependent on uPARbound uPA (Yebra et al 1996).

1.4.2.2 Angiogenesis
Angiogenesis is the formation of new blood vessels by the endothelium and
is important in embryo and organ development, wound healing and
tumour growth. It is a complex process which involves the degradation of
the BM by endothelial cells; the migration of endothelial cells towards an

angiogenic stimulus; infiltration of endothelial cells into the perivascula
stroma; and proliferation of endothelial cells to form the new lumen
(Ausprunk & Folkman 1977). Several protease systems have been
implicated in angiogenesis particularly the PA and metalloproteases systems
which play key roles in BM/ECM degradation and the invasive process of
angiogenesis (Mignatti et al 1989).

Numerous studies have shown that endothelial cells can bind (Hajjar et al
1986; Miles et al 1988; Felez et al 1993) and activate pig via the presence
specific plg-Rs such as actin (Dudani et al 1996) and Annexin II (Hajjar et
1994). Both uPA (Miles et al 1988) and tPA (Beebe 1987; Hajjar et al 1987;

Cheng et al 1992; Felez et al 1993) can bind to endothelial cells. Migrating
endothelial cells have been shown to upregulate both uPAR expression and
uPA production via bFGF (Pepper et al 1993). This results in an increase in
receptor-bound uPA which in turn increases PA.
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Angiogenesis seems to be regulated by various cell:ECM/BM interactions in
addition to anti/angiogenic factors. bFGF is one such angiogeneic factor
which has been shown to increase the production of uPA and uPAR by

endothelial cells (Moscatelli et al 1986; Rifkin et al 1990; Mignatti et al 1
Plm can also cause the release of bound bFGF from ECM via the proteolytic
cleavage of proteoglycans (Rifkin et al 1990). Another potent angiogenic
factor is vascular endothelial growth factor (VEGF) which increases uPARexpression on endothelial cells (Mandriota et al 1995). TGFfi is an antiangiogenic factor which as been shown to be a potent inhibitor of

endothelial cell uPA production (Rifkin et al 1990). The activation of laten

TGFfi to TGFfi requires plm (Lyons et al 1990; Rifkin et al 1990). The TGFfi
thus formed causes an increase in PAI-1 in endothelial and smooth muscle
cells which acts to dampen any further TGFfi activation via plm (Rifkin et
1990; Sato et al 1990).

Recently, a 32kDa form of pig consisting of the internal 342 amino acid
fragment (i.e. Kl-3), has been found to act as an anti-angiogenic factor
(O'Reilly et al 1994). This protein, called angiostatin, has been found to
induce and sustain dormancy of human primary tumors in mice via
apoptotic mechanisms (O'Reilly et al 1996).

1.4.2.3 Inflammation
Cells that are involved in the inflammatory response such as monocytes,
macrophages and lymphocytes produce, secrete and/or utilise various
components of the PA system in order to migrate to inflammatory sites. For
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example, u P A R is polarised to the leading edge of migrating monocytes

(Estreicher et al 1990) and is also present on lymphocytes (Miles et a

Macrophages have been shown to secrete both uPA (Unkeless et al 1974)

PAI-2 (Wohlwend et al 1987) with uPA production being a marker of the
activation state of inflammatory macrophages (Vassalli et al 1992).
Additionally, uPAR in association with fi2-integrins is required for
migration to inflamed areas (May et al 1998).

Various inflammatory mediators have been shown to modulate
components of the PA system. PA is increased in the presence of IFNy

decreased in the presence of M-CSF (Vassalli et al 1992). Peripheral b

monocytes produce uPA and tPA in response to LPS and IL-4 (Hart et al

1989). PMA, LPS, IL-1 and TNF induce PAI-2 in monocytic cells while a

inflammatory agents such as dexamethasone and IL-4 downregulate PAI-2

(Kruithof et al 1995). Plg/plm receptors are decreased in response to
dexamethasone (Pollanen et al 1989). IL-1 increases uPA synthesis in
synovial fibroblasts (Hamilton et al 1991)

1.4.2.4 Bacterial Invasion

Numerous bacteria can bind and activate pig (refer Table 1.4) by virt

presence of plg-Rs, such as G3PDH, and it is the plm generated on the

of these cells which has been hypothesised to promote penetration int
tissue (Sako & Tsuchida 1983; Parkkinen & Korhonen 1989; Korhonen et

1993). Infact, plm generation on the surface of Borrelia burgdoferi en

the penetration of endothelial monolayers (Coleman et al 1995). PA occ
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on the surface of Helicobacter pylori which has been proposed to be a
mechanism for gastric tissue penetration (Pantzar et al 1998). Cell surface

uPA has been found to be critical for the spread of Yersinia pestis from the
original site of infection (Sodeinde et al 1992). The ability of both
Streptcoccus enterica (Lahteenmaki et al 1995) and Haemophilus influenzae

(Virkola et al 1996) to penetrate a reconstituted BM is due to cell-surface
Pathogenic strains of group A streptococci, not only possess plg-Rs but can

also secrete SK which generates plm (Wang et al 1994). A similar story holds
for certain strains of Staphylococcus aureus which produce STA (Sako &
Tsuchida 1983). Thus certain bacteria are equipped with both plg-Rs and pig
activators which would appear to contribute to their virulence.

1.4.3 Activation of prohormones and growth factors

Evidence is emerging that plm can activate a variety of proteases and growth
factors that are important for processes like tissue remodelling,
inflammation and angiogenesis. Plm has been shown to directly or

indirectly activate connective tissue metalloproteinases such as stromelysi
collagenase and gelatinase (Murphy et al 1992). Specifically, plm is
responsible for activating proMMP-1, 3 and 9 (Nagase & Salvesen 1993).
Several studies have shown that plm-dependent ECM degradation can

actually release bound growth factors such as bFGF (Rifkin et al 1990; Falc

et al 1993 & 1994) and TGF-fi (Taipale et al 1992; Falcone et al 1993 & 1994
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1.4.4 Tissue remodelling and development
The development, differentiation and remodelling of tissues consists of
three steps that involve the direct input of the PA system - detachment

cells from the substratum (ECM/BM) and surrounding cells, cell migration
and cell adhesion. From the earliest moments of life, plm-catalysed ECM
degradation and cell adhesion occur. For example, uPA is temporally

expressed in trophoblast cells during both the implantation and early g
of the embryo (Sappino et al 1989).

Cell detachment utilises the direct proteolytic input of plm which degr
various ECM components such as laminin (Moser et al 1993), fibronectin

(Wang et al 1994), type IV collagen (Mackay et al 1990) and proteoglycan

(Richardson et al 1988). Plm can also activate metalloproteases (He et a

1989; Mazzieri et al 1997) which inturn can promote ECM degradation. One
of the key regulatory mechanisms of cell detachment is the localisation

various components of the PA system to sites where detachment is initia

uPA is located at descrete cell:substratum and cell:cell contacts (Poll

1987); scuPA, tcuPA and uPAR are confined to focal adhesions and cell-ce

contacts (Myohanen et al 1993); cell surface uPA co-localises with vincu

(Myohanen et al 1993; Hebert & Baker 1988) and is found in close proximi

to avfi3 integrin at focal adhesion sites (Myohanen et al 1993). In contr

the broad distribution of pig throughout the ECM by virtue of its specif
interaction with various ECM components (refer section 1.2.6.7.1).
Additionally PAI-1 is distributed evenly over the cellular substratum
(Pollanen et al 1987).
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Evidence is accumulating that u P A / u P A R

contributes to cell adhesion

independent of plm generation. The adhesion and migration of monocytic
cells requires both uPAR and inactive uPA (Nusrat & Chapman 1991;
Gyetko et al 1994) which led some to hypothesise (Chapman 1997) that uPAR
could couple to the cytoskeleton and mediate adhesion and migration.
Vitronectin can bind with high affinity to uPAR (Hoyer-Hansen et al 1992)
which is a logical explanation for the ability of uPAR to promote cell
adhesion. Additionally the association of uPAR with leukocyte fi2-integrins
is required for leukocyte endothelial cell interactions and migration to

inflamed areas (May et al 1998). Pig itself has been shown to be essential fo
the adhesion of leukemic cells to type I collagen (Martinez & Santibanez
1994).

There is evidence that PA also plays a role in normal epidermal
differentiation. Studies have shown that PAI-2 is distributed throughout
the epidermis (Kruithof et al 1995). Additionally, uPA and PAI-1 are
associated with the least differentiated keratinocytes while tPA is found
associated with more differentiated keratinocytes (Chen et al 1993).

1.4.5 Ovulation
Ovulation is the process whereby oocytes are released from a mature

ovarian follicle via the proteolytic degradation of the follicular wall. Thi
a particularly complex and dynamic process that is preceded by the
development and differentiation of the follicle. The collective process of
follicular development, differentiation and ovulation involves numerous
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extracellular proteolytic events including the generation of plm.

Early

studies indicated a positive correlation between ovulation and PA (Beers

1975; Beers et al 1975; Strickland & Beers 1976). Additionally, ovulation can
be suppressed with a2-AP or a-tPA antibodies (Tsafriri et al 1989).

Pig is found in follicular fluid at levels equivalent to that in serum (Beers
1975), with uPA, tPA and PAI-1 all found to be present in ovaries (Beers
1975; Liu et al 1991). tPA and PAI-1 appear to be the main regulators of
ovarian PA with the levels of both being regulated by the same set of
hormones that control ovulation (Ny et al 1993). tPA levels in granulosa

cells and follicular fluid are increased sharply just prior to ovulation (Lu

al 1991; Peng et al 1993; Reich et al 1986) while a corresponding decrease in

PAI-1 levels occur (Reich et al 1986). The secretion of tPA by granulosa cell
is stimulated by the major ovulatory hormones follicle stimulating
hormone and luteinizing hormone (Ny et al 1993).

Oocytes themselves are able to sythesize tPA (Huarte et al 1985; Liu et al 19
Sappino et al 1989) with levels increasing dramatically during ovulation

(Liu et al 1985; Sappino et al 1989; Bicsak et al 1989). The role of oocyte t
unknown but it has been speculated that plm could facilitate follicular
disruption and prevent premature clot formation in the ovarian stigma
(Huarte et al 1985). Additionally plm could prevent premature arrest of the
preimplantation embryo by blocking egg adhesion to fibrin deposits
(Liedholm & Astedt 1975; Huarte et al 1985; Sappino et al 1989). uPA
sythesized by epithelial cells in the male genital binds to spermatozoa and
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m a y then participate in the proteolytic events involved in capacitation and
fertilisation (Huarte et al 1987).

1.4.6 Cell death
Necrosis and apoptosis are the two mechanisms whereby cells die. Necrosis
is a non-specific form of cell death characterised by a loss in plasma
membrane integrity, cytomplasmic swelling and progressive damage to
organelles (Wyllie et al 1980). In contrast, apoptosis is a genetically
controlled form of cell death which contributes to development and tissue
homeostasis (Wilson 1998) in addition to a variety of diseases including
AIDS, cancer, alzheimer's disease, stroke (Whyte 1996) and rheumatoid
arthritis (Hasunuma et al 1997). Apoptosis is a complex process involving a
myriad of structural and biochemical changes ultimately leading to the
dissolution and resorption of cells by the body. Apoptosis consists of three
distinct stages: (1) induction which involves a cell receiving a death signal
from a specific apoptotic inducer (e.g chemical, inflammatory mediator, uv

light etc); (2) execution where a series of biochemical changes induced by the
death signal progress to a point where the cell is committed to die - the
'point of no return'; (3) degradation where the cells are essentially
autodigested and packaged ready for engulfment by macrophages.

Apoptosis is characterised by an ordered progression of morphological
changes yet a heterogenous series of biochemical changes involving several
pathways that utilise different genes and enzymes (Sen & DTncalci 1992;
Williams & Smith 1993). The biochemical events of the initiation phase are
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determined by the type of apoptotic inducer and vary from one cell type to
another. During the execution phase the heterogenous pathways of
initiation converge into a homogenous death pathway that ultimately leads
to the degradative phase. The major changes occurring during apoptosis
include chromatin condensation (Wyllie et al 1980), decreased membrane

phospholipid packing (Mower et al 1994), cell shrinkage (Mower et al 1994),
plasma membrane blebbing, internucleosomal DNA fragmentation, and

phosphatidyserine (PS) exposure, the latter being important for stimulatin
phagocytosis of apoptotic cells by macrophages thereby preventing
inflammation (Savill et al 1993). Each of these characteristics can be
measured using a variety of techniques, for example cell shrinkage and
membrane blebbing can be measured microscopically or by flow cytometry,
DNA fragmentation can be measured using agarose gel electrophoresis and
PS exposure can be measured via the flow cytometric analysis of Annexin-V
binding.

1.4.6.1 The role of proteases in apoptosis
Numerous proteases are involved in both the initiation and progression of

apoptosis including caspases (e.g ICE, CPP32, Nedd-2/Ich-lL, TX ICErel II/Ich
ICErel III, Mch2), perforin, serine proteases (e.g granzymes, fragmentin-2,

elastase) and calpains (Patel at al 1996). The targets of apoptotic proteas

include both structural (e.g fi-actin, laminin, histones, fodrin, non-lami
nuclear matrix proteins) and functional proteins [e.g poly (ADP-ribose)
polymerase, 70kDa polypeptide of the Ul small nuclear ribonuclear protein,

endonucleases, nucleolin, PITSLREfil protein kinase, topoisomerase 1] (Pat
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et al 1996). Therefore apoptotic proteases are responsible for activating other
proteases/factors or digesting the cellular architecture which leads to the
characteristic morphological changes. Apoptosis then must be considered as
being regulated, to some extent, by proteases.

1.4.6.2 The role of serine proteases in apoptosis
A group of serine proteases called granzymes (granule-associated enzymes)

are critical for induction of apoptosis in virally infected and malignant cell
by cytotoxic T lymphocytes (CTL) and natural killer (NK) cells. The
recognition and subsequent interaction of a CTL with the target cell causes
the exocytosis of cytoplasmic granules which contain a 66-70kDa poreforming protein called perforin (Smyth et al 1995). Perforin monomers
insert into the target cell membrane and aggregate to form pores which
facilitate the entry of granzymes into the target cell (Liu et al 1995).
Granzymes thus synergise with perforin to induce target cell DNA
fragmentation and chromatin condensation (Jans et al 1988).

Granzymes have been divided into three categories: (1) tryptases such as
Granzyme A (GrA) and Tryp-2; (2) aspases such as Granzyme B (GrB), and (3)
metases (elastase-like) such as Met-1 (Smyth et al 1996). The division of
granzymes is based on both genetic information and their substrate
specificities, with each group able to preferentially cleave one or more
specific amino acid residues. Granzymes contain the same catalytic triad that

is characteristic of all serine proteases - His57, Asp102 and Ser1" (Smyth et al
1996). GrA or fragmentin-1 is the most abundant granzyme and cleaves
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target proteins such as nucleolin (Pasternack et al 1991), IL-lfi (Irmler et al
1995) and the thrombin receptor (Suidan et al 1994) at basic amino acid
residues (Poe et al 1991). GrB (or fragmentin-2) cleaves target proteins at

aspartic acid and glutamic acid residues (Poe et al 1991) and has been shown
to participate in apoptosis via the activation of caspase-10. GrB also
participates in a secondary apoptotic mechanism involving the activation of

other caspases such as caspase 7 and 3 (Talanian et al 1997). Both GrA and B
have been shown to accumulate in the nucleus via a novel nuclear import

pathway that requires perforin (Jans et al 1998). The specificity of several
granzymes (such as granzymes C to H) remains to be defined (Smyth et al
1996).

Increasing evidence suggests a prominent role for the serine protease
thrombin in apoptotic cell death. Apoptotic smooth muscle cells were
shown to generate significant levels of thrombin following PS exposure
(Flynn et al 1997). This process could be inhibited with Annexin V
suggesting that pro/thrombin binds to PS during serum starvation-induced
apoptosis. Additionally, thrombin has been shown to decrease neutrite
length, neutrite branching and induce motoneuron death via an apoptotic
mechanism (Turgeon et al 1998).

1.4.6.3 The role of PA in cell death
Evidence is accumulating that components of the PA system are somehow
involved in cell death processes. Some confusion exists since it has been
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suggested that P A m a y contribute to the death process or play as yet
undefined cytoprotective roles.

Independent studies have shown that pig binding is increased on dead

epithelial cells (Green 1978), damaged amniotic epithelial cells (Burgos et a

1982; Jenkins et al 1983) necrotic breast cancer epithelial cells (Burtin et
1985; Ranson et al 1998) and apoptotic/necrotic U937 cells (O'Mullane &
Baker 1998). Equally, "knockout" mouse studies have suggested that PA

plays a role in tPA-mediated neuronal cell degeneration (Tsirka et al 1997a &
b) where pig synthesis increases during kainic acid-induced
neurodegeneration. Here PA may contribute to neuronal death by
disrupting cell:ECM interactions (Matsuoka et al 1998). In contrast, other
studies have shown that pig may act as a neuroprotectant against nitric
oxide-induced neuronal apoptosis (Toku et al 1998). Additionally, uPA
mRNA is increased in granulosa cells undergoing apoptosis (Johnson et al

1997). Apoptosis of large dysplastic hepatocytes is associated with an increa
in uPA (Santonirugiu et al 1996). Also, tPA is increased 50-fold in X-ray
irradiated melanoma cells (Boothman et al 1991) and may play a role in
inducible repair systems of mammalian cells (Boothman et al 1994). In
contrast, apoptotic endothelial cells were shown to have greatly reduced
levels of tPA, PAI-1, PAI-2 and uPAR, however uPA levels remained
unchanged compared to their non-apoptotic counterparts (Zoellner et al
1998). Inflammatory mediators such as TNFa, that are known to induce
apoptosis in a range of cell types, can also increase uPA mRNA (Simonitsch
& Krupitza 1998) and this has led some to suggest that uPA may facilitate
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anoikis (cell detachment) during TNFa-induced apoptosis (Simonitsch &
Krupitza 1998). Thrombin activity can be generated by apoptotic vascular
smooth muscle cells after phosphatidylserine exposure (Flynn et al 1997)
which in turn could activate uPA and subsequently pig. Finally,
overexpression of pig has been shown to be cytotoxic to mammalian cells
(Busby et al 1991).

PAIs have been recently implicated in protection against some apoptotic

stimuli. For example, a cleaved intracellular PAI-2 isoform was found to be
a biochemical marker of apoptosis in the human promyelocytic leukemic

cell line NB4 (Jensen et al 1994) and overexpression of intracellular PAI-2
resulted in protection against TNFa-induced apoptosis (Dickinson et al

1995), the cytopathic effects of alphavirus infection (Antalis et al 1988) a
infection of human macrophages with Mycobacterium avium (Gan et al

1995). As uPA and tPA are established cognate serine protease targets of PA

2 it is logical to assume that the cytoprotective ability of PAI-2 might ha

been due to the inhibition of either uPA or tPA activity, however, this has

not been shown. Equally the ability of PAI-2 to act as a competitive substr
in these models has not been examined. Recent evidence however, has
shown that PAI-2 can induce IFN-a/fi and ISGF3 genes, which subsequently

stimulate antiviral genes (Antalis et al 1998) and that the distribution of
2 in hair and nail is appropriately positioned to protect epithelial cells
apoptosis (Lavker et al 1998).
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1.5 Conclusion

PA is vital for a range of extracellular biological processes due to th
substrate specificity of plm. It is subtle changes in the cell-surface

concentrations of pig, pig activators, serpins, plm inhibitors, receptor

binding determinates and substrates that determines the role of PA at a
given time.

Although the regulatory input of uPAR has been extensively studied duri
such processes as tumor cell invasion and metastasis, only fundamental

studies on plg-Rs have been performed. This has probably been due to th

fact that plg-R candidates are a heterogenous group of molecules that s
to be restricted to specific cell types. It is imperative to determine

contribution of plg-Rs to biological processes such as cell migration s
they are a critical regulatory component of PA.

The list of roles for PA is growing with recent evidence suggesting a r

PA in cell death playing either a cytodestructive or cytoprotective rol

There is clearly a need to examine the contribution of plg-Rs and hence
to cell death.

1.6 Thesis Objectives

This thesis examines the binding of native human pig to viable and non-

viable subpopulations of cancer cells with an emphasis on the role of p

binding and activation during apoptosis. A major component of this thes
is the development of novel flow cytometric assays for measuring pig
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binding (i.e plg-R expression) and P A (i.e p l m generation) on specific
subpopulations of cells (i.e viable, apoptotic and necrotic cells). The
following chapter is a preliminary investigation into both plg-R expression
on several cancer cell lines utilising

125

I-plg binding assays, and the isolation

of several plg-R candidates from HCT116 colon carcinoma cells. Chapter 3
describes the development of a flow cytometric pig binding assay and the
characterisation of pig binding to viable and non-viable subpopulations of
cells. Chapter 4 utilises this assay to investigate plg-R expression on
apoptotic cells. Chapter 5 details the development of a flow cytometric PA
assay and measures PA on viable, apoptotic and necrotic cells. Finally,
Chapter 6 chronicles plg-R expression during apoptosis and the influence of
pig on the entry of cells into apoptosis.

Chapter 2

Preliminary Plasminogen Binding
and Receptor Isolation Studies
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2.1 INTRODUCTION
Cellular pig binding is a dynamic process with numerous studies suggesting
that it is specific, lysine-dependent, reversible, concentration dependent and

saturable. Another important characteristic is its low affinity with reported K
ranging from 0.024-200nM on prokaryotes (refer Table 1.4) and 0.0158-5uM on
eukaryotes (refer Table 1.5). Although a specific receptor for uPA has been

identified (Cubellis et al 1986) that facilitates uPA binding to a variety of c
types (refer Table 1.1), plg-Rs appear to be a heterogenous group of molecules
that are typically proteins with C-terminal lysine residues. Although pig
binding is a widely observed phenomenon, most proteinacious plg-R

candidates appear to be restricted to specific cell types (refer Table 1.3). Th
contribution of cell surface carbohydrates or lipids to pig binding has been
poorly studied which is puzzling considering that some non-proteinacious

molecules, such as gangliosides, have been reported to function both as pig and
uPA binding sites on U937 cells (Miles et al 1989).

Pig binding has been historically studied using radioligand binding assays.
Typically pig is labelled with

125

I, incubated with cells and the amount of

radioactivity then quantified using a scintillation counter. The ability of lys
analogues such as TA and e-ACA to inhibit pig binding has formed an integral
component of these assays as they enable the measurement of non-specific (i.e
non lysine-independent) binding. Although non-specific binding can also be
measured using a large (i.e 50-100-fold) molar excess of unlabelled pig all
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researchers have appeared to favour the use of lysine analogues. Besides the
handling and disposal of radioactive material, one of the major disadvantages
of using

125

I-plg binding assays is that they do not enable the measurement of

pig binding on specific subpopulations of cells (e.g cells in different stages o

cell cycle). Thus if pig binding varies between subpopulation of cells within the
total population these differences will be undetectable. An additional problem
is the need to wash away unbound

125

I-plg in order to measure cell-associated

radioactivity. This action affectively reduces the free concentration of ligand
(i.e pig) and since pig binding is a concentration-dependent and reversible
interaction, cell-bound pig will dissociate in order to re-establish equilibrium
binding (i.e where the concentration of free pig is in equilibrium with bound

Pig)-

The identification of the cell-surface molecules responsible for pig binding has
predominantly focussed on proteins with little credence given to the input of
cell-surface lipids or carbohydrates. All of the proteinacious plg-R candidates
identified to date have been isolated using pig-affinity chromatography.
Typically, pig is coupled to CNBr'-activated Sepharose 4B and a sample likely to
contain plg-Rs (e.g solubilised whole cell lysates or plasma membrane
preparations) is adsorbed. Plg-Rs are then eluted using high concentrations of
lysine or e-ACA, analysed by SDS-PAGE and then usually microsequenced.
One criticism that can be levelled at most of the work on proteinacious plg-Rs
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is that they have been isolated from whole cell lysates rather than plasma
membrane preparations.

Although there is ample evidence to suggest that uPA/uPAR plays a role in
tumour cell invasion and metastasis (refer section 1.4.2.1) no studies have
examined the role of plg-Rs in the invasive phenotype. Several plg-R
candidates have been identified on cancer cells including cytokeratin 8 on
hepatocellular carcinoma and breast cancer cells (Hembrough et al 1995), aenolase on breast cancer cells (Lopez-Alemany et al 1994) and a 50-60kDa

protein on rat colon carcinoma cells (Durliat et al 1992). Additionally pig ha

been found to bind to leukemic cells (Plow et al 1986; Felez et al 1990; Edelb

et al 1990; Gonzalez-Gronow et al 1991; Felez et al 1993; Santibanez et al 199
mammary carcinoma cells (Correc et 1990; Burtin et 1993), fibrosarcoma cells

(Pollanen 1989; Felez et al 1993), osteosarcoma cells (Campbell et al 1994) an
colon adenocarcinoma cells (Burtin & Fondaneche 1988; Comacho et al 1989.

The aim of this chapter was to: (1) measure pig binding on several cancer cell
lines using
from (1)

125

I-plg binding assays; and (2) isolate plg-Rs on a cell line sel
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2.2 MATERIALS A N D M E T H O D S

2.2.1 Materials

All cell culture reagents and plasticware were purchased from Trac

BioSciences (Sydney, Australia) except for FCS, which was purchas

(Melbourne, Australia). Human glu-plg was purified according to me

Grant (1990) or was generously provided by American Diagnostica (
(Greenwich CT, USA).

125

I was purchased from Amersham (Sydney, Aust

and Iodo-beads were purchased from Pierce (Rockford, IL, USA). Pr
NAP10 columns (Sephadex G25), Lysine Sepharose 4B, CNBR-activated
Sepharose, prepacked Superdex™ 75 HR 10/30 column, prepacked NHS-

activated Superose HR 10/2 and low molecular weight size exclusio

were purchased from Amrad Pharmacia Biotech (Sydney, Australia). S

PAGE standards, precast polyacrylamide gels, silver staining kit a

assay were purchased from Bio-Rad (Sydney, Australia). 0.2|iM and

syringe filters were purchased from Sartorius (Sydney, Australia).

indicated, all chemicals were purchased from Sigma (Sydney, Austra

2.2.2 Cell lines and cell culture

The human breast cancer cell lines MCF-7 and MDA-MB-231 were obta

from Dr R. Sutherland (Garvan Institute, Sydney Australia). The hu

cancer cell line HCT116 was provided by Dr M Baker (Dept. Biologic

University of Wollongong, Australia). The human monocytic leukemic
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line U937 was obtained from the American Type Culture Collection. All cell
lines were cultured in RPMI1640/10% FCS at 37°C in a humidified atmosphere
of 5% CO2. Adherent cells were passaged using 0.05% (w/v) trypsin/5mM
EDTA/phosphate buffered saline (PBS) to lift them into suspension.

2.2.3 Radio-iodination of plasminogen
Pig was iodinated using lodo-beads™ according to the manufacturer's
instructions (Pierce, Rockford IL, USA). Just prior to use, three beads were
washed twice with 3ml 0.1M phosphate buffer (pH 7.2). lOjal

125

I (lmCi) was

added to 0.5ml 0.1M phosphate buffer (pH 7.2) in an eppendorf tube and

allowed to react for 5min/RT. Pig (800|ig) in 500ul 0.1M phosphate buffer (pH
7.2) was added, mixed gently and allowed to react for 15min/RT. To separate
125

I-plg from free

125

I a prepacked column of Sephadex G-25 was equilibrated

with phosphate buffered saline (PBS) (pH 7.4) and the 1ml reaction sample

loaded. 12 x 0.5ml fractions were collected and the radioactivity in a 2ul sa
from each fraction measured using a y-counter (Cobra Auto Gamma, Canberra
Packard, Canberra, Australia). Those fractions containing the first peak of
radioactivity were pooled, aliquoted and stored at -20°C.

2.2.4 Preparation of Lysine Sepharose 4B

Lysine Sepharose 4B was prepared according to the manufacturer's instructions
(Amrad Pharmacia Biotech, Sydney, Australia) by swelling the powder in PBS
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overnight at 4°C. Lysine Sepharose 4B was stored in PBS containing 0.1% (w/v)
NaN3 at 4°C until required

2.2.5 Depletion of pig from FCS
FCS was heat inactivated at 56°C for 30min, cooled then filtered through a
0.45uM syringe filter to remove any particulate matter. FCS (500ml) was
circulated overnight through a 50ml Lysine Sepharose column that had been
equilibrated with PBS. All FCS was collected and filter sterilised through a
0.2|iM syringe filter aliquoted and stored at -20°C.

2.2.6 I-plg binding assays
Cells were cultured in RPMI1640/10% (v/v) pig-depleted FCS for 24h.
Adherent cells were detached using a solution of 5mM EDTA in Hank's
Balanced Salt Solution (HBSS) (pH 7.4) (Ca/Mg-free) and washed thrice with
HBSS at 37°C. Cells were incubated for lh on ice with

125

I-plg in HBSS

containing 0.1% BSA, ImM CaCl2 and ImM MgCl2. Cells were washed thrice
with HBSS at 4°C and cell-associated radioactivity measured using a y-counter
(Cobra Auto Gamma, Canberra Packard, Canberra, Australia). Lysinedependent (specific) pig binding was calculated as the difference in the
radioactivity of cells incubated solely with
incubated with

125

12D

I-plg (total binding) and cells

I-plg and lOmM TA (non-specific binding).
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2.2.7 Viable Cell counts

A lOOul aliquot of cells that had been washed once with HBSS was mixed with
lOOfil 0.4% (w/v) Trypan blue and a small amount loaded onto a
haemocytometer. Viable cells (those excluding Trypan blue) were counted in
the four 1mm corner squares. The number of viable cells/ml = average count
per four corner squares x 2 (dilution factor) x 104.

2.2.8 Plasma membrane isolation
Plasma membranes were isolated, using an established two phase polymer
system consisting of PEG and dextran, which was modified from the methods
of Klockman and Deppert (1983), and Rana and Majumber (1987). The two-

phase polymer system was prepared as follows: Dextran (Mr = 266,000) and PEG

(Mr = 20,000) were dissolved in 0.1M phosphate buffer (pH 6.5) at concentrat
of 5.5% (w/v) and 4.2% (w/v) respectively. Both phases were allowed to

separate overnight at 4°C in a separating funnel, collected and stored at 4
until required.

Adherent cells were scraped off flasks into HBSS using a cell scraper. All
were washed thrice with HBSS and resuspended in ice-cold 5mM Tris-HCl (pH
7.4) containing 5mM EDTA and ImM PMSF. Cells were allowed to swell for
15min on ice then disrupted using a dounce homogeniser. The degree of cell
breakage was monitored by light microscopy every 5 strokes, until over 80%

the cells had lysed. Cells were centrifuged at 5000rpm for lOmin in corex t
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using a Sorvall HB-4 swing-out rotor. The pellet was resuspended in 10ml top
phase (PEG) and mixed thoroughly with 10ml bottom phase (dextran) then

centrifuged at 8000rpm for lOmin at 4°C using a Sorvall HB-4 swing-out roto
Plasma membranes were aspirated from the interface of the two phases,

transferred to a clean corex tube, and the remainder of the two phases adde
the same tube. The sample was centrifuged at 8000rpm for lOmin at 4°C, the
plasma membranes aspirated off and diluted in 4 volumes of MilliQ HzO.
Plasma membranes were pelleted at 8000rpm for lOmin at 4°C and resuspended
in 1ml of solubilisation buffer [PBS (pH 7.4), ImM CaCl2 and ImM MgCl2, 1%
v/v Triton-X-100, 1% (w/v) sodium deoxycholate, ImM PMSF, 5mM EDTA].
Plasma membranes were solubilised overnight at 4°C by end-over-end mixing.
Unsolubilised material was removed by ultracentrifugation at 100,000g for
4°C. The supernatant was collected and stored at -80°C until required.

2.2.9 Coupling pig to CNBr"-activated Sepharose

CNBr'-activated Sepharose 4B was pretreated according to the manufacturer's

instructions (Amrad Pharmacia Biotech, Melbourne, Australia). Briefly, 2g d
gel was pre-swollen in 20ml ImM HC1 then washed on a glass sintered filter
with 50ml ice-cold ImM HC1. Glu-plg (lOmg) was reconstituted in 10ml
coupling buffer (0.1M NaHCO3/0.5M NaCl pH 8.3), the washed gel added and
mixed end-over-end overnight at 4°C. The plg-Sepharose was washed with 5

volumes of coupling buffer, resuspended in 10ml blocking buffer (0.1M TrisHCl pH 8) and mixed end-over-end overnight at 4°C. The gel was washed
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alternatively thrice with 0.1M sodium acetate/0.5M NaCl (pH 4) and 0.1M TrisHC1/0.5M NaCl (pH 8). Plg-Sepharose was stored in PBS/0.1% NaN3 at 4°C.

2.2.10 Coupling pig to NHS-activated Superose HR 10/2
Pig was coupled to pre-packed NHS activated Superose HR 10/2 according to
the manufacturer's instructions by FPLC (Amrad Pharmacia Biotech,
Melbourne, Australia). The column was washed with 10 column volumes of

ImM HC1 at a flow rate of lml/min. Glu-plg (lOmg) was reconstituted in 10m
coupling buffer (0.2M NaHCO3/0.5M NaCl pH 8.3) and circulated through the
column for lh at a flow rate of lml/min. The column was washed
alternatively with five column volumes of 0.1M Tris-HCl (pH 8)/0.5M NaCl
followed by ten column volumes of 0.1M sodium acetate (pH 4). This was
repeated once and the column allowed to stand for lh in 0.1M Tris-HCl (pH
8)/0.5M NaCl. The wash procedure was then repeated twice and then the
column equilibrated with Buffer A [PBS, ImM CaCl2, ImM MgCl2, ImM PMSF,
0.2% Triton-X-100 (reduced)] overnight at a flow rate of 0.5ml/min. The
column was stored in 0.1% NaN3 (v/v) in Buffer A.

2.2.11 Pig affinity chromatography

Batch elution : Plg-Sepharose was washed extensively with PBS to remove th

storage solution and equilibrated with Buffer A overnight at 4°C by end-ov
end mixing. Plasma membrane preparations were incubated with plg-

Sepharose overnight at 4°C with gentle agitation. Plg-Sepharose was washed
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extensively with buffer A and pig-binding proteins eluted with Buffer B (Buffer

A containing 0.2M TA) at 4°C with gentle agitation. Samples containing plgwere concentrated and desalted using a microconcentrator with a 10K Mr cutoff.
FPLC (fast protein liquid chromatography) Plg-Sepharose was packed into an
FPLC column (HR 5/2, Amrad Pharmacia Biotech, Melbourne, Australia) and
equilibrated with Buffer A overnight at 4°C at a flow rate of 0.5ml/min.

Alternatively plg-Superose was equilibrated with Buffer A overnight at a f
rate of 0.5ml/min. Plasma membrane preparations were loaded onto the
column via a 15ml or 1ml sample loop, depending on the volume, at a flow
rate of 0.5ml/min. Plg-Rs were eluted from plg-Sepharose or plg-Superose
using a 0-0.2M TA gradient according to the following program:
0.00 CONC %B 0.0
0.00 ML/MIN 0.5
0.00 PORT.SET 6.0
0.00 VALVE.POS 1.2
0.00 VALVE.POS 5.7
0.00 VALVE.POS 6.7
30.00 CONC %B 0.0
30.00 PORT.SET 6.1
30.00 VALVE.POS 1.1
60.00 CONC %B 30.0
60.00 CONC %B 100
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70.00 C O N C % B

100

70.00 CONC %B 0.0
80.00 CONC %B 0.0

0.5ml fractions were collected and those containing protein were concentra
using microconcentrator with a 10K Mr cut-off.

2.2.12 Size exclusion chromatography
Size exclusion chromatography was performed by FPLC using a pre-packed
Superdex™ 75 HR 10/30 column which has a fractionation range of 3-70kDa.
The column was equilibrated with PBS at a flow rate of 0.5ml/min and

calibrated with low molecular weight standards consisting of ribonuclease A
(13.7kDa), chymotrypsinogen A (25kDa), ovalbumin (42kDa), bovine serum
albumin (67kDa) and blue dextran (2000kDa). The void volume of the column
was determined using blue dextran 2000. The Kav for each standard was
calculated as follows: Kav = (Ve-V0)/(Vt-V0) where V0 = void volume of the
column, Ve = elution volume of the protein and Vt = the total bed volume.
The following standard curve was constructed and used to determine the
molecular weight of any proteins:
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2.2.13 SDS-PAGE
All reagents and gel preparation for SDS-PAGE mini-gels were based on the
method of Laemmli (1970). Samples were mixed with an equal volume of 2x

non-reducing sample buffer [Tris-HCl (pH 6.8), 20% (v/v) glycerol, 4% (w/v)

SDS, and 0.005% (w/v) bromophenol blue] and electrophoresed on either 4-20%

or 10% precast polyacrylamide gels (Bio-Rad, Sydney, Australia) using a Bio

Rad protein apparatus. Broad-range molecular weight standards consisting of

myosin (200kDa), fi-galactosidase (116.5kDa), phosphorylase B (97.4kDa), bov

serum albumin (66.2), ovalbumin (45kDa), carbonic anhydrase (31kDa), soybean

trypsin inhibitor (21.5kDa), lysozyme (14.4) and aprotinin (6kDa) were incl
for comparison. Samples were electrophoresed for 3h at 100V (20-40mAmp).
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2.2.14 Silver staining

Protein bands were visualised by silver staining using a commercially availa

kit according to the manufacturer's instructions (BioRad, Sydney, Australia)

2.2.15 Ligand blotting
Following SDS-PAGE, proteins were transferred to polyvinylidene difluoride

(PVDF) membrane, at 15V for 20min, using a semi-dry transfer system (BioRad,

Sydney, Australia). PVDF had been pre-equilibrated with transfer buffer [48m
Tris-base, 39mM glycine, 0.037% (w/v) SDS and 20% (v/v) methanol] for 15min
prior to use. The semi-dry transfer cell was configured as follows:

-ve
5x whatman filter paper

5x whatman filter paper

+ve
PVDF was blocked overnight in blotto then incubated with 1.5|ig/ml

biotinylated-plg (kindly provided by Nicholas Andronicus, Dept of Biological
Sciences, University of Wollongong) in PBS containing 0.1% tween-20 (PBS-T)
for 90min/RT. PVDF was washed thrice for lOmin with PBS-T then incubated
with streptavidimhorseradish peroxidase (ljig/ml) in PBS-T for lh/RT. PVDF
was washed thrice with PBS-T then once with PBS and then developed with
0.06% (w/v) 4-chloro-l-naphthol in 0.1M Tris-HCl (pH 7.4), 20% (v/v)
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methanol, 0.03% (v/v) H 2 0 2 for 30min/RT. The blot was washed extensively
with water then air dried.

2.2.16 Autoradiography
Following electrophoresis, gels were fixed in methanohacetic acid:H20 (4:1:5)
for lh/RT. Gels were dried using a gel drier (BioRad, Sydney, Australia) and
exposed to X-ray film (Amersham, Sydney, Australia) overnight at -80°C. Film
was developed with GBX developer (Kodak, Sydney, Australia) for 2min/RT,
fixed with GBX fixer (Kodak, Sydney, Australia) for 2min/RT

2.2.17 Molecular weight determination
Gels and autoradiograms were scanned using an imaging densitometer Model
GS170 (Bio-Rad, Sydney, Australia). The molecular weights of any bands were
determined by comparison with molecular weight standards using Molecular
Analyst software (Bio-Rad, Sydney, Australia).

2.2.18 Protein assay
Protein concentrations were measured using a detergent compatible microplate
protein assay according to the manufacturer's instructions (Bio-Rad, Sydney,
Australia). This assay is based on the method of Lowry et al (1951).
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2.2.19 Photography
Cells were photographed using a MPS45 photoautomat (Wild Heerbrugg,
Switzerland) and 100ASA film (Kodak, Sydney Australia) attached to an
inverted light microscope (Leitz, Sydney, Australia).

2.2.20 Data analysis
All experimental measurements were performed in triplicate. Unless
indicated, all results are expressed as means + 1 SEM.

2.3 RESULTS

2.3.1 Labelling of pig with 12T
In the current study, Iodobeads™ were used to iodinate glu-plg to a specific
activity of 0.41 + 0.0807jxCi/jig (N=ll) which is comparable with a previous

study (Gonias et al, 1989). As shown in Fig 2.3.1A, 25I-plg was eluted as the f
radioactive peak from a Sephadex G25 column and unconjugated 12T was
eluted in the second peak. Autoradiography confirmed that the iodinated
material had an apparent molecular weight consistent with that of pig (Fig
2.3.1B).

2.3.2 Morphological alterations to cells cultured in pig-depleted media

A previous study had reported that pig from different species could bind to th
same cell types (Durliat et al 1991). It is logical to assume then that cells
cultured in FCS would have a proportion of their plg-Rs occupied by bovine

82

pig. To eliminate the potential problem of bovine pig competing with h u m a n
pig during binding assays, all cell lines were cultured in pig-free media.
Preliminary observations indicated that the adhesion of the breast carcinoma
cell line MCF-7 was altered when they were cultured in pig-free media
however this phenomenon was not evident on other adherent cell lines such
as HCT116 and MDA-MB-231 cells.

To investigate the hypothesis that pig is important for cell adhesion, MCF-7
cells were cultured in pig-free media + 2|iM human glu-plg, or standard media
containing FCS. 18h after passaging control cells were obviously well-adhered

with individual cobblestone-like cells clearly evident (Fig 2.3.2). In contrast
cells cultured in pig-free media were poorly adhered with clumps of cells
appearing rounded with the perimeter of individual cells unclear. Cells
cultured in the presence of human pig exhibited a similar morphology as
control cells (Fig 2.3.2). At 36h after passaging, there was a marked increase

the adhesion of cells cultured in pig-free conditions (Fig 2.3.2), however some
clumps of poorly adhering cells were still evident. By 72h after passaging the

level of adhesion of all cells was virtually the same. Collectively these resul

suggest that pig plays a non-essential role in the initial adhesion of MCF-7 ce
to plastic tissue culture flasks.
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control

pig-free

2LIM

pig

Fig 232: Influence of pig on the adhesion of MCF-7 cells. M C F - 7 cells were
passaged into media containing either 1 0 % (v/v) FCS (control), 1 0 % (v/v)
pig-free FCS or 1 0 % (v/v) pig-free FCS + 2 u M h u m a n glu-plg. At 18, 36
and 72h the relative adhesion of cells was microscopically examined and
photographed.
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2.3.3125I-plg binding studies
The presence of plg-Rs (i.e specific pig binding) was analysed on the colon
carcinoma cell line HCT116, the monocytic leukemic cell line U937 and the
breast carcinoma cell lines MCF-7 and MDA-MB-231. Specific

125

I-plg binding

was detected on HCT116, MDA-MB-231 and U937 cells, but was absent on MCF-

7 cells (Fig 2.3.3A). HCT116 cells exhibited the highest level of specific pig
binding relative to the other cell lines and was subsequently chosen as the
candidate from which to isolate proteinacious plg-Rs. An obvious problem

with the binding data was the high level of interassay variability (Fig 2.3.3B
For example, specific pig binding was detected on MDA-MB-231 in only 50% of
experiments. This variability suggests that

125

I-plg binding assays may not be

the ideal method for analysing cellular pig binding on certain cell lines.

2.3.4 Isolation of plg-Rs from HCT116 cells
Plasma membranes from HCT116 cells were isolated, solubilised then batch
adsorbed to plg-Sepharose or Superose. Pig binding proteins were eluted with
200mM TA and then analysed by SDS-PAGE. Following silver staining, three
major proteins with molecular weights of >250, 50 and 42kDa (Fig 2.3.4A) were
evident. When these 'plg-Rs' were transferred to PVDF they could not be

detected by ligand blotting (Fig 2.3.4B, lane 3) indicating that they had lost

pig binding
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Fig 2.33: Comparison of pig binding on a variety of cancer cell lines. HCT116,
U937, M C F - 7 and M D A - M B - 2 3 1 cells were cultured in pig-free media for48h
then analysed for pig binding (i.e plg-R expression) using a 1251-plg binding
assay. A. Comparison of 1251-plg binding to each cell line showing total binding
(cells incubated solely with 1251-plg), non-specific binding (cells incubated with
1251-plg and l O m M T A ) and specific binding (the difference between total and
non-specific binding). Each bar represents the m e a n of triplicate determinations
+ 1SEM). The absence of error bars indicates that the error was smaller than the
graphical symbol. B. Interassay variability in the detection of specific pig binding
to each cell line.
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ability. In contrast, ligand blotting of solubilised H C T 1 1 6 plasma m e m b r a n e s
revealed proteins of 250kDa and a doublet band at approximately 42kDa that

possessed pig binding ability (Fig 2.3.4B, lane 2). These results indicate tha
several pig-binding species are present in the plasma membranes of HCT116s
but they lose their pig-binding ability following isolation.

In a further attempt to separate the three pig binding proteins, HCT116 plasma
membranes were adsorbed to plg-Superose or Sepharose then eluted with a 0200mM TA gradient. A typical elution profile is shown in Fig 2.3.5A with
proteins eluted at 2, 16 and 22mM TA. Several protein bands were evident in

each of the three fractions following SDS-PAGE and silver staining (Fig 2.3.5B
suggesting that the three proteins could not be adequately separated by FPLC.
Peak 1 contained a single major protein band of 42.8kDa, peak 2 contained two
proteins of 48 and 43.7kDa and peak 3 contained a protein of 38.4kDa. In all
experiments overstaining of gels was necessary to visualise protein bands
indicating that these proteins were present in very low concentrations. The
>250kDa protein that was detected by ligand blotting was never observed
following FPLC. Plg-Rs isolated by FPLC, like batch elution, could not be
visualised by ligand blotting which indicated that they had either lost their

binding ability, or were present in extremely low concentrations. Several larg
scale purifications were attempted, however the yield of plg-Rs was not

improved. Additionally, the efficiency of pig affinity media appeared to rapid
decline with use so generally it could be used but once.
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In a further attempt to isolate individual pig binding proteins, plg-Rs were

firstly isolated using the batch pig-affinity technique and then fractionated by
size exclusion chromatography using a Sephadex G75 column. Two protein
peaks were detected possessing molecular weights of >100kDa and 73.45kDa (Fig
2.3.6A). Because the amount of protein in each fraction was very low, each
fraction was iodinated with

125

I, electrophoresed and then visualised by

autoradiography. Numerous iodinated protein bands were evident in both
fractions including major proteins of >205kDa and 80kDa (Fig 2.3.6B) and

minor ones of 50 and 40kDa. Collectively these results indicate that several pig
binding proteins are present in plasma membrane preparations from HCT116
cells but they appear to be difficult to isolate possibly due to their similar
affinities for pig. Additionally these plg-Rs appear to lose their pig binding
ability once isolated.

2.4 DISCUSSION
These preliminary studies were targeted at analysing plg-R expression (i.e pig
binding) on several different types of cancer cells. An unexpected observation

was that the absence of pig appeared to reduce the rate of adhesion of the breas

carcinoma cell line MCF-7 to tissue culture flasks (Fig 2.3.2). This suggested t
pig plays a role during the adhesion of MCF-7 cells and is supported by a
previous study showing that murine leukemic cells require pig for adhesion to
collagen type I (Martinez & Santibanez 1994). Several other components of the
PA system including uPA and uPAR are located at focal contacts and cell:cell
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contacts (Pollanen et al 1987; Hebert & Baker 1988; Mayohanen et al 1993; Kanse
et al 1996; Chapman 1997) where they are likely to contribute to processes of

adhesion and migration. Other evidence also indicates that plg-R expression is
increased during fil-integrin-dependent cell adhesion (Kim et al 1996).
Whatever the role of pig during cell adhesion it appears to be cell-specific
attachment of HCT116 and MDA-MB-231 cells to tissue culture flasks was

unaffected by the absence of pig (Fig 2.3.2). Additionally, the mechanism of p

dependent adhesion does not appear to require specific pig binding sites as no
plg-Rs were detected on MCF-7 cells (Fig 2.3.3).

Nearly all studies of cellular pig binding have utilised

125

I-plg binding assay

the current study, considerable variability was evident in the detection of
specific (i.e lysine-dependent) pig-binding on U937, MDA-MB-231 and HCT116

cells (Fig 2.3.3B). For example, in only 50% of experiments specific pig bindi
was detected on MDA-MB-231 and U937 cells. Additionally specific pig binding

could not be detected on MCF-7 cells (Fig 2.3.3A) which contrasts with previou

studies on the same cell line (Correc et al 1990; Burtin et al 1993). Numerous
125

I-plg binding studies have been performed on U937 cells (Plow et al 1986;

Felez et al 1990; Edelberg et al 1990; Gonzalez-Gronow et al 1991; Felez et a
however, no comment was made regarding any variability in the data. One
possible explanation is that plg-R expression varies between different
populations of cells due to factors linked to the cell cycle. An alternative
scenario is that cells could sustain damage to their plasma membranes during
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experimental manipulation which alters the number of plg-Rs (i.e plg-R

expression is linked to cell viability). Regardless of the cause it is clearly
evident that in their current format

125

I-plg binding assays are not a satisfac

means of measuring pig binding and alternative methods should be developed.

Despite the aforementioned limitation with

125

I-plg binding assays, repeated

attempts were made to isolate proteinacious plg-Rs from HCT116 cells as they
appeared to specifically bind the highest level of pig compared to U937, MDA-

MB-231 and MCF-7 cells (Fig 2.3.3). Several pig-binding proteins were isolated
from HCT116 plasma membrane preparations using pig-affinity
chromatography, however the molecular weight species isolated varied
depending on the purification technique used. For example, >250, 50 and
42kDa proteins were isolated using a batch elution technique where the pig

binding proteins were eluted with a single concentration of TA (Fig 2.3.4); 38

43 and 48kDa proteins were isolated using a FPLC TA gradient (Fig 2.3.5); >100

80 50 and 40kDa proteins were isolated using a combination of affinity and siz
exclusion chromatography (Fig 2.3.6). Two proteins were repeatedly isolated
using all techniques and had molecular weights between 40-43kDa and 4850kDa. The molecular weights of these proteins is comparable with several
eukaryotic plg-R candidates such as a-enolase (54kDa) (Miles et al 1991),
Annexin II (40kDa) (Hajjar et al 1994), actin (45kDa) (Dudani et al 1996).

Additionally a 50-60kDa pig-binding protein has been identified on the surface
of rat colon carcinoma cells (Durliat et al 1992). Although >250kDa and 40kDa
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proteins could be detected by ligand blotting of plasma m e m b r a n e preparations
(Fig 2.3.4B) no isolated plg-Rs were ever visualised by ligand blotting. This

could be due to the low concentration of isolated plg-Rs or to the loss of pigbinding ability by isolated plg-Rs.

In summary, pig appears to play a non-essential role during in vitro cell
adhesion on of some cell lines. The current study also throws doubt on the
reliability of using

12o

I-plg binding assays to measure plg-Rs due to high

interexperimental variability. This consistent observation indicates that more
robust methods for measuring pig binding need to be developed. Several pig
binding proteins were found associated with the plasma membranes of HCT116
cells. The identity of these 'plg-Rs' remains to be determined however they do
have molecular weights similar to several reported plg-R candidates.

Chapter 3

Development of a Flow Cytometric
Plasminogen Binding Assay
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3.1 INTRODUCTION

Flow cytometry is a technique for measuring both the physical att

fluorescent emission from single, intact cells. Cells are passed i

laser beam and any light that is scattered by or emitted from ind

detected using various sensors. Light which is scattered in the f

direction (forward scatter or FSC) is indicative of cell size whi
sideways (side scatter or SSC) indicates granularity or how

differentiated/internally complex the cell is. If the cells are s

fluorescently-labelled probe, such as an antibody, then cell-asso

fluorescence is detected with a sensor set to the wavelength emis

fluorophore. Flow cytometry can be used to detect extracellular an
intracellular proteins, in ligand binding studies, measurement of

RNA content, cell cycle analysis, measurement of intracellular ca

various metabolites, membrane potential, membrane lipids and enzy
activity.

One of the key advantages of using flow cytometry is that specific

subpopulations of cells can be analysed separately from other cel

sample. This is extremely useful, particularly if the parameter be

is linked to another parameter or process. For example, if the pre

certain surface protein is linked to the cell cycle, then flow cy

the measurement of that protein on cells in different stages of t
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Only a few studies have utilised flow cytometry to measure pig binding (Miles
et al 1991; Felez et al 1993; Reinartz et al 1993). Two shortcomings were
apparent in these studies: firstly, flow cytometry formed a minor part of each
study - the development of these flow cytometric assays was not adequately

described or considered; secondly, single-colour fluorescence only was utilised
i.e. samples were not stained with PI to differentiate between viable and nonviable cells which is a standard component of flow cytometric analysis.

Irrespective of any other work, observations described in the previous chapter
indicated that data generated using 25I-plg binding assays were highly variable

(Fig2.3.3B). HCT116 cells were found to specifically bind relatively high level
of pig (judged by the ability of TA to inhibit

125

I-plg binding), however very lo

and variable levels of plg-Rs were isolated from plasma membrane
preparations (Fig 2.3.4-6). This variability in the level and types of plg-Rs

isolated could be a product of the variability in the initial binding assay - i
R expression varies due to cellular attributes which cannot be determined
using

125

I-plg binding assays. Collectively these data warrant the development

of other methods for measuring cellular pig binding.

There are numerous advantages in using flow cytometry to measure plg-R
expression (i.e pig binding) compared to other techniques such as
binding assays:

125

I-plg
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(1) There are no health or safety issues associated with handling and disposing
of radioactive material.
(2) Unbound pig does not need to be removed (by washing) as only cellassociated pig is detected. This is achieved by 'gating' specific
subpopulations of cells based on some parameter such as viability (i.e PI
uptake) and then measuring pig binding only on that population. This is a
significant advantage due to the low affinity of pig - removing unbound pig
by washing (a feature of all radioligand binding assays) reduces the
concentration of free pig which could cause cell-bound pig to dissociate in
order to re-establish equilibrium binding.

(3) Pig binding can be measured on specific subpopulations of cells, for example
viable versus non-viable cells or cells in different stages of the cell cycle.
This is important particularly if plg-R expression varies between
subpopulations of cells within the sample.
(4) Pig binding can be measured simultaneously with other cellular attributes
(e.g cell size, expression of differentiation antigens etc.).
(5) Pig binding is measured on intact cells. Any damage or cellular changes
occurring during experimental manipulation can be determined.

The aim of this chapter was to develop a robust and reliable flow cytometric pig

binding assay that can be used to measure plg-Rs (i.e specific pig binding) on a
variety of cells (i.e. adherent and non-adherent cells).
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3.2 MATERIALS A N D M E T H O D S

3.2.1 Materials

All cell culture reagents were obtained from Trace BioSciences (Sydney, N

Australia) except for FCS which was obtained from CSL, (Melbourne, Victor
Australia). Human glu-plg was either purified according to the method of
Grant (1990) or was generously provided by American Diagnostica (ADI)
(Greenwich CT, USA). Human lys-plg was obtained commercially (ADI,
Greenwich CT, USA). NAP-10 columns and Lysine-Sepharose 4B were

obtained from Amrad Pharmacia Biotech (Melbourne, Victoria, Australia). TA
BSA, PL dimethyl sulphoxide (DMSO), H202, hydroxylamine, Hepes, and FITC
were obtained from Sigma (Sydney, NSW, Australia). Carboxypeptidase B was
obtained from Calbiochem-Novachem (Sydney, NSW, Australia). PMA was
obtained from Boehringer Mannheim (Sydney, Australia). TNFa was

generously provided by Darren Saunders (Department of Biological Sciences

University of Wollongong). FACS tubes were obtained from Becton Dickinson.

3.2.2 Cell lines and cell culture
The human monocytic leukemic cell line U937 was obtained from the
American Type Culture Collection. The human colon cancer cell lines
HCT116, LIM1215 and KM12SM were provided by Dr M Baker (Dept. Biological

Sciences, University of Wollongong, Australia). All cell lines were cultur
RPMI1640/10% FCS at 37°C in a humidified atmosphere of 5% C02. Adherent
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cells were passaged using 0.05% (w/v) trypsin/5mM E D T A / P B S (pH 7.4) to lift
them into suspension.

3.2.3 Labelling pig with fluorescein isothyocyanate (FITC)
Glu-plg (2-5 mg/ml) was dialysed against 0.1 M carbonate buffer (pH 9) and a
fold molar excess of FITC added after being dissolved in DMSO. Pig was mixed
for 16h at 4°C in the dark and subsequently treated with 0.01% hydroxylamine
as for 30min at 4°C to remove all labile FLTGplg bonds. Unincorporated FITC
was separated from FITC-plg by gel filtration through a NAP-10 column using
HBSS (phenol red free) containing 20mM Hepes, ImM CaCl2, ImM MgCl2 (pH

7.4). In some instances, FITC-plg was adsorbed to lysine-Sepharose 4B, eluted
with 0.2M TA, then dialysed against HBSS. FITC-plg was aliquoted and stored
at -80°C until required. The number of molecules of FITC conjugated to each
pig molecule was determined using the following formula:
FTTC/pIg molecule = A495nm x dilution factor x 92.000
68,000 mg/ml pig
where A495nm is the absorbance maxima of FITC; 60,000 is the molar
extinction coefficient (cm^M1) of conjugated fluorescein and 92,000 is the
molecular weight of pig.

3.2.4 Flow cytometric pig binding assay
Cells were cultured for 24h in RPMI1640/10% pig-depleted FCS (prepared as

described in section 2.2.5). Adherent cells were lifted into suspension by fi
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washing them for 5min at R T with H B S S and then treating them with 5 m M
EDTA in HBSS (Ca and Mg free) for lOmin at 37°C. Cells (2xl05) were washed
twice with HBSS and resuspended in HBSS/0.1% BSA containing 0.5uM FITCplg ± ImM TA in a total volume of 200ul (the concentration of FLTC-plg and

TA was altered in certain experiments) and incubated for 60min at 4°C in the
dark. PI (5 Ug/ml) was added for 5min in order to differentiate viable from

non-viable subpopulations of cells. Cell-associated fluorescence was detecte

using a FACSort (Becton-Dickinson, Australia) using the following instrument
settings: FSC (forward scatter - cell size) (E00 Voltage, 1.00 AmpGain, Lin

Mode); SSC (side scatter - granularity) (360 Voltage; lAmpGain, Lin Mode); FL1 (630 Voltage, 1 AmpGain, Log Mode); FL-2 (475 Voltage. lAmpGain, Log
Mode); Compensation (FL-1: 0.8% FL-2: 0%). Twenty thousand events were

acquired for each sample. Viable and non-viable subpopulations of cells were
'gated' based on PI uptake (i.e. from FL-2 histograms). Cell-associated
fluorescence due to FLTC-plg binding was determined from FL-1 histograms.

Lysine-dependent (specific) pig binding was calculated as the difference in

fluorescence between cells incubated solely with FLTC-plg (total binding) a
cells incubated with FLTC-plg and ImM TA (non-specific binding). ImM TA
was experimentally found to be the optimal concentration for maximally

inhibiting FITC-plg binding (Fig 3.3.12). All experimental measurements were
performed in triplicate and each experiment repeated at least twice.
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3.2.5 Carboxypeptidase B treatment of cells

The effect of carboxypeptidase B treatment on pig binding to cells was assesse

as previously described (Miles et al 1991). Briefly U937 cells were cultured i
RPMI/10% pig depleted FCS for 24h at 37°C, washed thrice with HBSS, then
treated with 10, 25 and 50 U/ml carboxypeptidase B in HBSS for 30min at 37°C.
Cells were washed thrice with HBSS and pig binding measured as described in
3.2.4.

3.2.6 PMA treatment of cells
A stock solution of PMA was made by dissolving PMA in DMSO, aliquoting
and storing at -20°C. Cells were treated with PMA as previously described

(Felez et al 1990) by culturing cells for 48h in 0, 0.1,10, 20, 40 and 80mM PM
Cells were washed thrice with HBSS then pig binding assessed as described in
3.2.4

3.2.7 Peroxide treatment of cells
Cells were washed thrice with HBSS (Ca/Mg-free) then incubated in PBS
containing 0, 0.1, 1, 5,10, and 20mM H2Oz for 30min/37°C in the dark. Cells
were washed thrice with HBSS then pig binding assessed as described in 3.2.4.

3.2.8 TNFa treatment of cells
Cells were cultured in the presence of 0 and lOng/ml TNFa for 24h. Cells were
washed thrice with HBSS then pig binding assessed as described in 3.2.4
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3.2.9 Data analysis
All flow cytometric data was analysed using CellQuest (v3.1, Becton-Dickinson,
Sydney Australia). Each experiment was performed in duplicate or triplicate
and each experiment repeated at least twice. Unless indicated all results are
expressed as means + 1 SEM and each experiment repeated at least twice. To

test for statistical differences data were analysed using JMP statistical analys

software (v6). Statistically significant differences between two treatments were
assessed using a student's t-test. Differences between treatments were
considered significant when p<0.05.

3.3 RESULTS

3.3.1 FITC-labelling of pig

Pig was labelled with FITC via its reactive amino groups (lysine) according to a
well established procedure (Goding 1976) and purified by size exclusion
chromatography or lysine-Sepharose 4B chromatography. The mean number
of FITC molecules conjugated to each pig molecule was 3.72 ± 1.220 (N=9)
which is consistent with previous studies that have described 2-4 FITC
molecules per pig (Felez et al 1990).

3.3.2 Gating strategy for analysing pig binding by flow cytometry
One of the key aspects of developing any flow cytometric assay is determining
how the cells should be analysed - i.e. what cellular attributes are important
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and h o w different subpopulations of cells should be distinguished from other
subpopulations of cells. This is achieved by placing a border or marker around
the subpopulation of cells - called a 'gate'. As some adherent cells tend to

clump together it is important to differentiate single cells from clumps of cell

The other two important cellular characteristics are cell viability and obviousl
pig binding.

The gating strategy for measuring pig binding on non-adherent cells is

illustrated in Fig 3.3.1 using U937 cells as the example. Fig 3.3.1A is a densit
plot of FSC versus SSC and shows the general physical characteristics of U937
cells - a single dense population of cells is apparent. For U937 cells it was
unnecessary to place a gate around this population as there were no other
subpopulations of cells. When U937 cells were stained with PI (to differentiate
viable from non-viable cells) two distinct subpopulations of cells were evident
as shown Fig 3.3.IB: these were viable (no PI uptake) and non-viable cells
(maximum PI uptake). Viable (Fig 3.3.1C) and non-viable cells (Fig 3.3.1D) were
gated and analysed separately for pig binding. Cellular autofluorescence is
represented by the shadowed profile - autofluorescence of non-viable cells was
noticeably higher than that of viable cells. Fluorescence peaks due to total
FITC-plg binding (dark line) and non-specific FITC-plg binding (light line) are
also shown in both histograms. Markers were placed over both total and nonspecific binding peaks and the mean fluorescence intensity calculated using
CellQuest software. The difference between total FITC-plg and non-specific
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Fig 3.3.1: G a t i n g strategy for m e a s u r i n g pig b i n d i n g o n U 9 3 7 cells. U937 cells were
cultured in pig-free media for 24h then incubated with 0.5|J.M FITC-plg + I m M T A for 60min at 4°C.
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binding. D. FITC-plg binding to non-viable cells.

106

FITC-plg binding was a measure of specific FITC-plg binding.

The gating

strategy for adherent cells was similar to that for non-adherent cells except

cells were gated firstly on size in order to discriminate between single cells
clumps of cells (Fig 3.3.2).

3.3.3 Establishing a relationship between cell viability and pig binding
The next step in the development of the flow cytometric pig binding assay was

to select a suitable buffer that would maintain cell integrity for up to severa
hours. The viability (level of PI uptake) of U937 and HCT116 and LIM1215 cells
was assessed after two hours incubation in PBS, HBSS or RPMI1640. In all cell

lines, cell viability (i.e the proportion of viable cells) was highest in RPMI1
followed by HBSS and then PBS (Fig 3.3.3). Based on this information PBS was
excluded as an incubation buffer. RPMI1640 was also excluded because it
contains small concentrations of lysine and arginine which could potentially
interfere with pig binding. By a process of elimination HBSS, containing ImM
Mg, ImM Ca and 0.1% BSA, was chosen as the binding buffer. U937 cells

appeared to be the most robust of the cell lines studied followed by LIM1215 an
then HCT116.

When U937 cells were stained with PI and analysed by flow cytometry two
distinct subpopulations of cells were evident (Fig 3.3.4A): these were viable

(negligible PI uptake) and non-viable (full PI uptake). Typically, 90-95% of ce
were viable and 5-10% were non-viable. The addition of 0.5 uM FITC-plg (Fig
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3.3.4B) caused a marked increase in fluorescence associated with viable and
non-viable cells compared to their respective controls (Fig 3.3.4A), indicating
that pig binds to both subpopulations. Non-viable cells exhibited dramatically
higher (~100-fold) fluorescence than did viable cells, indicating an enormous
increase in their ability to bind pig. The presence of ImM TA resulted in the
marked reduction of the fluorescence associated with non-viable cells (-95%)
but this was not evident with viable cells (Fig 3.3.4C).

An almost identical result was observed on HCT116 cells (Fig 3.3.5). When
HCT116 cells were stained with PI and analysed by flow cytometry viable and
non-viable cells were also evident (Fig 3.3.5A). HCT116 cells were relatively
fragile and thus the typical proportion of viable cells was 75-80% and nonviable cells was 20-25%. Additionally a diffuse intermediate PI staining
population was evident. The addition of 0.5|iM FITC-plg (Fig 3.3.5B) also
caused a marked increase in fluorescence on viable and non-viable cells

compared to their respective controls (Fig 3.3.5A), indicating that pig binds to
both subpopulations of HCT116 cells. Like U937 cells, non-viable HCT116 cells
exhibited dramatically higher (~100-fold) fluorescence than did viable cells,
indicating an enormous increase in their ability to bind pig. The presence of
ImM TA resulted in the marked reduction of the fluorescence associated with
non-viable HCT116 cells {-75%) but this was not evident with viable cells (Fig
3.3.5C).
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These observations on both U937 and H C T 1 1 6 cells indicate that non-viable
cells bind magnitudes more FITC-plg than viable cells and that a large
proportion of this binding is lysine-dependent. In contrast, pig binding to
viable cells appeared to be essentially lysine-independent. Collectively these

data suggest that there is a direct relationship between cell viability (PI upt
and the magnitude of lysine-dependent pig binding.

3.3.4 Pretreatment of adherent cells
One of key features of developing a ligand binding assay is to ensure that both

the culture and manipulation of cells does not modify the level of receptors. In

the current study, all cells were cultured in pig-free conditions to minimise th
occupation of plg-Rs with bovine pig. Adherent cells are usually passaged
using trypsin/EDTA to lift them into suspension. This treatment is likely to
digest plg-Rs as they have previously been shown to be susceptible to trypsin
treatment (Camacho et al 1989). To confirm this observation, HCT116 cells
were detached from tissue culture flasks with either 0.05% (w/v) trypsin or
5mM EDTA in HBSS (Ca and Mg free). Passaging HCT116 cells with trypsin
reduced the level of plg-Rs (i.e. specific pig binding) on non-viable cells by
+ 3.8% (N=3) (Fig 3.3.6B) compared to cells passaged using 5mM EDTA.
Although no specific pig binding was detected on viable HCT116 cells, total pig
binding was decreased by 11.1 + 0.42% (N=3) and non-specific binding increased
by 6.9 + 1.7% (N=3) when cells were passaged using trypsin (Fig 3.3.6B).
Passaging HCT116 cells with trypsin also increased the number of non-viable
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cells by 28.4 + 4.6% (Fig 3.3.7B).

When HCT116 cells were treated with higher concentrations of trypsin (i.e 0.10.5% w/v) a different affect occurred with trypsin reducing total and nonspecific pig binding on both viable and non-viable cells (Fig 3.3.8). On nonviable HCT116 cells, specific pig binding was increased by 22.9 + 6.58% (N=3)
following mild trypsin treatment (i.e 0.1% w/v) (Fig 3.3.8B) which contrasts
with the above affect of 0.05% (w/v) trypsin (Fig 3.3.6B), however it is

consistent with previous studies (Camacho et al 1989; Ouimet et al 1994; Gase e
al 1996). Treatment of HCT116 cells with 0.25% (w/v) trypsin was found to also
increase specific pig binding to non-viable cells by 56 + 7.02% (Fig 3.3.6B).
Surprisingly, 0.5% (w/v) trypsin was found to cause a slight reduction in

specific pig binding to non-viable HCT116 cells (Fig 3.3.8B). Collectively these
observations indicate that: (1) adherent cells should be detached using 5mM
EDTA prior to flow cytometric pig binding assays, and (2) the affect of trypsin
plg-R expression is concentration dependent.

3.3.5 Establishing the time of equilibrium pig binding

One of the key features in any ligand binding study is the time required to rea
equilibrium binding as this indicates the incubation time necessary for
completion of the assay and also provides some information on the relative
affinity of the ligand for its cellular receptor/s. U937 and HCT116 cells were
incubated with 0.5uM pig for various time periods until equilibrium binding
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was attained. Specific pig binding reached equilibrium on non-viable U937

and HCT116 cells at approximately 60min (Fig 3.3.9B & Fig 3.3.10B respectively
Although no specific pig binding was detected on viable cells, total and nonspecific pig binding to viable U937 and HCT116 cells reached equilibrium at
approximately 30min (Fig 3.3.9A & Fig 3.3.10B). Based on these results, 60min
was used as the standard incubation period for flow cytometric pig binding
assays on all cell lines.

3.3.6 Effect of removing unbound pig on the measurement of pig binding
One of the key advantages of using flow cytometry to study low affinity

receptor:ligand interactions (such as pig binding) is that unbound ligand does
not need to be removed in order to measure cell-associated ligand. To
determine if removing unbound pig by washing cells had any affect on pig
binding, HCT116 cells were incubated with pig, washed with HBSS up to four
times and the level of pig binding measured. Pig binding to both viable and
non-viable cells was markedly reduced when cells were washed once (Fig

3.3.11). Both total and non-specific pig binding to viable cells was reduced b
approximately 70% when washed once (Fig 3.3.11A). Increasing the number of

afterwashes did not further reduce the level of total and non-specific binding

on viable cells (Fig 3.3.11A). Total pig binding was reduced by 32 ± 3.4% (N=3

on non-viable cells with a single afterwash. Non-specific binding to non-viabl
cells remained constant regardless of the number of afterwashes. Importantly,

specific pig binding to non-viable cells was reduced by 59.5 ± 3.9 % with a si
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afterwash with a small but steady decrease evident with increased afterwashes
(Fig 3.3.11B). These results indicate that afterwashing removes more than half
of the pig specifically bound to non-viable cells and consequently it should not
be employed in pig binding assays. These results also suggest that two types of

specific pig binding occur on non-viable cells - a low affinity interaction which
is easily removed by afterwashing, and a higher affinity interaction which is
reasonably resistant to afterwashing. Based on these results unbound FITC-plg
was not removed by washing prior to flow cytometric analysis.

3.3.7 Specificity of cellular pig binding

It was clear that specific pig binding was restricted to non-viable cells. The ne
series of experiments were aimed at determining the specificity of pig binding
to viable and non-viable subpopulations of cells. U937 cells were incubated
with FLTC-plg in the presence of either increasing concentrations of TA or
unlabelled glu or lys-plg. FITC-plg binding to viable U937 cells could not be
inhibited with up to lOOmM TA (Fig 3.3.12A) or 100-fold molar excess of
unlabelled glu or lys-plg (Fig 3.3.13A & 3.3.14A) confirming that pig binding to

viable cells is a lysine-independent (i.e non-specific) interaction. In contrast,
ImM TA maximally inhibited FITC-plg binding to non-viable cells, while
increasing the concentration of TA beyond ImM reduced the level of

inhibition (Fig 3.3.12B). This observation indicated that the level of inhibition
of FITC-plg binding to non-viable cells was dependent on the concentration of
TA. TA concentrations below ImM did not display a higher capacity to inhibit
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FITC-plg binding (data not shown).

Additionally, FITC-plg binding to non-

viable U937 cells was inhibited over a range of concentrations of unlabelled gl
and lys-plg (Fig 3.3.13B and 3.3.14B). For example, a 100-fold molar excess of

and lys-plg inhibited FITC-plg binding to non-viable U937 cells by 30 ± 1.3% an
80 ± 7.5% respectively. These results confirmed that specific pig binding was
restricted to non-viable U937 cells.

3.3.8 Proteinacious C-terminal lysine residues function as plg-Rs on non-viable
cells
Proteinacious C-terminal lysine residues have previously been shown to
function as plg-Rs and are consequently susceptible to carboxypeptidase B
treatment. The aim of this experiment was to examine the effect of
carboxypeptidase B treatment on pig binding to viable and non-viable
subpopulations of U937 cells. When U937 cells were pretreated with increasing
concentrations of carboxypeptidase B, specific FITC-plg binding to non-viable

cells was reduced (Fig 3.3.15B) indicating that proteins with C-terminal lysine
residues function as plg-Rs on non-viable cells. For example, pretreatment of
U937 cells with 50U/ml carboxypeptidase B reduced pig binding to non-viable

cells by 37 ± 2.4%. A student's t-test indicated that 25 (p<0.05) and 50 (p<0.0
but not lOU/ml (p>0.05) carboxypeptidase B caused a statistically significant

reduction in FITC-plg binding on non-viable cells. As no specific (i.e. lysinedependent) pig binding occurred on viable U937 cells carboxypeptidase B had
no effect (3.3.15A).
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3.3.9 Saturability of pig binding to viable and non-viable cells
U937 cells were incubated with increasing concentrations of pig in order to
determine the saturating concentration of pig and subsequently its affinity (i.e

Kd). Scatchard analysis is currently not possible using flow cytometry as suitabl
standards (i.e beads with defined numbers of lysine binding sites) are
unavailable. Although pig binding to viable U937 cells is a non lysinedependent interaction, both total and non-specific pig binding were saturated at
approximately 4^M (Fig 3.3.16A) which translates to a Kd of 2^iM. This is both
the concentration of pig in serum and the average reported Kd in the scientific
literature. Specific pig binding to non-viable U937 cells reached an apparent
maximum at 1-2JXM (Kd = 0.5-luM), however binding did not appear to reach a
stable equilibrium as increasing concentrations of pig resulted in a progressive
reduction in the level of binding (Fig 3.3.16B). Collectively these results

confirm that specific pig binding is restricted to the surface of non-viable U937

cells and has at least a 4-fold higher affinity for non-viable cells than the non
lysine-dependent binding detected on viable cells.

3.3.10 Can any specific pig binding be generated on viable U937 cells ?
All evidence indicated that plg-Rs were absent on viable U937 and HCT116
cells, and that a loss of cell viability (detected as an increase in PI uptake)
increased plg-R expression. The next series of experiments were undertaken in
an attempt to generate plg-Rs on viable cells without causing a loss in cell

viability.
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Fig 3.3.16: Pig concentration curves for viable (A) and non-viable U937 cells.
U937 cells were cultured in pig-free media for 24h then incubated with 0600|ig/ml FITC-plg ± I m M T A for 60min at 4°C. PI (5|ig/ml) was added prior to
flow cytometric analysis to differentiate viable from non-viable cells. Each
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error bars indicates that the error was smaller than the graphical symbol.
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U937 cells were cultured for 48h in media containing 0-80mM P M A as P M A

has previously been shown to increase plg-R expression on U937 cells (Felez et
al 1990). No specific pig binding could be detected on viable U937 cells that
been treated with increasing concentrations of PMA (Fig 3.3.17A). Although

the level of specific pig binding to non-viable U937 cells fluctuated followin
PMA treatment no clear pattern was evident (3.3.17B). These observations
indicate that PMA does not increase plg-R expression on viable U937 cells.
Additionally, PMA had no affect on cell viability (data not shown).

TNFa is an inflammatory mediator which has previously been shown to
increase uPAR expression in U937 cells (Lu et al 1988), peripheral blood

monocytes (Kirchheimer et al 1988) and colon cancer cells (Wang et al 1988). T

investigate the affect of TNFa on plg-R expression, U937 cells were cultured i

10|4.g/ml TNFa for 48h and the level of pig binding measured. Plg-Rs (specific
pig binding) could not be detected on viable U937 cells that had been treated

with TNFa for 48h (Fig 3.3.18A). A 52.6 ± 4.33% (N=3) reduction in specific pi
binding was observed on non-viable U937 cells that had been treated with
TNFa (Fig 3.3.18B) despite the fact that TNFa caused an approximate 5-fold
increase in the proportion of non-viable cells (Fig 3.3.18C). These results
indicate that TNFa does not increase plg-R expression on viable U937 cells.
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In a further attempt to generate plg-Rs on viable cells, U937 cells were treated
with 0-20mM peroxide for 30min and then pig binding measured. The

rationale for this approach was to attempt to modify cell-surface proteins using
an oxidative agent with the aim of generating pig binding sites. Peroxide
treatment did not generate any plg-Rs (i.e specific pig binding) on viable U937
cells (Fig 3.3.19A) and also appeared to have no affect on specific pig binding
non-viable cells (3.3.19B). Additionally, peroxide treatment had no affect on
cell viability (data not shown).

A further attempt was made to generate plg-Rs on viable cells by quiescing
them for 24h in the absence of serum (i.e.). The rationale for this approach is
that FCS could contain factors (e.g. cytokines or growth factors) that prevent

plg-R expression on viable cells. No specific pig binding was detected on viable
U937 cells that had been cultured in the absence of FCS for 24h (Fig 3.3.20A).
Additionally, serum starvation did not modify specific pig binding (i.e plg-R

expression) on non-viable U937 cells (Fig 3.3.20B) or affect cell viability (dat
not shown).

3.3.10 Comparison of pig binding on several cell lines

It was clear that pig binding was dramatically elevated on non-viable cells with
no specific pig binding detected on viable U937 and HCT116 cells. To confirm
these observations, pig binding was measured on two other colon cancer cell
lines, LIM1215 and KM12SM. Additionally pig binding to three breast
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carcinoma cell lines, M D A - M B - 2 3 1 , M C F - 7 and T47D was independently
measured by Ranson et al (1998) using the flow cytometric pig binding assay

developed in this chapter. No specific pig binding was detected on the surfac
of viable U937, HCT116, LIM1215 and KM12SM cells while specific pig binding
to non-viable cells has highly elevated on all cells lines (Fig 3.3.21). The
of plg-R expression on non-viable cells varied with U937 and HCT116 cells
exhibiting the highest level of specific pig binding (Fig 3.3.21B). LPM1215
expressed approximately half the level of plg-Rs as U937 and HCT116 cells

while KM12SM exhibited the lowest level of specific pig binding. Low levels o
specific pig binding were detected on viable MCF-7, T47D and MDA-MB-231

cells with MDA-MB-231 cells expressing the highest level of plg-Rs (Ranson et
al 1998). Specific pig binding was also dramatically elevated on non-viable

breast carcinoma cells (Ranson et al 1998). These comparative data confirm th

the dramatic increase in plg-R expression on non-viable cells is a widespread
phenomenon with the level of plg-Rs dependent on the cell type. Although no

specific pig binding was detected on any viable cell types within the current

study some viable breast cancer cells have subsequently been shown to possess
plg-Rs (Ranson et al 1998).

3.4 DISCUSSION
A novel flow cytometric pig binding assay was developed to enable the
measurement of pig binding on a range of cell types (i.e adherent and non-

adherent) and on various subpopulations of cells (e;g viable and non-viable).
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Dual-colour staining of cells with both FITC-plg and PI revealed that a direct

relationship exists between cell viability and pig binding with non-viable cell
binding up to 100-fold more pig than viable cells (Fig 3.3.4 & 3.3.5).
Comparative studies confirmed this observation on several cell lines including
U937, HCT116, LTM1215, KM12SM, MCF-7, T47D and MDA-MB-231 cells [Fig
3.3.21 and Ranson et al (1998)]. These results indicated that increased plg-R
expression on non-viable cells is a widespread phenomenon, however some

non-viable cell types have a greater capacity to specifically bind pig than oth
do.

Although a few recent studies have utilised flow cytometry to detect cellular

pig binding (Miles et al 1991; Felez et al 1993; Reinartz et al 1993), the majo
of studies have exclusively employed

125

I-plg radioligand binding assays. The

observations described in this chapter clearly indicate that radioligand bindin
assays are no longer a satisfactory method of examining pig binding due to the

direct relationship between cell viability (PI uptake) and lysine-dependent pig
binding. By using

125

I-plg binding assays specific pig binding to viable cells

could easily be overestimated due to the increase in plg-Rs on non-viable cells

Care should also be taken when examining the effect of any factor (e.g protease

growth) on pig binding as the treatment itself may cause a loss of cell viabili

and consequently artifactually elevate pig binding. For example, in the current
study TNFa (Fig 3.3.18) and mild trypsin treatment (Fig 3.3.7) were shown to
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increase the proportion of non-viable U 9 3 7 cells by approximately 5-fold and
non-viable HCT116 cells by 1.3-fold respectively.

The disparity between the observation that viable U937 cells express no plg-Rs
and previous studies employing the same cell line but using

125

I-plg binding

assays (Plow et al 1986; Felez et al 1990; Edelberg et al 1990; Gonzalez Gronow

al 1990), can be explained simply by the failure of radioligand binding assays t

discriminate pig binding on viable and non-viable cells. It should be noted that
plg-Rs are present on some viable cell types and can be detected using the
current flow cytometric assay as validated by Ranson et al (1998) who found
that specific pig binding occurs on viable breast carcinoma cells.

In the current study pig bound to viable U937 cells in a non-lysine dependent
manner as TA could not inhibit binding (Fig 3.3.12A), despite the observation
that binding was saturable (Fig 3.3.16A). Pig binding to viable U937 cells was

not inhibited by either unlabelled glu or lys-plg (Fig 3.3.13A & 3.3.14A) furthe
confirming that pig binding to viable U937 cells appears to be a non-specific
interaction. The absence of C-terminal lysine residues on viable U937 cells was
confirmed when carboxypeptidase B treatment failed to reduce pig binding (Fig
3.3.15A). Although pig binding to viable U937 cells was non-specific it was
saturated at a pig concentration of 4[iM pig (Kd = 2^M) (Fig 3.3.16A) which is
comparable with previous affinity measurements generated using scatchard
analysis and

125

I-plg binding assays (refer Table 1.5).
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Pig binding to non-viable U937 cells was specific and predominantly lysinedependent with binding inhibited with both TA (Fig 3.3.12B) and unlabelled

glu and lys-plg (Fig 3.3.13B & 3.3.14B). Additionally, lys-plg was more affect

than glu-plg at competing with FITC-plg for non-viable binding sites suggestin

that lys-plg has a higher affinity for cellular plg-Rs, as has previously been

reported (Ellis et al 1986; Silverstein et al 1988; Kuusela & Saksela 1990). A
unexpected observation was that 100-fold molar excess of unlabelled glu-plg

poorly inhibited FITC-plg binding to non-viable cells (Fig 3.3.13B). A possibl
explanation for this result is that FLTC-plg has a higher affinity for plg-Rs
non-viable cells than unlabelled glu-plg.

Low concentrations of TA strongly inhibited cellular pig binding while higher
concentrations were less inhibitory (Fig 3.3.12B). Pig has been shown to
undergo a large conformational change upon binding to lysine analogues such
as TA (Markus et al 1978; Mangel et al 1990; Christensen 1991). This
conformational change is likely to expose hidden LBS in the pig molecule such
as the one located in K4 (Vali & Patthy 1981). Thus low concentrations of TA

are affective at blocking pig binding because they interact with a single stro

LBS in K5. Higher concentrations of TA are less affective because they interac
with more than one LBS due to the TA-induced conformational change. A TA

concentration should be reached which saturates all of the five LBS in the pig
molecule, however as shown in the present study, pig binding to non-viable
U937 cells could not be completely abolished by either TA or unlabelled pig.
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This result suggests that a proportion of cellular pig binding (-10-30%) involves
non lysine-dependent mechanisms which is consistent with previous
observations showing that a relatively small proportion of cellular pig binding
is non lysine-dependent (Hajjar et al 1986; Campbell et al 1994).

Equilibrium pig binding was reached on both U937 and HCT116 cells at
approximately 60min. An interesting observation was that specific pig binding
to non-viable HCT116 cells (Fig 3.3.10B) appeared to be less stable than that
occurring on non-viable U937 cells (Fig 3.3.9B) with the level of specific pig
binding fluctuating over time. This result suggests that the mechanism of pig
binding to non-viable HCT116 cells is different to that on U937 cells possibly
due to the presence of different plg-Rs.

Carboxypeptidase B pretreatment of U937 cells reduced pig binding to nonviable cells (Fig 3.3.15B) clearly implicating proteins with C-terminal lysine
residues as plg-Rs. Pig binding to non-viable cells was never completely
abolished by treatment with carboxypeptidase B again suggesting that not all

plg-Rs are susceptible to carboxypeptidase B (Miles et al 1991; Felez et al 1993

Pig had a relatively high affinity for non-viable cells compared to viable cells
with apparent saturation occurring at a pig concentration of l|iM pig (Kd =
0.5uM) (Fig 3.3.16B).

141

The increase in plg-R expression on non-viable cells suggests that plg-Rs might
play a role during cell death. In support of this observation are independent
histochemical studies showing that pig binding is increased on dead or

damaged epithelial cells (Green 1978; Burgos et al 1982; Jenkins et al 1983) an
on necrotic breast carcinoma tissue (Burtin et al 1985). The dramatic increase
plg-R expression on non-viable cells could be the result of the direct

upregulation of plg-Rs during death. Intracellular stores of uPAR exist in some
cells that do not express cell-surface uPAR (Jardi et al 1996) and it is also
possible that intracellular stores of plg-Rs exist which could become

externalised during death. In support of this hypothesis is the fact that sever

plg-R candidates such as annexin II (Hajjar et al 1994), a-enolase (Miles et al

1991), actin (Dudani et al 1996) and G3PDH (Broder et al 1991) are intracellula
proteins.

Another explanation for the increase in plg-Rs on non-viable cells is the
exposure of cryptic C-terminal lysine residues during death. In the current
study, trypsin treatment was shown to have varying effects on the level of

specific pig binding to non-viable HCT116 cells. A relatively low concentration

of trypsin (that would normally be used to passage cells) caused a reduction in

specific pig binding to non-viable cells (Fig 3.3.8B) presumably by degrading p
Rs (i.e lysine residues). In contrast, higher concentrations of trypsin caused
increase in specific pig binding (Fig 3.3.8B) which is consistent with several

previous studies (Camacho et al 1989; Ouimet et al 1994; Gase et al 1996). This
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observation suggests that trypsin can either degrade or generate plg-Rs on nonviable HCT116 cells depending on its concentration. These results illustrate
that the level of plg-Rs (i.e specific pig binding) on non-viable cells can be
altered by proteolytic modification of the cell surface.

Plg-R expression on viable U937 cells could not be induced by PMA (Fig

3.3.17A), TNFa (Fig 3.3.18A), peroxide (3.3.19A) or serum starvation (Fig 3.3.20
PMA has previously been shown to increase plg-R expression on U937 cells

(Felez et al 1990) and uPAR on a variety of cells (Stopelli et al 1985; Estrei

al 1989; Picone et al 1989; Lund et al 1991; Wang et al 1994; Jardi et al 1996)
however no evidence of any modulation of plg-R expression was observed on
PMA-treated U937 cells. The observation made by Felez et al (1990) that PMA
increases plg-R expression could have been due to PMA causing cell death
thereby elevating pig binding. TNFa has been shown to increase uPAR
expression on U937 cells (Lu et al 1988) as well as several other cell lines
(Kirchheimer et al 1988). An interesting observation made during the current
study was that TNFa appeared to decrease plg-R expression on non-viable U937
cells (Fig 3.3.18B). This effect of TNFa could have been due to the inhibition
pathways that increase plg-R expression on non-viable cells (such as the

translocation of plg-Rs to the cell surface) or to the actual assembly/synthes

the receptor/s. It is possible that other factors (e.g cytokines, hormones etc.
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could induce plg-R expression on viable cells and would be worthy of further
investigation.

In summary, the development of a novel flow cytometric pig binding assay has
enabled the measurement of pig binding on specific subpopulations of cells (i.e
viable and non-viable). This assay has proven to be a superior technique to

125

I-

plg binding assays due to the direct relationship between cell viability (PI

uptake) and lysine-dependent (i.e specific) pig binding. It is envisaged that thi

assay could be easily adapted for the analysis of plg-R expression in relation to

other cellular processes such as cell adhesion, differentiation, division, growth
and migration. Furthermore these studies have shown that plg-R expression is
dramatically elevated on non-viable cells and suggest that plg-Rs could play a
role during cell death (either necrosis or apoptosis).

Chapter 4

Measurement of Plasminogen
Receptors on Apoptotic Cells
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4.1 INTRODUCTION

Observations described in the previous chapter showed that plg-Rs were highly

elevated on non-viable cells which suggested that they might play a role duri

cell death. Two types of cell death are known to occur in the body. As describ

in Section 1.6, necrosis is a non-specific form of cell death which is induce

sudden loss in cellular homeostasis and is characterised by a loss in membran
integrity and cellular lysis. The physiological outcome of necrosis is
inflammation which often leads to tissue damage. In contrast, apoptosis is a
specific, highly regulated form of cell death characterised by an ordered
progression of morphological and biochemical changes. Apoptosis does not
cause inflammation or tissue damage.

A subpopulation of non-viable cells could consist of apoptotic and/or necroti
cells. In order to assess the involvement of plg-Rs in either apoptosis or

necrosis it is necessary to differentiate between the two subpopulations of no

viable cells. There are a variety of morphological and biochemical differences

between apoptotic and necrotic cells that can be measured flow cytometrically
(Darzynkiewicz et al 1992).

Several components of the PA system have been found to change during
apoptosis. uPA mRNA is increased in apoptotic granulosa cells (Johnson et al

1997) with uPA antigen increased on apoptotic hepatocytes (Santonirugiu et al
1996). In contrast, other studies have shown that tPA, PAI-1, PAI-2 and uPAR
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levels decrease during endothelial cell apoptosis (Zoellner et al 1998). Evidence

is also accumulating that PAI-2 protects cells from certain apopto

(Dickinson et al 1995; Gan et al 1995; Antalis et al 1998). Based o

and data generated in the previous chapter, it is logical to hypot
Rs and other components of the PA system may be modulated during
apoptosis.

The aim of this chapter was to: (1) measure pig binding on apoptot

(2) visualise pig binding to apoptotic cells by fluorescence micro
measure uPA and uPAR expression on apoptotic U937 cells.

4.2 MATERIALS AND METHODS

4.2.1 Materials

All cell culture reagents were obtained from Trace BioSciences (Sy

Australia) except for FCS which was obtained from CSL, (Melbourne,

Australia). Human glu-plg was either purified according to the meth

Grant (1990)] or was generously provided by American Diagnostica (

(Greenwich CT, USA). Murine antibodies to human uPAR (#3936) and uP

(#394) were purchased from ADI (Greenwich CT, USA). FITC conjugate

mouse secondary antibody was obtained from Silenus (Melbourne, Vic

Australia). NAP-10 columns and Lysine-Sepharose 4B were obtained fr
Amrad Pharmacia Biotech (Melbourne, Victoria, Australia). TA, BSA,
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amino-actinomycin D (7-AAD), dimethyl sulphoxide (DMSO), hydroxylamine,
cycloheximide (CHX), Hepes, and FITC were obtained from Sigma (Sydney,
NSW, Australia). Annexin-V-fluos (FITC- labelled) annexin V was purchased
from Boehringer Mannheim (Sydney, Australia). TNFa was generously

provided by Darren Saunders (Department of Biological Sciences, University
Wollongong, Australia), FACS tubes were obtained from Becton Dickinson.
400 AS A film was purchased from Kodak (Sydney, Australia).

4.2.2 Cell lines and cell culture
The human monocytic leukemic cell line U937 was obtained from the
American Type Culture Collection and cultured in RPMI1640/10% FCS at 37°C
in a humidified atmosphere of 5% CO2.

4.2.3 Induction of apoptosis in U937 cells
U937 cells were routinely induced to undergo apoptosis using the protein
synthesis inhibitor CHX. Cells were cultured in RPMI1640/10% pig depleted
FCS overnight and fresh medium containing 10ng/ml CHX added for 24h at
37°C. In some experiments cells were induced to undergo apoptosis by
culturing them for 24h in media containing lOng/ml TNFa.
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4.2.4 Differentiation of viable, apoptotic and late apoptotic/necrotic cells by
nuclear staining and flow cytometry

Apoptotic cells were differentiated from viable and necrotic/late apoptotic c
by staining with 7-AAD (Schmid et al 1994) or by supravital exposure to PI

(Zamai et al 1996). Cells were stained with either 5|ig/ml 7-AAD or lOug/ml P
(both in HBSS) for 15min/4°C and then analysed immediately by flow
cytometry. 7-AAD and PI staining were measured using FL-3 and FL-2 detectors

respectively. Apoptotic cells were gated as an intermediate staining populati
on FL-2 and FL-3 histograms. PI was routinely used in most experiments as it

more clearly differentiated apoptotic cells from viable and necrotic cells th

AAD.

4.2.5 Measurement of internucleosomal DNA fragmentation (DNA laddering)
U937 cells (lxl06/ml) were cultured for 24h in 10|ig/ml CHX and 4-5xl06 cells
washed thrice in HBSS then quickly resuspended in 400(il pre-heated (50°C)
0.5M Tris (pH 9.0), 2mM EDTA, lOmM NaCl, 2% w/v SDS and 0.3mg/ml
proteinase K. Cells were incubated overnight at 50°C then three successive
phenol/chloroform extractions performed followed by one chloroform
extraction. One tenth the volume of 3M sodium acetate and 2.5 volumes of ice
cold 100% ethanol were added, mixed by inversion and incubated at -20°C
overnight. DNA was pelleted by centrifugation at maximum speed in a
microfuge and washed once with 80% v/v ethanol. DNA was pelleted once
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again then air-dried for lh/RT. D N A was resuspended in 50-lOOjil TE buffer
[lOmM Tris (pH 7.4), ImM EDTA, 0.1% v/v Tween-20].

The concentration of DNA was determined using a microplate assay using a

SpectroMax microplate reader and utilising Softmax™Pro (Molecular Devices,

Sydney Australia). Water (100uL) was added to each well of a SPECTRAplate-

disposable and background absorbance corrected. Each well was then 'spiked
with a 2(il DNA sample (2ul buffer for the control) and the amount of DNA
determined using Softmax™Pro which utilises the formula: DNA/2fil sample
= OD260nm x (100/0.006) ng/2ul sample. Each lOjxg of DNA was treated with
l(il RNAse for 30min/RT. DNA sample buffer was added and incubated at

60°C/5min. Samples were then placed immediately on ice until required. Eac

sample was loaded into a 1.6% agarose gel and electrophoresed at 60V for 4
Gels were stained with ethidium bromide for 30min/RT then destained for
20min in water. Gels were visualised and photographed using a gel
documentation system (NovaLine, Sydney, Australia).

4.2.6 Measurement of phosphatidylserine (PS) exposure
PS exposure was measured using FITC-annexin-V (Annexin-V-Fluos)
according to the manufacturer's instructions (Boehringer Mannheim, Sydney
Australia). Briefly, cells were washed twice with HBSS and once with
incubation buffer [lOmM Hepes/NaOH (pH 7.4), 140mM NaCl, 5mM CaCl2]

then incubated in 50ul Annexin-V-Fluos labelling solution (20|il Annexin-
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Fluos diluted in lOOOul incubation buffer) for 15min/4°C. Cells were diluted to
400ul with incubation buffer (containing lOug/ml PI) and analysed by flow
cytometry. The percentage of PS positive cells was calculated from FL-1
histograms.

4.2.7 Fluorescence microscopy
Cells were incubated with HBSS/0.1% BSA containing 50ug/ml FITC-plg +
ImM TA for 45min at 4°C in the dark. PI (10 ug/ml) was added and the cells
incubated for a further 15min at 4°C. Cells were washed thrice with HBSS and
seeded into 96-well tissue culture plates and allowed to settle for lOmin at
temperature. Cell associated fluorescence due to FITC-plg binding and PI
uptake were viewed using a Leitz DMIL fluorescence microscope. Photographs
were taken using a MPS45 photoautomat (Wild Heerbrugg, Switzerland) and
400ASA film (Kodak) with an exposure time of lmin.

4.2.8 Flow cytometric pig binding assay
Pig binding to apoptotic cells was measured as described in 3.2.4. with the
exception that apoptotic cells were differentiated from viable and apoptotic
as described in 4.2.4.

4.2.9 Measurement of uPAR on apoptotic cells
U937 cells were cultured for 24h in media containing lOug/ml CHX. To
remove any cell-surface uPA, cells were treated with 50mM glycine-HCl (pH 3)
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containing 0.1 M NaCl for 3min/RT. This was neutralised with one-fifth the
volume of 0.5M Hepes (pH 7.5) containing 0.1M NaCl. Cells were washed twice
with HBSS (pH 7.4) and incubated with 20ug/ml murine anti-uPAR antibody
(#3936) for 30 min/4°C Control cells were incubated with 20ug/ml of an
isotype control. Cells were washed thrice with HBSS and then incubated with
FITC conjugated anti-mouse immunoglobulin for 30min/4°C in the dark.
Cells were washed thrice with HBSS and resuspended in 200ul of HBSS
containing lOug/ml PI for 15min in the dark at 4°C prior to flow cytometric
analysis. Specific uPAR expression was calculated as the difference in the

fluorescence of cells incubated with the isotype control and the fluorescen
cells incubated with anti-uPAR antibody.

4.2.10 Measurement of uPA on apoptotic cells
U937 cells were cultured for 24h in media containing lOug/ml CHX, washed
thrice with HBSS, then incubated with HBSS/0.1% BSA containing 20ug/ml
murine anti-uPA antibody (#394) for 30min/4°C. Cells were washed thrice
with HBSS and incubated with HBSS/0.1% BSA containing 20ug/ml FITC
conjugated anti-mouse immunoglobulin for 30min/4°C in the dark. Control
cells were incubated with 20ug/ml of an isotype control. Cells were washed
thrice with HBSS and resuspended in 200ul of HBSS, containing lOug/ml PI,
and incubated for 15min in the dark/4°C Specific uPA expression was

calculated as the difference in the fluorescence of cells incubated with the

isotype control and the fluorescence of cells incubated with anti-uPA antib
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4.2.11 Data Analysis
All experimental measurements were performed in triplicate and each

experiment repeated at least twice. Unless indicated all results are expressed a
means + 1 SEM. To test for statistical differences data were analysed using JMP

statistical analysis software (v6). Statistically significant differences betwe
two treatments were assessed using a student's t-test. Significant differences
among greater than two treatments were assessed by one-way analysis of
variance (ANOVA) with a Tukey-Kramer multiple comparison test.
Differences between treatments were considered significant when p<0.05.

4.3 RESULTS

4.3.1 Apoptotic cells can be differentiated from viable and late
apoptotic/necrotic cells using 7-AAD or PI staining
In order to measure plg-Rs on apoptotic cells it was necessary to differentiate
them from viable and late apoptotic cells/necrotic cells. This was achieved by
measuring 7-AAD or PI uptake by apoptotic cells using flow cytometry. When
U937 cells were cultured in the presence of an apoptotic inducer such as CHX or
TNFa and stained with 7-AAD, apoptotic cells were differentiated as an
intermediate staining subpopulation of cells (Fig 4.3.1). Density plots of
forward scatter (FSC) (size) versus 7-AAD uptake on control cells revealed two

distinct subpopulations of cells: viable cells which were large (i.e. had high F
but did not stain with 7-AAD; and dead cells which were smaller (i.e. had low
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FSC) and stained positive with 7 - A A D (Fig 4.3.1A). The corresponding plot for
CHX-treated U937 cells (Fig 4.3.1B) shows the presence of an intermediate

staining population of apoptotic cells which were also smaller than both viable

and necrotic cells. Apoptotic cells were also distinguishable on FL-3 histogram
of 7-AAD uptake as an intermediate-staining population (Fig 4.3.1 D). This
histogram also illustrates the overlap in staining of viable, apoptotic and
necrotic cells which is one of the limitations to using 7-AAD to differentiate
apoptotic cells.

A similar staining pattern was achieved using PI, however PI was observed to
more clearly differentiate apoptotic cells from viable and necrotic cells (Fig

4.3.2). As illustrated in both the density plot of FSC versus PI uptake (Fig 4.

and the FL-2 histogram of PI uptake (Fig 4.3.2D), minimal overlap in PI stainin
of viable, apoptotic and necrotic cells was evident. In all subsequent
experiments apoptotic cells were differentiated from viable and necrotic cells
based solely on PI uptake (i.e. from FL-2 histograms) (Fig 2.3.2D).

4.3.2 CHX induces apoptosis in U937 cells
In order to establish an optimised model system for analysing pig binding
during apoptosis, the induction of apoptosis with various concentrations of
CHX or TNFa over time was investigated. The effect of each concentration of
CHX or TNFa on the percentage of viable, apoptotic and dead cells was

154

CONTROL

CHX-TREATED
B.
*- i
1 apoptotic

cells
necrotic cells

J V V P ^ ' I - F i 11 i i • i (l

50

100 150 200 250
Forward Scatter

50

100
150 200
Forward Scatter

250

Forward Scatter

D.
viable
cells

viable cells

apoptotic c ells
dead cells
necrotic zells

i i iMini

i<r

10

i i 1 1 1 m i T"i iiin| i i m m
10
10*
1<T
7aad

I II llll
10 u

10 1

7AAD uptake
Fig 4.3.1: Differentiation of apoptotic cells from viable and necrotic/late apoptotic cells
by 7 - A A D staining. A . Density plot of forward scatter (size) versus 7 - A A D uptake of
control cells showing viable and dead subpopulations of cells. B. Density plot of
forward scatter (size) versus 7 - A A D uptake of CHX-treated cells showing viable,
apoptotic and and dead subpopulations of cells. C. and D. 7 - A A D histograms for
control and CHX-treated cells showing viable, apoptotic and dead subpopulations of
cells.

CONTROL

CHX-TREATED

A.

B.
o -J

JrliM ..'•: ..viabi^-jpfells.-' »...*•• i •
Ll

3

O - ^ . |t|<1|ft I I I I

50

o+#F
^ 100
0
50

150
FSC-H

100 150 200 250
FSC-H

200 250

Forward Scatter

D.

c.
o

o
If).
1^

CJ

g

IT) •
Csl

viable cells

O
O

o
o.

. ,,
viable

•

late apoptotic/
r r
..
necrotic

O
IO •

w —
*^
i-H

U

E
3
o O
O Oo

d e a d cells

T

in

^

10'

'2" T I I mi |,s
10
1(T
FL3-H

\

10

o10 u

101

1<T
FL3-H

10*

10"

PI uptake

Fig 4.32: Differentiation of apoptotic cells from viable and necrotic/late apoptotic
cells by PI staining. A. Density plot of forward scatter (size) versus PI uptake of
control cells showing viable and dead subpopulations of cells. B. Density plot of
forward scatter (size) versus PI uptake CHX-treated cells showing viable apoptotic
and dead cells. C. and D. Histogram plots of PI uptake for control and CHX-treated
cells showing viable, apoptotic and dead subpopulations of cells.

156

A,

B.

lOO-i

§

80-1

60-

40-

2010

20

30

—r
40

-1
50

30-i

c.
c

25

10|ig/ml CHX

0

• *H

•*->

rt

3{X
o
PW

o

20

^o

--o—•

100ng/ml CHX

"L\

lOng/ml TNF

-ffl--'

50ng/ml TNF

15

Ol

U

50^g/ml CHX

10
5-

10

lOOng/ml TNF

~T
20

l

30

40

50

Time (h)

Fig 4.3.3: Induction of apoptosis in U937 cells over time with C H X or T N F a .
U937 cells were cultured for 48h in the presence of 10, 50 and 100u.g/ml C H X or
10, 50 and lOOng/ml T N F a . At various times the proportion of viable (A.),
apoptotic (B.) and necrotic/late apoptotic (C.) cells was determined by PI
staining. Each point represents the m e a n of triplicate determinations ± 1 S E M .
The absence of error bars from certain points is due to the error being smaller
than the graphical symbol.

157

measured, based on differential PI uptake, and indicated that C H X was a m u c h
better inducer of apoptosis than TNFa (Fig 4.3.3). The lowest concentration
CHX tested (lO^g/ml) was found to induce the fastest rate of apoptosis over
as shown by the rate of disappearance of viable cells (Fig 4.3.3A) and the
concomitant increase in the proportion of apoptotic (Fig 4.3.3B) and late

apoptotic/necrotic cells (Fig 4.3.3C). Higher concentrations of CHX (i.e. 50

lOOug/ml) were actually found to be less affective at inducing apoptosis ove

48h (Fig 4.3.3). Low concentrations of TNFa (lOng/ml) appeared to induce low

levels of necrosis as shown by the absence of any intermediate PI staining c

(Fig 4.3.3B) and a the presence of a small percentage of necrotic/dead cell
4.3.3C). Higher concentrations of TNFa (50 and lOOng/ml) induced low level

apoptosis in U937 cells over 48h (Fig 4.3.3). Based on these data a 24h expo

to 10|ig/ml CHX was chosen to routinely induce apoptosis in U937 cells as th
resulted in the best spread of cells over each subpopulation (~ 55% viable,
apoptotic and 20% dead).

To confirm that U937 cells treated for 24h with 10ng/ml CHX were apoptotic,
internucleosomal DNA fragmentation and PS exposure were measured as they
are two of the distinguishing characteristics of apoptosis. Genomic DNA was

extracted from control and CHX-treated U937 cells and analysed by agarose ge
electrophoresis. A clear pattern of DNA laddering was evident in the CHX-

treated cells compared to control cells where no laddering was observed (Fig
4.3.4). The presence of DNA laddering confirmed that CHX could induce
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Fig 4.3.4: Agarose gel showing evidence of D N A laddering in CHX-treated U937 cells.
U937 cells were cultured for 24h in the presence or absence of 10|ig/ml C H X .
Genomic D N A was extracted as descibed in section 4.2.5. and D N A laddering
visualised by agarose gel electrophoresis. Lane 1 = D N A from U937 cells cultured
in the absence of C H X ; Lane 2 = D N A from U937 cells cultured in the presence of
10ng/ml C H X ; Lane 3 = lOObp D N A ladder.
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apoptosis in U 9 3 7 cells. PS exposure w a s measured by measuring the binding
of Annexin V to cells by flow cytometry. Dual-colour staining of control cells
with Annexin-V-Fluos and PI revealed two distinct subpopulations of cells:
these were viable (negative for both PI uptake and Annexin V binding) and
dead (positive for both PI uptake and Annexin V binding) (Fig 4.3.5 A). CHX-

treated U937 cells exhibited both viable and non-viable subpopulations of cells

in addition to an early apoptotic subpopulation that was negative for PI uptake

but positive for PS exposure (Fig 4.3.5 B). PS exposure could also be represent
by FL-1 histograms of Annexin-V-Fluos binding (Fig 4.3.5). Control cells
displayed a viable cell peak and a minor PS positive peak (apoptotic and dead

cells). CHX-treated cells exhibited a significantly larger PS positive peak. Th
results confirm that some (-30%) CHX-treated U937 cells are apoptotic because
they exhibit both DNA laddering and PS exposure whilst failing to take up PI.

4.3.3 Plg-Rs are elevated during apoptosis
Having confirmed that CHX can induce apoptosis in some U937 cells and that
apoptotic cells can be differentiated from viable and dead cells by PI uptake,

attention was focussed on measuring plg-Rs (i.e. pig binding) on apoptotic cell
Specific pig binding was found to be dramatically elevated on both apoptotic

and necrotic cells while no binding was detected on viable cells (Fig 4.3.6). A
student's t-test indicated that there was no significant difference in plg-R
expression between apoptotic and necrotic cells (t=2.01, df=4, P>0.05).
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Fig 4.3.6: Plg-R expression on viable, apoptotic and late apoptotic/necrotic U 9 3 7
cells. CHX-treated U937 cells were incubated with 0.5|iM FITC-plg ± I m M T A
for 60min and the level of pig binding measured by flow cytometry. PI
(10|ig/ml) w a s added prior to to flow cytometric analysis to differentiate
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Fig 4.3.7: Visualisation of FITC-plg binding to CHX-treated U937 cells by
fluorescence microscopy. CHX-treated U937 cells were incubated with 0.5(xM
FITC-plg + I m M T A for 60min and the level of pig binding visualised by
fluorescence microscopy. Some samples were dually-stained with FITC-plg and PI
(10ng/ml). A. control cells (bright field); B. CHX-treated cells (bright field); C.
control cells stained with PI; D. CHX-treated cells stained with PI; E. Control cells
stained with FITC-plg; F. CHX-treated cells stained with FITC-plg; G. Control cells
stained with FITC-plg and TA; H. CHX-treated cells stained with FITC-plg and
T A ; I. Control stained with FITC-plg and PI; J. CHX-treated cells stained with
FITC-plg and PI; K. Control cells stained with FITC-plg and T A and PI; L. C H X treated cells stained with FITC-plg a n d T A and PL (NB: Fields of view were
selected and photographed which most clearly illustrated a particular result).

163

To visualise pig binding on apoptotic cells, CHX-treated cells were stained for
both pig binding and viability (PI uptake) and examined by fluorescence
microscopy. CHX-treated U937 cells exhibited the classic morphological
changes characteristic of apoptosis when viewed under bright field (Fig 4.3.7B)
compared to control cells (Fig 4.3.7A) including cell shrinkage, membrane
blebbing, invagination of the plasma membrane and condensation of nuclear
material. PI staining of CHX-treated cells clearly showed nuclear fragmentation

and blebbing which are also characteristic of apoptosis (Fig 4.3.7D). Control ce

failed to take up any PI except for the occasional (<5%) dead cell (Fig 4.3.7C).

Apoptotic cells bound high levels of FITC-plg (Fig 4.3.7F) whereas control cells

exhibited negligible fluorescence (Fig 4.3.7E). Pig appeared to bind evenly over

the surface of apoptotic cells and could be abolished with TA (Fig 4.3.7H) while

control cell fluorescence remained negligible (Fig 4.3.7G). There appeared to be
variation in the level of plg-Rs expressed on CHX-treated cells with some cells
binding more FITC-plg than others (Fig 4.3.7F). Dual colour staining of
apoptotic cells with FLTC-plg and PI confirmed that high levels of pig binding
were restricted to apoptotic cells (Fig 4.3.7J): the even green fluorescence
associated with FITC-plg binding and the fragmented, globular Pi-stained nuclei
are clearly visible. Some CHX-treated cells bound high levels of FITC-plg but
were negative for PI staining suggesting that elevated pig binding might
preceed PI uptake during cell death. Control cells were consistently negative
for both FITC-plg binding and PI staining (Fig 4.3.71). The presence of TA
dramatically inhibited (-90%) pig binding to apoptotic cells that were doubly
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stained with FITC-plg and PI (Fig 4.3.7L) while control cells exhibited negligible

fluorescence (Fig 4.3.7K). These results confirmed that plg-Rs are elevated on
apoptotic U937 cells and that CHX can induce apoptosis in U937 cells.

4.3.4 uPA and uPAR expression are altered on apoptotic U937 cells
Several independent studies have shown that both uPA and uPAR levels are
altered during apoptosis and consequently experiments were undertaken to
determine if uPA and uPAR levels, like plg-Rs, change during CHX-induced
apoptosis in U937 cells.

CHX-treated U937 cells were probed for cell surface uPA with a murine anti-

uPA antibody. All subpopulations of cells (i.e. viable, apoptotic and necrotic
expressed cell-surface uPA as assessed by flow cytometry (Fig 4.3.8). An

approximately 30-fold increase in uPA levels occurred on apoptotic cells while

necrotic cells exhibited a 24.3 ± 0.35% reduction in uPA expression relative t
viable cells. A one-way ANOVA indicated that uPA levels were significantly

higher on apoptotic cells compared to viable and necrotic cells (F=1195.26, df
p<0.05; Tukey-Kramer). Additionally, uPA expression on necrotic cells was
significantly lower than that on viable cells (p<0.05). These observations
provide evidence that cell-surface uPA is significantly increased during CHXinduced apoptosis in U937 cells.

CHX-treated U937 cells were then probed for u P A R by firstly pretreating cells
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late apoptotic/necrotic U937 cells. Control and CHX-treated U937 cells were
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with low p H (pH 3) buffer to dissociate any receptor-bound u P A that could
interfere with uPAR detection. This treatment had a marked affect on the

proportion of viable, apoptotic and dead cells (Fig 4.3.9). Acid elution of uPA

from on control cells reduced the proportion of viable cells by 15.8 + 0.80%,wi

a concomitant equivalent increase in the proportion of dead cells (Fig 4.3.9A).
A student's t-test confirmed that acid elution significantly reduced the

proportion of viable cells (t=19.83, df=4, p<0.05) and increased the proportion
dead cells (t=25.00, df=4, p<0.05) compared to their respective controls. Acid
elution of uPA from CHX-treated cells almost doubled the proportion of
apoptotic cells (Fig 4.3.9B) which was also determined to be statistically
significant when compared to the control (t=12.86, df=4, P<0.05). Collectively
these data show that utilising a low pH buffer to remove receptor bound uPA
has a significant impact on cell viability.

When CHX-treated cells were probed with a murine anti-uPAR antibody,
uPAR was found to be expressed on all subpopulations of cells (viable,

apoptotic and dead) with apoptotic and necrotic cells displaying a 5-fold and 2
fold decrease in uPAR expression compared to viable cells (Fig 4.3.10). A oneway ANOVA indicated that uPAR expression was significantly different
between all subpopulations of cells (i.e viable, apoptotic and necrotic cells)
(F=2844.41, df=2, p<0.05; Tukey-Kramer). These observations provide evidence
that uPAR expression is altered during CHX-induced apoptosis in U937 cells.
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4.4 D I S C U S S I O N
Although previous studies have indicated that pig binding is increased on

necrotic cells (Green 1978; Burtin et al 1985) no studies have directly meas
pig binding during apoptosis. In the current investigation both plg-Rs (i.e.
specific pig binding) and cell-surface uPA were increased on apoptotic U937
cells which suggests that PA may play a role in apoptosis.

Numerous studies have utilised U937 cells to examine both pig (Plow et al

1986; Felez et al 1990; Edelberg et al 1990; Gonzalez-Gronow et al 1991; Fel

1993) and uPA binding (Cubellis et al 1986; Plow et al 1986; Felez et al 1990)

This coupled with the fact that U937 cells have been used extensively to stu
apoptosis justified the use of this cell line to investigate the expression
components of the PA system during apoptosis.

U937 cells were induced to undergo apoptosis using the protein synthesis
inhibitor CHX which has previously been shown to cause apoptosis in U937

cells (Kochi & Collier 1993; Bicknell et al 1994; Dini et al 1996). An advant

using CHX is that any cellular changes that occur during apoptosis are not d
to new protein synthesis. Microscopic examination of cells (Fig 4.3.7) in
addition to the measurement of PI/7-AAD uptake (Fig 4.3.1, 2 & 3), DNA

fragmentation (Fig 4.3.4) and PS exposure (Fig 4.3.5) confirmed that CHX co
induce apoptosis in U937 cells. TNFa also appeared to induce apoptosis in
U937 cells but was much less potent than CHX (Fig 4.3.3).

170

Flow cytometric analysis revealed that plg-Rs (i.e. specific pig binding) were

dramatically elevated on apoptotic U937 cells (Fig 4.3.6). The level of plg-Rs

apoptotic cells was similar that on late apoptotic/dead cells which suggests t
increased plg-R expression is maintained throughout the apoptotic process.

These results are the first reported evidence that plg-Rs (i.e specific pig b
are increased during apoptosis. Dual-colour fluorescence microscopy of
apoptotic cells confirmed that elevated pig binding was predominantly

restricted to apoptotic U937 cells (Fig 4.3.7), however there was some evidenc
that plg-Rs were increased on some PI negative cells (Fig 4.3.7J). This later
result suggests that plg-R expression may precede changes in cells relative
permeability to PI during apoptosis.

Other components of the PA cascade, namely uPA and uPAR were also found

to be modulated during CHX-induced apoptosis. A large increase in cell-surface
uPA was measured on apoptotic U937 cells with uPA levels dropping sharply

on late apoptotic/necrotic cells (Fig 4.3.8). This transient increase in cell-

uPA contrasts with the stable increase in plg-Rs during apoptosis. The increas
in uPA during apoptosis is supported by the recent finding that uPA mRNA is
increased in granulosa cells undergoing apoptosis (Johnson et al 1997) and on
apoptotic dysplastic hepatocytes (Santonirugiu et al 1996). TNFa, which can

induce either apoptosis or necrosis (Laster et al 1989), has also been shown t
stimulate uPA production by endothelial cells (Niedbala & Stein 1991) and uPA
mRNA in ovarian cancer cells (Simonitsch & Krupitza 1998).
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u P A R expression was decreased during apoptosis with low levels present o n
both apoptotic and late apoptotic/necrotic cells (Fig 4.3.10). It is difficult

reconcile the fact that cell-surface uPA increased during CHX-induced apoptosis
without a similar increase in uPAR. However, a recent study (Zoellner et al
1998) reported a decrease in uPAR on apoptotic endothelial cells while uPA
levels remained unchanged. It is possible that uPA may be bound to sites other
than uPAR on apoptotic cells such as gangliosides which have been shown to
bind both uPA and pig (Miles et al 1989). The uPAR data needs to be
interpreted with caution as the acid wash that was used to remove any uPAoccupied uPAR markedly affected the proportion of viable, apoptotic and dead
cells (Fig 4.3.9).

Collectively these results show, for the first time, that both plg-Rs (i.e. sp
pig binding) and cell-surface uPA are dramatically elevated on U937 cells
undergoing CHX-induced apoptosis. This begs the question as to whether PA is
similarly elevated on apoptotic cells considering that the two components
necessary for activation (i.e pig and uPA) are present. In order to test this
hypothesis it would be necessary to measure pig activation (i.e. plm) on
apoptotic cells. As this has not been done before it would require the
development of a flow cytometric PA assay.

Chapter 5

Development of a Flow Cytometric
Plasminogen Activation Assay
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5.1 INTRODUCTION
Results from the previous chapter indicated that plg-Rs and cell

were increased on apoptotic U937 cells. Although this suggested t

components of the PA system might play a role in CHX-mediated apo

U937 cells, in order to give these results any physiological cred
necessary to measure PA on apoptotic cells. If plm were found to

on apoptotic cells then this would support the hypothesis that PA
in apoptosis.

The conventional method for measuring cellular PA is to analyse p
formation (i.e. plm activity) using a chromogenic or fluorogenic

Examples of commonly used chromogenic plm substrates are H-D-valy

leucyl-L-lysine-p-nitroanilide dihydrochloride (S-2251) and H-D-n

hexahyrotyrosyl-lysine-p-nitroanilide diacetate salt (Spectrozyme
substrates are cleaved by plm to release p-nitroanilide which is

spectrophotometrically. The major limitation to chromo/fluorogeni
assays, like
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I-plg binding assays, is they do not allow the meas

on specific subpopulations of cells. There is clearly a need then

alternative cellular plm assays which enable the measurement of P
different subpopulations of cells.

The trypsin-like serine protease inhibitor aprotinin has previous

labelled with FITC and used in non-cytometric plm assays with dat
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shown to be equivalent to that generated using S-2251 (Ellis et al 1987).

Additionally, the relatively small size of aprotinin (6kDa) make
probe for cell-surface plm (i.e. PA).

The aim of this chapter was to develop a flow cytometric pig act

using FITC-aprotinin, to measure plm formation on the surface of
apoptotic and late apoptotic/necrotic U937 cells.

5.2 MATERIALS AND METHODS

5.2.1 Materials

All cell culture reagents were obtained from Trace BioSciences (

Australia) except for FCS which was obtained from CSL, (Melbourn

Australia). Human glu-plg was either purified according to the m

Grant (1990)] or was generously provided by American Diagnostica
(Greenwich CT, USA). NAP-10 columns and Lysine-Sepharose 4B were

obtained from Amrad Pharmacia Biotech (Melbourne, Victoria, Austr
BSA, PI, dimethyl sulphoxide (DMSO), hydroxylamine, cycloheximide

Hepes, and FITC were obtained from Sigma (Sydney, NSW, Australia)
specific uPA inhibitor glu-gly-arg-chloromethylketone (EGR-CMK)

specific plm inhibitor valine-phenylalanine-lysine-chloromethylk

CMK) were obtained from Calbiochem-Novachem (Sydney, NSW, Austral
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Human

PAI-2 and Spectrozyme™

PL were obtained commercially (ADI,

Greenwich CT, USA).

5.2.2 Cell lines and cell culture
The human monocytic leukemic cell line U937 was obtained from the
American Type Culture Collection and cultured in RPMI1640/10% FCS at 37°C
in a humidified atmosphere of 5% CO2.

5.2.3 Induction of apoptosis with CHX
U937 were induced to undergo apoptosis with CHX as described in 4.2.3.

5.2.4 Labelling of aprotinin with FITC

Aprotinin (5 mg/ml) was dissolved in 0.1 M carbonate buffer (pH 9) and a 5

fold molar excess of FITC added after being dissolved in DMSO. Aprotinin w
mixed for 16h at 4°C in the dark and subsequently treated with 0.01%
hydroxylamine for 30min/4°C to remove all labile FLTOaprotinin bonds.
Unincorporated FITC was separated from FITC-aprotinin by gel filtration
through a NAP-10 column using Hank's balanced salt solution (HBSS)
containing 20mM Hepes, ImM CaCl2, ImM MgCl2 (pH 7.4). Typically, 2-4 FITC
molecules were bound to each aprotinin molecule. FITC-aprotinin was

aliquoted and stored at -80°C until required. The number of molecules of F
conjugated to each aprotinin molecule was determined using the following
formula:
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FITC/aprotinin molecule = A 4 9 5 n m x dilution factor x 6,000
68,000 mg/ml aprotinin
where A495nm is the absorbance maxima of FITC; 60,000 is the molar
extinction coefficient (cm^M1) of conjugated fluorescein and 6,000 is the
molecular weight of aprotinin.

5.2.5 Spectrozyme™ PL microplate assay
Spectrozyme™ PL was reconstituted to a 5mM stock solution in MilliQ water
according to the Manufacturer's instructions (ADI, Greenwich CT, USA),
aliquoted and stored at -80°C until required. 0.5fiM plm + equivalent molar
concentrations of aprotinin or FITC-aprotinin in PBS (pH 7.4) (200fxl total
volume) was incubated for 30min/RT in triplicate wells of a microplate.
Spectrozyme™ PL was added to a final concentration of 0.5mM and the plate
incubated for a further 45min/37°C The plate was read at 405nm using a

SpectroMax microplate reader (Molecular Devices, Sydney, Australia). Control
absorbances (wells containing only Spectrozyme™ PL in PBS) were subtracted
from all samples.

5.2.6 Flow cytometric PA assay
U937 cells were cultured in RPMI1640/10% pig-depleted FCS for 24h at 37°C,
washed thrice with HBSS and resuspended in HBSS/0.1% BSA ± 2uM pig.

Cells were incubated for 60min at 37CC, washed thrice with ice cold HBSS the
resuspended in HBSS/0.1% BSA containing 2^iM FITC-aprotinin ± 100-fold

177

molar excess of unlabelled aprotinin, and incubated for 45min at 4°C in the
dark. Cells were washed thrice in HBSS and resuspended in HBSS containing
lOug/ml PI. Specific FITC-aprotinin binding (indicating the presence of cell-

surface plm) was calculated as the difference between the fluorescence of cells
incubated solely with FITC-aprotinin (total binding) and cells incubated with
FITC-aprotinin and 100-fold molar excess of unlabelled aprotinin (non-specific
binding). In all experiments, preincubation of cells with pig was required for
specific FITC-aprotinin binding to occur.

5.2.7 Data analysis
All experimental measurements were performed in triplicate and repeated at

least twice. Unless indicated all results are expressed as means + 1 SEM. To te
for statistical differences data were analysed as described in section 4.2.11.

5.3 RESULTS

5.3.1 Cytotoxicity of Spectrozyme™ PL
Cellular PA is typically measured using artificial plm substrates with little

consideration for the potential cytotoxicity of these compounds. To investigate
the toxicity of Spectrozyme™ PL, U937 cells were incubated with 0-0.5mM
Spectrozyme™ PL for up to 2h and the proportion of viable and non-viable

cells assessed flow cytometrically (i.e. by measuring PI uptake). The effect of
Spectrozyme™ PL on cell viability was striking with O.lmM Spectrozyme™ PL
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increasing the proportion of non-viable cells by approximately 3-fold, 0 . 2 5 m M
increasing the proportion of non-viable cells 16-fold and 0.5mM increasing the

proportion of non-viable cells 20-fold (Fig 5.3.1B). In all samples the increas
non-viable cells was mirrored by an equivalent decrease in viable cells (Fig

5.3.1A). These results indicate that Spectrozyme™ PL is highly cytotoxic and is
thus unsuitable for any cellular-based PA assays where cell death is being
examined.

5.3.2 FITC-aprotinin can be used to detect cell-surface plm
Aprotinin was labelled with FITC according to an established procedure
(Goding 1976) with 2.5 ±1.7 (N=4) molecules of FITC conjugated to each
molecule of aprotinin. This level of conjugation is a magnitude higher than
that previously reported (Ellis et al 1987). The capacity of FITC-aprotinin to
inactivate plm was investigated utilising the Spectrozyme™ PL assay. FITCaprotinin was equally affective as unlabelled aprotinin at inhibiting plm (Fig
5.3.2). This was confirmed using a student's t-test which indicated that there
was no significant difference in the inhibitory ability of aprotinin or FITC-

aprotinin (t=0.96, df=4, p>0.05). These results indicated that conjugating FITC
aprotinin does not significantly alter its plm-inhibitory activity.

Feasibility studies were undertaken to assess the use of FITC-aprotinin in

detecting cell-surface plm (i.e PA) by flow cytometry. Apoptosis was induced in
U937 cells with CHX and the amount of total, non-specific and specific FITC-
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Fig 5.3.1: Effect of Spectrozyme™ PL on the viability of U937 cells. U937 cell
were incubated with 0, 0.1, 0.25 and 0.5mM Spectrozyme™ P L and at various
times u p to 2h the proportion of viable and non-viable cells determined flow
cytometrically by measuring PI uptake. A. Effect of various concentrations of
Spectrozyme™ P L on the % of viable U937 cells over time. B. Effect of various
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aprotinin binding (indicating the presence of active trypsin-like serine
proteases) measured by flow cytometry. To determine whether any

endogenous cell-surface plm (or other trypsin-like proteases) was present, cells
were either preincubated with or without pig. Additionally the experiment
was performed at 4 and 37°C to assess the temperature dependence of PA.

Viable U937 cells did not bind any FITC-aprotinin either specifically or non-

specifically at 4 or 37°C regardless of whether cells had been pretreated with p

(Fig 5.3.3). These results indicated that PA does not occur on viable U937 cells
and that no endogenous trypsin-like proteolytic activity is present on these

cells. Apoptotic U937 cells (i.e. cells taking up an intermediate level of PI) t
had not been pretreated with 2uM pig at both 4 and 37°C failed to specifically
bind FITC-aprotinin indicating the absence of plm and hence PA on the cell
surface (Fig 5.3.4). In contrast, apoptotic U937 cells that had been pretreated
with 2|iM pig for 60min could specifically bind FITC-aprotinin (as shown by the
inhibition of FITC-aprotinin binding with a 25-fold molar excess of unlabelled
aprotinin) at both 4 and 37°C (Fig 5.3.4). These results indicate that although
endogenous trypsin-like activity is found on apoptotic cells exposure to
physiological concentrations of pig can lead to PA at 4 and 37°C. These results

also indicate that pretreatment of cells with pig is an absolute requirement for
PA to occur. Virtually no specific FITC-aprotinin binding was detected on
necrotic cells when U937 cells were preincubated with pig. Additionally
necrotic cells possessed no endogenous trypsin-like activity (Fig 5.3.5).

cells + FITC-aprotinin (total binding)
cells + FITC-aprotinin + 25-fold excess
unlabelled aprotinin (non-specific binding)

10"

10'

10" IO3
FL1-H

]0A

101

10°

10 2 io 3 io"1
FL1-H

D.
OO

1 •«, 37°C + plg

O)

Xi
3
O

s

\

I

(J

u

i n- • ••"•!." • " • l ? " " " U ' " " ^ d
U
1
J
H

10

10

10* 10
FL1-H

10

\
o -:/
ll i • m . |

10U

101

i i in.|

i • ••••! i i I I I ^

10* 10J 10
FL1-H

FITC-aprotinin binding

Fig 5.3.3: Histogram plots showing the absence of FITC-aprotinin binding to viable
U 9 3 7 cells. U 9 3 7 cells cultured in pig-free conditions for 24h were treated with or
without 2 u M pig for lh at 4 or 37°C then incubated with 2|iM FITC-aprotinin + a 25fold molar excess of unlabelled aprotinin for 45min at 4°C. PI (10[ig/ml) was added
prior to flow cytometric analysis to differentiate viable from apoptotic and necrotic/late
apoptotic cells. A. Viable cells incubated in the absence of pig at 4°C. B. Viable cells
incubated in the absence of pig at 37°C. C. Viable cells incubated with 2 u M pig at 4°C.
D. Viable cells incubated with 2|iM pig at 37°C. (NB: specific and non-specific FITCaprotinin binding overlap).
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Fig 5.3.4: Histogram plots showing FITC-aprotinin binding to apoptotic U 9 3 7 cells.
U 9 3 7 cells were cultured in pig-free conditions in the presence of 10|ig/ml C H X for 24h
then treated with or without 2 u M pig for lh at 4 or 37°C then incubated with 2 u M FITCaprotinin ± a 25-fold molar excess of unlabelled aprotinin for 45min at 4°C. PI
(lOug/ml) was added prior to flow cytometric analysis to differentiate apoptotic from
viable and necrotic/late apoptotic cells. A. Apoptotic cells incubated in the absence of
pig at 4°C. B. Apoptotic cells incubated in the absence of pig at 37°C. C. Apoptotic
cells incubated with 2u.M pig at 4°C. D. Apoptotic cells incubated with 2 u M pig at
37°C. The difference between total FITC-aprotinin binding (dark line) and non-specific
FITC-aprotinin binding (light line) indicates specific FITC-aprotinin binding (i.e plm).
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Fig 5.3.5: Histogram plots showing FITC-aprotinin binding to necrotic U937
cells. U937 cells were cultured in pig-free conditions in the presence of lOug/ml
C H X for 24h then treated with or without 2 u M pig for lh at 4 or 37°C then
incubated with 2 u M FITC-aprotinin ± a 25-fold molar excess of unlabelled
aprotinin for 45min at 4°C. PI (10|ig/ml) w a s added prior to flow cytometric
analysis to differentiate apoptotic from viable and necrotic/late apoptotic cells.
A. Necrotic cells incubated in the absence of pig at 4°C. B. Necrotic cells
incubated in the absence of pig at 37°C. C. Necrotic cells incubated with 2(iM pig
at 4°C. D. Necrotic cells incubated with 2 u M pig at 37°C. The difference
between total FITC-aprotinin binding (dark line) and non-specific FITC-aprotinin
binding (light line) indicates specific FITC-aprotinin binding (i.e plm).
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The comparative activation of pig on viable, apoptotic and dead cells is

presented in Fig 5.3.6. The top density plot of PI uptake (cell viability) versu
FITC-aprotinin binding (PA) shows viable, apoptotic and dead cells - apoptotic
cells taking up an intermediate level of PI. Apoptotic cells bound the highest
level of FITC-aprotinin, followed by dead cells and viable cells bound none.
The presence of 100-fold molar excess of unlabelled aprotinin significantly
reduced FITC-aprotinin binding to both apoptotic and dead cells. These results
confirm that PA is predominantly restricted to apoptotic U937 cells.

5.3.3 Optimisation of the flow cytometric PA assay
With preliminary experiments indicating that PA (i.e plm generation) could be
measured by flow cytometry and that PA seemed to be predominantly restricted
to apoptotic U937 cells, studies were undertaken to optimise the flow
cytometric PA assay. For example, the time necessary for FITC-aprotinin
binding to reach equilibrium was determined by incubating CHX-treated U937
cells with FITC-aprotinin for various times up to 90min. The binding of FITC-

aprotinin to apoptotic U937 cells (i.e. cells taking up an intermediate level of

was relatively fast with the majority of binding occurring within the first 5min
(Fig 5.3.7). There was a gradual increase in FITC-aprotinin binding from 5min
until a plateau was reached at approximately 45min. Based on these results
cells were routinely incubated with FITC-aprotinin for 45min.

The optimal concentration of FITC-aprotinin was determined by incubating

apoptotic cells

necrotic cells
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Fig 5.3.6: Density plots s h o w i n g simultaneous m e a s u r e m e n t of P A o n viable,
apoptotic and necrotic subpopulations of U 9 3 7 cells. CHX-treated U937 cells
were treated with 2yM pig for lh then probed for plm with FITC-aprotinin + 100-fold molar
excess of unlabelled aprotinin. PI (lOug/ml) was added prior to flow cytometric analysis to
differentiate viable, apoptotic and necrotic/late apoptotic subpopulations of cells. A. Density
plot of PI uptake versus FITC-aprotinin binding for cells incubated solely with FITC-aprotinin
(total binding). B. Density plot of PI uptake versus FITC-aprotinin binding for cells incubated
with FITC-aprotinin and 100-fold molar excess of unlabelled aprotinin (non-specific binding).
The difference between total FITC-aprotinin binding (A) and non-specific FITC-aprotinin binding
(B) is a measure of spedfic FITC-aprotinin binding (i.e plm formation).
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Fig 5.3.7: Timecourse of FITC-aprotinin binding to apoptotic U937 cells. C H X treated U937 cells were pretreated with 2 u M pig for lh then incubated with
2 u M FITC-aprotinin for up to 90min. At various times the level of FITCaprotinin binding to apoptotic cells was measured by flow cytometry. Each
point represents the m e a n of triplicate measurements ± 1 SEM. The absence of
error bars indicates the error was smaller than the graphical symbol.
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CHX-treated U 9 3 7 cells, that had been pretreated with 2|iM pig, with increasing
concentrations of FITC-aprotinin. FITC-aprotinin bound to apoptotic cells in a
linear fashion up to a concentration of 2(iM whereupon a plateau was reached
(Fig 5.3.8). Assuming that all of the pig added to cells was converted to plm,
these results suggest that the stoichiometry of FITC-aprotinin binding to cellsurface plm was a 1:1 interaction. The specificity of FITC-aprotinin binding to
apoptotic cells was determined by inhibiting FITC-aprotinin binding to
apoptotic cells with increasing concentrations of unlabelled aprotinin.

FITC-aprotinin binding to apoptotic cells was highly specific as the presence of

0-100 fold molar excess of unlabelled aprotinin caused a progressive decrease in
FITC-aprotinin binding (Fig 5.3.9). For example, a 1-fold molar excess of
unlabelled aprotinin reduced FITC-aprotinin binding to apoptotic cells by 73 +
0.58% (N=3). In all subsequent experiments 100-fold molar excess of unlabelled
aprotinin was used to assess non-specific FITC-aprotinin binding as it
maximally inhibited FITC-aprotinin binding [90 ±0.21% (N=3)].

To determine the kinetics of cell-surface PA on apoptotic U937 cells CHXtreated cells were incubated with 2uM pig at 37°C and cell-surface plm
measured at various times over lh. Plm formation appeared to be rapid with
near maximal levels of specific FITC-aprotinin binding detected within lOmin
(Fig 5.3.10). The level of cell-surface plm appeared to remain relatively
constant over 60min with some slight fluctuations observed between 10 and
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Fig 5.3.8: Concentration curve of FITC-aprotinin binding to apoptotic U937 cells.
CHX-treated U 9 3 7 cells were pretreated with 2 u M pig for lh then incubated
with various concentrations of FITC-aprotinin u p to 5 u M for 45min. PI
(10|ig/ml) w a s added prior to flow cytometric analysis to differentiate apoptotic
from viable and necrotic/late apoptotic cells. Each point represents the m e a n of
triplicate measurements + 1 S E M . The absence of error bars indicates the error
was smaller than the graphical symbol.
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Fig 5.3.9: Inhibition of FITC-aprotinin binding to apoptotic U937 cells by
increasing molar excesses of unlabelled aprotinin. CHX-treated U937 cells were
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2|iM FITC-aprotinin + 0-100-fold molar excess of unlabelled aprotinin. PI
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Fig 5.3.10: Kinetics of cell-surface plm formation on U937 cells. CHX-treated
U937 cells were incubated with 2|iM pig and at various times over lh the level
of plm formation measured. PI (10(ig/ml) was added prior to flow cytometric
analysis to differentiate apoptotic from viable and necrotic/late apoptotic cells.
Specific FITC-aprotinin binding (indicating the presence of active plm) was
calculated as the difference in the fluorescence of cells incubated solely with
FITC-aprotinin (total binding) and residual fluoresence of cells incubated with
FITC-aprotinin and 100-fold molar excess of unlabelled aprotinin (non-specific
binding). Each point represents the m e a n of triplicate measurements + 1 S E M .
The absence of error bars indicates the error was smaller than the graphical

symbol.

192

60min. These results show that exogenously added pig is rapidly converted to
plm on the surface of apoptotic U937 cells.

The time over which plm remains active or bound to the cell surface could

indicate the time over which this serine protease would be able to participat
extracellular proteolytic events. To determine the stability of cell-surface

once generated, CHX-treated U937 cells were incubated with pig and at various

times probed for plm. Plm could be detected on the surface of apoptotic cells
with FITC-aprotinin both immediately and for up to 2h after activation had

occurred. From lh post activation the level of plm appeared to begin to stead

decrease (Fig 5.3.11). These results suggest that plm generated on the surfac

apoptotic U937 cells is relatively stable and remains active for several hour

5.3.4 PA can be blocked by inhibiting pig binding

The presence of plg-Rs and thus specific pig binding is considered to be ess

for PA to proceed. Logically then PA could be stopped by inhibiting pig bindi
CHX-treated U937 cells were preincubated with pig and 1 or lOmM TA or 10%

(v/v) FCS and the level of specific FITC-aprotinin binding (i.e. PA) measured
PA was blocked with 1 and lOmM TA by 63 ± 11.5% and 96 ± 1.2% (N=3)

respectively (Fig 5.3.12). 10% (v/v) FCS (expected to contain bovine pig) was

also found to inhibit PA by 48 + 17% (N=3) (Fig 5.3.12). These results show t

inhibiting pig binding can block PA and supports the essential role for plg-R

during PA.
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Fig 5.3.11: Stability of plm activity generated on the surface of apoptotic U937
cells. CHX-treated U937 cells were incubated with 2 u M pig for lh, washed and
then incubated at 37°C in H B S S for 2h. At various times the level of active cellsurface plm was measured flow cytometrically using FITC-aprotinin. PI
(lOfig/ml) was added prior to flow cytometric analysis to differentiate apoptotic
from viable and necrotic/late apoptotic cells. Specific FITC-aprotinin binding
(indicating the presence of active plm) was calculated as the difference in the
fluorescence of cells incubated solely with FITC-aprotinin (total binding) and
residual fluoresence of cells incubated with FITC-aprotinin and 100-fold molar
excess of unlabelled aprotinin (non-specific binding). Each point represents the
m e a n of triplicate measurements ± 1 S E M . The absence of error bars indicates
the error w a s smaller than the graphical symbol.
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Fig 5.3.12: Inhibition of cell-surface P A on apoptotic U937 cells with T A or FCS.
CHX-treated U 9 3 7 cells were incubated with 2|iM pig in the presence of 1 or
l O m M T A or with 1 0 % (v/v) FCS. The level of active cell-surface plm was
measured flow cytometrically using FITC-aprotinin. PI (lOjig/ml) was added
prior to flow cytometric analysis to differentiate apoptotic from viable and
necrotic/late apoptotic cells. Specific FITC-aprotinin binding (indicating the
presence of active plm) w a s calculated as the difference in the fluorescence of
cells incubated solely with FITC-aprotinin (total binding) and residual
fluoresence of cells incubated with FITC-aprotinin and 100-fold molar excess of
unlabelled aprotinin (non-specific binding). Each point represents the m e a n of
triplicate measurements ± 1 S E M . The absence of error bars indicates the error
w a s smaller than the graphical symbol.
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5.3.5 Inhibiting u P A can block P A
As uPA was previously shown to be highly elevated on apoptotic U937 cells
(Fig 4.3.8) experiments were undertaken to determine if PA on apoptotic U937
cells could be blocked with uPA inhibitors. When CHX-treated U937 cells were
incubated with pig in the presence of PAI-2 or the specific uPA inhibitor EGRCMK, PA (i.e. specific FITC-aprotinin binding) was reduced by 21 + 1.4% and 65
± 2.0% respectively (N=3) (Fig 5.3.13). A student's t-test indicated that EGR-

CMK was significantly better at inhibiting PA than PAI-2 (t=5.09, df=4, p<0.05)
however neither were observed to totally inhibit PA. These results indicate

that in this system, uPA plays an important role in the activation of pig on th
surface of apoptotic U937 cells.

5.3.6 FITC-aprotinin binding to apoptotic U937 cells can be inhibited with a
specific plm inhibitor.
Observations thus far indicated that the presence of pig was essential for plm
generation (specific FITC-aprotinin binding) on the surface of apoptotic U937

cells (Fig 5.3.4) and also that uPA appeared to be crucial for this process t

(Fig 5.3.13). In order to eliminate the possibility that other trypsin-like se
proteases were involved in PA on apoptotic U937 cells, CHX-treated U937 cells
were incubated with pig and then probed with FITC-aprotinin with or without
the specific plm inhibitor VFK-CMK (ImM). FITC-aprotinin binding to
apoptotic U937 cells was completely blocked with ImM VFK-CMK (Fig 5.3.14).

This experiment indicates that FITC-aprotinin binding to apoptotic U937 cells i
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Fig 5.3.13: Inhibition of cell-surface P A with E G R - C M K or PAI-2. CHX-treated
U937 cells were incubated with 2|iM pig in the presence of I m M E G R - C M K or
I n M PAI-2 for lh at 37°C The level of active cell-surface plm was measured
flow cytometrically using FITC-aprotinin. PI (10|ig/ml) was added prior to flow
cytometric analysis to differentiate apoptotic from viable and necrotic/late
apoptotic cells. Specific FITC-aprotinin binding (indicating the presence of
active plm) was calculated as the difference in the fluorescence of cells
incubated solely with FITC-aprotinin (total binding) and residual fluoresence of
cells incubated with FITC-aprotinin and 100-fold molar excess of unlabelled
aprotinin (non-specific binding). Each bar represents the m e a n of triplicate
measurements ± 1 S E M . The absence of error bars indicates the error was
smaller than the graphical symbol.
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solely due to the presence of cell-surface plm and not due or derived from
some other trypsin-like serine protease.

5.3.7 PA on viable, apoptotic and dead cells
With the flow cytometric PA assay developed on U937 cells attention was then
directed toward actually measuring PA on viable, apoptotic and dead
subpopulations of U937 cells. As shown in Fig 5.3.15, plm formation was

dramatically elevated on apoptotic U937 cells, low levels of plm were detected
on dead cells and none on viable cells. A one-way ANOVA confirmed that
plm generation was significantly different among all subpopulations of cells

viable, apoptotic and dead) (F=3689.42, df=2, p<0.05). These results lend supp
to the hypothesis that PA plays a role during CHX-induced apoptosis in U937
cells.

5.4 DISCUSSION
Numerous studies have utilised chromogenic plm substrates to measure PA
on a variety of both pro and eukaryotic cells. A major disadvantage of using
these chromogenic-based assays is that PA cannot be measured on specific
subpopulations of cells. Additionally, a commonly used plm substrate,
Spectrozyme™ PL, has been shown in this study to be highly cytotoxic at

concentrations routinely used to measure cell-generated plm (Fig 5.3.1). In th
current study, a novel flow cytometric PA assay was developed which utilised

FITC-aprotinin to measure plm on specific subpopulations of cells (i.e viable,
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apoptotic and necrotic). The development of this assay w a s crucial in order to

test the hypothesis that PA is involved in CHX-induced apoptosis in U937 cells.
FITC-aprotinin has proved to be a useful probe for cell-surface plm due to a
number of characteristics: its relatively small size (6kDa); other specific
proteinacious plm inhibitors, such as a2-MG and a2-AP, cannot inhibit cellsurface plm (Plow et al 1986; Hall et al 1991); it has been used previously in
non-cytometric plm assays (Ellis et al 1986); it remains active after FITC

conjugation (Fig 5.3.2); it is specific for trypsin-like serine proteases. Alth

FITC-aprotinin could potentially detect any trypsin-like protease (e.g. trypsin
chymotrypsin, killikrein, plm) the specific binding of FITC-aprotinin to
apoptotic U937 cells in the current study was entirely due to plm because: (1)
cells absolutely required pretreatment with pig in order for specific FITCaprotinin binding (plm formation) to occur (Fig 5.3.3-5); (2) specific FITCaprotinin binding (plm formation) was almost completely blocked by inhibiting
pig binding with TA (Fig 5.3.12); (3) specific FITC-aprotinin binding (plm
formation) was markedly reduced when cells were treated with uPA inhibitors
PAI-2 and EGR-CMK (Fig 5.3.13); and (4) specific FITC-aprotinin binding was
completely blocked with the specific plm inhibitor VFK-CMK (Fig 5.3.14).

The binding of FITC-aprotinin to pig-treated apoptotic U937 cells was rapid (Fi

5.3.7), saturable (Fig 5.3.8) and specific (Fig 5.3.9). PA was also observed to
rapid with the majority of plm generated within lOmin after the addition of

exogenous pig (Fig 5.3.10). This is in contrast with previous cellular studies,
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using chromogenic plm substrates, which have shown a steady increase in p l m
generation over several hours (Felez et al 1990; Osada et al 1991; LopezAlemany et al 1995).

When PA was measured on viable, apoptotic and dead cells, using the newly

developed PA assay, striking differences were seen in the level of specific FIT
aprotinin binding (Fig 5.3.6 & 5.3.15). No binding was detected on the surface

viable U937 cells (Fig 5.3.6 & 5.3.15), in contrast to previously reported data

(Ellis et al 1989; Felez et al 1990) which was generated using chromogenic-base
plm assays. Like
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I-plg binding assays, chromogenic plm assays do not allow

discrimination of PA on specific subpopulations of cells (i.e viable apoptotic
and dead) which is the most likely explanation for the disparity between these
results and the current study. A dramatic increase in PA (specific FITCaprotinin binding) was observed on apoptotic U937 cells while only very low
levels of activation were detected on dead cells (Fig 5.3.6 & 5.3.15). If one

considers the data in Fig 5.3.6 it appears that PA is switched on as cells unde

apoptosis and is then switched off as cells progress into late apoptosis/necros

Cell-surface plm was detected by the addition of FITC-aprotinin for at least 2h
after activation (Fig 5.3.11). These data suggest that plm generated on the
surface of apoptotic U937 is relatively stable.

The observation that TA could almost completely abolish PA (Fig 5.3.12), when
incubated simultaneously with pig, on apoptotic U937 cells indicates that
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specific pig binding (i.e plg-Rs) is paramount for P A to proceed. This result is
consistent with previous studies which have shown that lysine analogues can

inhibit PA on U937 cells (Ellis et al 1989), corneal fibroblasts (Lopez-Alema
al 1995) and keratinocytes (Reinartz et al 1993). In support of this premise

fact that PA did not occur on viable U937 cells (Fig 5.3.3, 6 & 15) because n

Rs were present, irrespective of the presence of uPA (refer Fig 4.3.8). Based
these observations it would appear that plg-Rs are a key determinant of
whether PA proceeds on U937 cells. Hence it would be important to examine
when plg-Rs are increased during apoptosis. uPA was also shown to be crucial
for PA during apoptosis as activation was inhibited with the specific uPA
inhibitor EGR-CMK and also PAI-2. EGR-CMK and PAI-2 were never observed
to completely block PA which suggests that other proteases might participate

PA on apoptotic U937 cells. These data also indicate that PAI-2 can inhibit c
bound uPA as previously described (Baker et al 1990; Stephens et al 1990).

Although the flow cytometric PA assay developed in this chapter was utilised

to measure plm generation on viable, apoptotic and necrotic U937 cells it cou

easily be adapted to measure PA on other cell lines (e.g adherent or transfec

cell lines) and other subpopulations of cells (e.g cells in various stages of

cell cycle). For example, Ranson et al (1998) used the current assay to measu
plm formation on viable breast carcinoma cell lines.
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In s u m m a r y , a dramatic transient increase in P A w a s detected on apoptotic
U937 cells using a novel flow cytometric PA assay. This observation is
consistent with previous data showing that both plg-Rs (i.e. specific pig
binding) and uPA are elevated during CHX-induced apoptosis (Fig 4.3.6 & 4.3.8
respectively) and provides evidence that PA plays a physiological role during
apoptosis. Plm could feed into a broader proteolytic network prevalent during
apoptosis and degrade a range of cellular targets or activate other protease
classes. As PA appears to be confined to the cell surface, its role may be
restricted to extracellular proteolytic events, for example, the separation of

apoptotic cells from neighbouring cells (i.e. anoikos) or the extracellular matr
within a specific tissue location.

Chapter 6

The Role of Plasminogen receptors
in Apoptosis
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6.1 Introduction
PA is involved in numerous cell-surface proteolytic events including tumour
cell invasion, angiogenesis, tissue remodelling and inflammation. An adjunct
to these roles is increasing evidence that PA, or components of the PA system,

play a role in cell death. Pig and tPA-deficient mice exhibit resistance to kai
acid-induced neurodegeneration implicating the PA system in neuronal death
(Tsirka et al 1997a & b). Overexpression of pig can be cytotoxic to mammalian

cells due to the generation of intracellular plm (Busby et al 1991). This 'toxi
can be prevented via the co-expression of physiological levels of oc2-AF (Busby
et al 1991). PAI-2 has also been shown to protect cells against TNFa-induced

apoptosis (Dickinson et al 1995), the cytopathic effects of alphavirus infectio
(Antalis et al 1988) and infection of human macrophages with Mycobacterium
avium (Gan et al 1995). Evidence suggesting a possible protective role for
components of the PA system is provided by the observation that pig can

protect neuronal cells against nitric oxide-induced apoptosis (Toku et al 1998)

Observations described in previous chapters indicated that relatively high
levels of plm are generated on the surface of apoptotic U937 cells as a
consequence of a concomitant increase in plg-Rs (which facilitated an increase
in specific pig binding) and cell-surface uPA. These results suggested that PA
plays a role in CHX-induced apoptosis in U937 cells where plm could degrade

structural proteins and/or activate other protease classes. It was also apparen
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from these studies that the increase in plg-Rs (detected as an increase in specific
pig binding) was critical for PA to occur (Fig 5.3.12).

Although apoptosis can be initiated by a diversity of molecules (refer Wertz &
Hanley 1996) the execution and degradative phases are characterised by an
ordered progression of morphological and biochemical changes that are largely
regulated by proteases (Martin & Green 1995). One of the earliest
morphological changes occurring during apoptosis is the externalisation of PS

from the inner to the outer leaflet of the plasma membrane (Martin et al 1995;
Zwaal & Schroit 1997). In some circumstances, the generation of cell-surface
serine proteolytic activity has been shown to require PS. For example,
thrombin activity can be generated on apoptotic vascular smooth muscle cells

following PS exposure (Flynn et al 1997). The most likely explanation for this
phenomena is that prothrombin binds to PS as 5fiM Annexin V could
significantly reduce thrombin generation. Based on this observation it seems
plausible to hypothesise that PS exposure could be important for plm
generation on apoptotic U937 cells. This hypothesis is supported by the
observation that pig can bind to immobilised PS via a lysine-dependent
mechanism (Nicholas Andronicus, Dept Biological Sciences, University of
Wollongong, Pers. Comm.).

To elucidate the role of plg-Rs during CHX-induced apoptosis in U937 cells it
important to establish the temporal relationship of plg-R expression to other
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apoptotic changes such as PS exposure, internucleosomal D N A fragmentation

and differential PI uptake. The aim of this chapter then was to investigate the
temporal relationship of plg-R expression to other apoptotic changes during
CHX-induced apoptosis in U937 cells and to ascertain whether pig plays a

cytoprotective or cytodestructive role in this model. In addition, the possible
cellular relevance of the in vitro binding of pig to PS was investigated.

6.2 MATERIALS AND METHODS
All materials, cell lines, methods and data analysis used were as described in
sections 3.2.1 4.2.1,4.2.5,4.2.6, 5.2.3 and 4.2.11.

6.3 RESULTS

6.3.1 Pig binding to PS

The binding of pig to cell-surface PS was investigated by examining the ability
of physiological concentrations of pig (2fiM) to inhibit Annexin-V-Fluos
binding to apoptotic (CHX-treated) U937 cells. When CHX-treated cells were
simultaneously incubated with Annexin-V-Fluos and 2p.M pig a 52.6 + 2.3%
(N=3) increase in Annexin-V-Fluos binding was observed (Fig 6.3.1). A

student's t-test indicated that the level of Annexin-V-Fluos binding to apopto

U937 cells was significantly higher in the presence of 2|iM pig (T=6.01, df=10,
p<0.05). This suggests that pig does not compete with Annexin-V-Fluos for
binding to PS on the surface of apoptotic U937 cells. Alternatively pig could

208

80-i

£

T

60-

\ \ \ \ \ \ l \ \ \ \ \ \
***f/*Y****/

CO

£
01

\ \ \ \ \ *«^«. \ \ \ \ \
************

o>

************

\ \ \ \ \ \ \ \ \ S \ \
cj

S \ \ \ \ S \ \ \ \ \ \

£

************
\\\\\\\\\\\\
************

40-

cj

\\\\\%\\\\\\
************

o>
-H

o
J3

E
E
«
oi

rTT-TTTXTTTTT
* * * * * r-* * * * * *

co

\ \ \ \ \ s \ \ \ \ \ \

20-

************
\\\\\\\\\\\\
************
\\\\\\\\\\\\
************
************
\ \ \ \ \ x \ \ \ \ \ \

************
\\\\\\\\\\\\
************
T

control

\ \ \ \ \ \ \ N \ \ \ \

************
\ \ \ \ \ s \ \ \ \ \ \

************
\ \ \ \ \ \ \ \ \ s \ \

\ \ \ \ \ \ S \ \ \ \ \

************
\ N \ \ \ S \ \ S \ \ \

************
\ \ \ \ \ S \ \ \ \ \ \

************
\ \ \ \ \ S \ \ \ \ \ N

************
\ \ \ \ \ S \ S \ \ \ \

************
\ \ S \ N S \ \ S \ \ \

************
\ \ \ \ \ \ \ \ \ S \ \

************

+ 2 u M pig

\ \ S \ \ \ \ \ \ \ N \

************

\ \ \ \ S \ \ \ \ \ \ \

************
\ \ \ S \ \ \ \ \ \ \ \

************
\\\\\\\\\\\\
************

************

\ \ S \ \ \ \ \ \ \ \ \

************
\\\\\\\\\\\\
************

************
\ \ \ \ \ s \ \ \ \ \ \

\ \ \ \ \ \ \ S \ \ \ S

************
\ \ \ \ S \ \ \ \ \ \ \

Fig 6.3.1: Effect************
of 2(iM pig on the binding
to apoptotic
\ \ \ S \of
\ \ Annexin-V-Fluos
\ \ \ \ \
\\\\\\\\\\\\
************
U937 cells were incubated with Annexin-V-Fluos in
U937 cells. CHX-treated
************
\ \ S \ \ \ \ \ \ \ \ \
the absence (control)
or
presence
of 2)iM.
Bars represent the m e a n of triplicate
\\\\\\\\\\\\
************
\ \ N \ \ \ \ \ N \ \ \
************
determinations\ \ +\ \1\ SEM.
N \ \ N \ \ N
************
************

\\\\\\\\\\\\
************
\\N\\\\\\,\.\\

************
\\\\\\\\\\\\
************
\ \ \ \ \ \ \ \ \ \ \ S

************
\ \ S \ \ \ \ \ \ \ S \

************

209

cause an increase in PS exposure in some w a y or could facilitate the binding of
Annexin-V-Fluos to cell-surface PS.

6.3.2 Increased plg-R expression is a late apoptotic event
U937 cells were induced to undergo apoptosis with CHX and at various times
the level of PS exposure, PI uptake, DNA fragmentation and pig binding
measured. Internucleosomal DNA fragmentation was apparent in CHX-treated

U937 cells over time with an increase appearing at 36h (Fig 6.3.2A). As reporte

by Martin et al (1995) and Zwaal and Schroit (1997) PS exposure was found to be

a relatively early apoptotic event with approximately 40% of cells expressing P
at 4h (Fig 6.3.2B). After 4h there was a steady increase in PS exposure albeit
lower rate until approximately 70% of the population displayed PS. The level
of PI uptake mirrored the level of pig binding over 36h with both displaying a

steady increase over time but at approximately half the rate as PS exposure (Fi
6.3.2B). Although previous microscopic analysis had suggested that some PI

negative cells could bind high levels of pig (Fig 4.3.7), the current observati

clearly indicated that in the majority of cells, the increase in plg-R expressi
during CHX-induced apoptosis is coincident with PI uptake.
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Figure 6.3.2: Temporal relationship of plg-R expression (pig binding) to
internucleosomal D N A fragmentation, PS exposure and PI uptake during
CHX-induced apoptosis in U937 cells. U937 cells were cultured in the presence
of lOue/ml C H X for 36h and at various times the level of D N A laddering, PS
exposure, PI uptake and pig binding measured. A. Agarose gel showing the
increase in D N A laddering over 36h. B. Graph showing the % of U937 cells
displaying PS exposure, PI uptake and plg-R expression (pig W i n g ) . Each
point represents the mean of triplicate determinations + 1 S E M . The absence of
error bars is due to the error being smaller than the graphical symbol.
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6.3.3 Effect of pig on the rate of CHX-induced apoptosis in U937 cells

Under certain conditions pig has been shown to act as either a cytotoxin (Busb
et al 1991) or a cytoprotectant (Toku et al 1998). To determine whether
physiological levels of pig can accelerate or reduce CHX-induced cell death,
U937 cells were cultured in pig-free media containing either CHX, pig or both
CHX and pig for up to 36h. At various times the percentage of cells with PS
exposure and the percentage of cells positive for PI uptake were determined.
The percentage of cells expressing PS (i.e both early and late apoptotic) was
determined from FL-1 histograms of FITC-Annexin-V binding while the

percentage of PI positive cells (i.e both apoptotic and late apoptotic/necroti
was determined from FL-2 histograms.

The relative percentage of U937 cells that were measured as PS or PI positive
remained constant in control samples over 36h in the absence of the apoptotic

stimuli CHX (Fig 6.3.3A & B open circles respectively). In contrast, the addit
of CHX resulted in a progressive increase in the percentage of U937 cells
measured as PS or PI positive (Fig 6.3.3A & B open triangles respectively).
Equally, the presence of 2uM human pig (-CHX) also increased (by -10%) the
relative proportion of PS positive U937 cells, with the most rapid rise seen

between 12h and 36h (Fig 6.3.3A open squares). In contrast the presence of pig

did not result in as obvious increases in relative percentages of cells that t
up PI (Fig 6.3.3B open squares). By far the most dramatic effect on PS and PI
positive cell numbers was seen when cells were cultured in the presence of
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Fig 6.3.3: Effect of physiological levels of pig on the rate of CHX-induced
apoptosis in U937 cells. U937 cells were cultured in pig-free media containing
either 2^iM pig, 10|ig/ml C H X or both 2 u M pig and 10|ig/ml C H X for 36h.
Control cells were incubated solely in pig-free media. At various times the
percentage of cells with PS exposure or positive for PI uptake were determined
flow cytometrically. A. percentage of U937 cells with PS exposure (i.e both early
and late apoptotic cells) over time. B. Percentage of PI positive U937 cells (i.e
both apoptotic and late apoptotic/necrotic) over time. Each point represents the
mean of triplicate determinations ± 1 SEM. The absence of error bars is due to
the error being smaller than the graphical symbol.
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both pig and C H X . The rate and level of PS exposure and PI uptake w h e n cells
were cultured in the presence of both pig and CHX was almost double that of
CHX alone (Fig 6.3.3A & B open diamonds respectively).

Statistical analyses were performed on the above data to ascertain the
significance of the effect of pig on the level of CHX-induced apoptosis (i.e
exposure and PI uptake). One-way ANOVAs indicated that PS exposure on

cells in all treatments was significantly different at 12 (F=141.91, df=3, p<
Tukey-Kramer HSD), 24 (F=849, df=3, p<0.05; Tukey-Kramer HSD) and 36h
(F=564.9681, df=3, p<0.05; Tukey-Kramer HSD). These results confirm that the

presence of 2pM pig significantly increases the level CHX-induced apoptosis i
U937 cells and that pig can increase PS exposure in the absence of CHX. Oneway ANOVA's also indicated that PI uptake was significantly different in all
treatments at 12 (F=74.57, df=3, p<0.05; Tukey-Kramer HSD) and 24h(F=397.27,
df=3, p<0.05; Tukey-Kramer HSD), while at 36h significant differences in PI
uptake were detected between all treatments (F=269.79, df=3, p<0.05; Tukey-

Kramer HSD) except between cells cultured in pig-free media (i.e control) and

cells cultured with 2uM pig (t=2.053, df=4, p>0.05). These analyses confirm t
the presence of physiological levels of pig enhances the rate at which U937
enter CHX-induced apoptosis (i.e PI uptake and PS exposure) and warrant

further investigation of how the presence of pig increases PS exposure in the
presence of apoptotic stimuli.
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To investigate whether pig can accelerate apoptosis once initiation has begun,
U937 cells were pre-exposed to CHX for 12 or 24h in pig-free media then
exposed to 2uM pig for an hour. PS exposure (Annexin-V-Fluos binding) and
PI uptake increased by 36 ± 1.2 % (N=3) and 31 ± 2.7% (N=3) respectively on

controls cells (i.e no-CHX treatment) when exposed to 2uM pig for lh (Fig 6.3.

Statistical analysis of these data using student t-test's indicated that 2uM p

significantly increased both PS exposure (t=75.58, df=4, p<0.05) and PI uptake
(t=24.43, df=4, p<0.05) on U937 cells in the absence of CHX. The presence of
2uM pig increased PS exposure and PI uptake by 3.4 + 0.13 % (N=3) and 20 +

1.4% (N=3) respectively on 12h CHX-treated U937 cells (Fig 6.3.4). This effect

pig on PS exposure was not significant (t=1.60, df=4, p>0.05) while the effect
pig on PI uptake was highly significant (t=17.86, df=4, p<0.05). The presence

2|iM pig had no significant effect on PS exposure (t=1.73, df=4, p>0.05) yet h
slightly significant effect on PI uptake (t=4.56, df=4, p<0.01) in U937 cells
had been exposed to CHX for 24h (Fig 6.3.4). These observations suggest that

physiological levels of pig can increase PS exposure (i.e apoptosis) and PI u
(i.e cell death) in U937 cells in the absence of apoptotic stimuli which is
consistent with earlier observations (Fig 6.3.3). Additionally this effect of
the level of PS exposure and PI uptake is diminished the longer the cells are

exposed to an apoptotic stimuli. These results indicate that cells that have b
sensitised with an apoptotic stimuli (CHX) in the absence of pig are not
'nudged' further along the apoptotic pathway if they are then exposed to pig.
These results also suggest that the persistent presence of pig during CHX-
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Fig 6.3.4: Effect of short-term exposure to physiological concentrations of pig on
PS exposure (A) and PI uptake (B) on U937 cells cultured in C H X for 12 or 24h.
U937 cells were cultured in the presence of 10u.g/ml C H X for 12 or 24h then
incubated with 2 u M pig for lh. Control cells were cultured in pig-free media
only. A. Percentage of U937 cells with PS exposure (i.e both early and late
apoptotic cells) over time. B. Percentage of PI positive U937 cells (i.e both
apoptotic and late apoptotic/necrotic) over time. Each bar represents the m e a n
of triplicate determinations ± 1 SEM. The absence of error bars is due to the
error being smaller than the graphical symbol.
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induced apoptosis is necessary for the observed effects.

6.4 DISCUSSION
Apoptosis is a complex process involving a myriad of structural and
biochemical changes ultimately leading to the resorption of cells by the body
a manner that avoids inflammation. Although apoptosis can be initiated by a

diversity of molecules the consensus of scientific opinion is that these 'deat

signals' converge into a single pathway leading to the characteristic cellular
changes associated with apoptosis. Extensive evidence implicates the
involvement of various protease systems in the execution and degradative
phases of apoptosis including PA. Various experiments have indicated that
intracellular PAI-2 can protect against TNFa, viral or bacterial apoptosis

(Dickinson et al 1995; Gan et al 1995; Antalis et al 1998). Studies have shown

role for tPA-catalysed PA in various types of neuronal death (Tsirka et al 199
& b). Other studies have revealed that uPA is increased during apoptosis in

heptocytes (Santonirugiu et al 1996), granulosa cells (Johnson et al 1997) and
ovarian cells (Simonitsch & Krupitza 1998). In contrast, endothelial cell
apoptosis is characterised by a decrease in tPA, PAI-1, PAI-2 and uPAR while
uPA is unchanged (Zoellner et al 1998). These disparate roles for PA in cell

death on different cell types can be explained by the hypothesis that the role

PA is cell-specific and is influenced by the manner in which death is initiate
(i.e the death signal).
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Thrombin activity has previously been shown to be generated on apoptotic
vascular smooth muscle cells following PS exposure (Flynn et al 1997) most
likely due to the binding of pro /thrombin to PS. In the current study
physiological levels of pig could not compete with Annexin V for binding to
cell-surface PS during CHX-induced apoptosis (Fig 6.3.1). Infact, exposure to
appeared to increase the level of Annexin-V-Fluos binding to CHX-treated
U937 cells. One explanation for this observation is that pig could indirectly

mediate the binding of annexin V to the cell surface. It is possible that whil
most Annexin V binds to exposed PS some could bind to receptor-bound pig
following the addition of pig. Another possibility is that pig increases the

of PS exposure on apoptotic cells which facilitates increased annexin V bindin
This later proposal is corroborated by consistent observations showing that
physiological concentrations of pig increase PS exposure (Annexin-V-Fluos
binding) by 5-10% on both viable and apoptotic cells (Fig 6.3.3 & 4).

The temporal relationship of plg-R expression (i.e specific pig binding) to
established apoptotic markers (PS exposure, DNA laddering and differential PI
uptake) during CHX-induced apoptosis was examined in order to determine

the likely apoptotic stage (i.e initiation, execution or degradation) that pl

play a role. PS exposure on CHX-treated U937 cells was found to be the earlies
apoptotic event which is supported by previous evidence showing that PS
exposure is an early and widespread event during apoptosis of a variety of
human and murine cells (Martin et al 1995). Low levels of internucleosomal
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D N A fragmentation (i.e D N A laddering) could be detected between 4-12h but by
far the majoratory was detected at 24 and 36h. Of the three markers, only PI
uptake was shown to be coincident with plg-R expression (Fig 6.3.2B) and is
supported by previous data in this thesis showing that there is a direct
relationship between PI uptake and the magnitude of lysine-dependent (i.e
specific) pig binding (Fig 3.3.4 & 3.3.5).

Observations reported in this chapter suggest that changes to the plasma
membrane of apoptotic U937 cells that make them moderately permeable to PI

co-occur with the increase in plg-R expression. The data does not indicate if
these two cellular events are linked. The exact mechanism of PI uptake by
apoptotic cells is unknown although evidence indicates that it is not due to
membrane damage (Vitale et al 1993). Therefore it is likely that membrane
damage is not responsible for the increase in plg-Rs on apoptotic cells. PI

uptake is generally considered to be a late apoptotic event associated with t

degradative phase of apoptosis and generally occurs at or around the same tim

as DNA fragmentation (Vitale et al 1993; Mower et al 1994). Collectively thes
observations suggest that plg-Rs are increased during late-stage cell death
they are likely to contribute to the degradative phase of apoptosis. Future
studies could be focussed at examining the temporal relationship of other
components of the PA cascade, such as uPA, uPAR, and PAI-2 during apoptosis.
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The presence of physiological levels of pig was found to dramatically increase
the rate and level of CHX-induced apoptosis in U937 cells (as measured by PS
exposure and PI uptake) (Fig 6.3.3). Studies examining the rates of DNA
fragmentation when physiological levels of pig are present remain to be

undertaken. These observations suggest that pig contributes to cell death in a
manner additive with apoptotic inducers (e.g CHX). The simultaneous
exposure of cells to both pig and CHX was necessary for the observed additive

effect as U937 cells pre-exposed to CHX were not noticeably 'pushed' along the
apoptotic pathway when exposed to physiological levels of pig (Fig 6.3.4).

An interesting observation was that pig itself could cause some death (PS

exposure and PI uptake) in cells cultured in the absence of CHX (Fig 6.3.3 6.3
which is consistent with a previous study showing that high levels of pig are
cytotoxic to mammalian cells (Busby et al 1991). The mechanism of this

cytotoxicity was via the generation of plm and it is thus possible that the ef
observed in the current study was also due to plm. A major weakness to this

explanation is that cell-surface PA was shown to be absent on viable U937 cell

(Fig 5.3.3, 5.3.6 & 5.3.15) so either plm is generated by some other mechanism
(e.g in solution) or pig cytotoxicity is due to a non-plm mechanism.
Alternatively, contaminating traces of plm in pig preparations could have
made a direct contribution to cell death.
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Numerous

intracellular

proteases

(e.g caspases, endonucleases,

serine

proteases) are involved in apoptosis so the role of cell-surface plm remains a
puzzle. It was previously shown that plm generated on the surface of apoptotic
U937 cells remains there for at least two hours so it is unlikely that plm is
internalised (Fig 5.3.11). Several independent studies have suggested that PA
might be involved in anoikis (cell detachment) during apoptosis (Matsuoka et

al 1998; Simonitsch & Krupitza 1998). Although this suggestion is attractive it
does not provide a direct explanation for the role of PA during apoptosis of a

non-adherent cell line (i.e. U937). As it is well established that PA can act i
concert with other proteases during processes such as ECM degradation, it is
tempting to speculate that plm could feed into the broader proteolytic network
that is prevalent during apoptosis. Whatever the role of pig during apoptosis
the current study indicates that it is not essential as CHX-induced apoptosis
proceeded in its absence albeit at a lower rate (6.3.3).

In conclusion, it is hypothesised that substrates such as proteases or structur

proteins can be activated or degraded respectively by the elevated levels of pl
generated on apoptotic cells in a manner which accelerates death. Without pig
these processes still occur but at a slower rate. Additionally, evidence is
provided that plg-Rs are increased on the cell surface during late-stage CHXinduced apoptosis in U937 cells suggesting that PA is likely to play a role in
degradative phase of apoptosis.

Chapter 7

General Discussion
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The focus of this thesis has been to extend our understanding of the manner in
which pig interacts with cancer cells. Initially, the binding of pig to the
monocytic leukemic cell line U937, the colon cancer cell line HCT116 and the
breast carcinoma cell lines MDA-MB-231 and MCF-7 was studied with the aim
of establishing a relationship between pig binding and metastatic potential.

Using the 'established' approach of radioligand binding assays it was difficu
repeatedly measure pig binding to these cell lines (Fig 3.3.3). Although

125

I-p

binding studies indicated the presence of plg-Rs on the highly metastatic col
cancer cell line HCT116 (Fig 3.3.3), the isolation and identification of

proteinacious receptors was unsuccessful (Fig 3.3.4-6). The variability of da
generated using

125

I-plg binding assays and the apparent discrepancy between

binding data and receptor isolation studies warranted the development of a
more reliable and robust technique for measuring cellular pig binding.

Flow cytometry was utilised to analyse cellular pig binding as it enabled the
measurement of pig binding on discreet subpopulations of cells, for example

viable and non-viable cells. A flow cytometric pig binding assay was develope
(Chapter 3) in order to enable the measurement of pig binding on specific

subpopulations of cells (i.e viable and non-viable). Repeated experimentation

clearly indicated that no specific (i.e lysine-dependent) pig binding occurre

a range of viable cell types including U937 cells and the colon carcinoma cel
lines LIM1215, HCT116 and KM12SM (Fig 3.3.21). Using U937 cells as a model

system it was shown that specific pig binding was restricted entirely to non-
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viable cells (Fig 3.3.4). In fact, pig binding to non-viable cells exhibited all of the
characteristics that have previously been attributed to viable cells (gathered
using

125

I-plg binding assays) including saturability (Fig 3.3.9, 3.3.10),

reversibility (Fig 3.3.11), inhibition by lysine analogues such as TA (Fig 3.3.
and cold pig (Fig 3.3.13, 3.3.14), and susceptibility to carboxypeptidase B
treatment (3.3.15). Plg-Rs could not be generated on viable U937 cells even

following treatment with PMA (Fig 3.3.17), TNFa (Fig 3.3.18), trypsin (Fig 3.3.

or peroxide (Fig 3.3.20). A direct relationship was also found to exist between
cell viability (PI uptake) and the magnitude of lysine-dependent pig binding
(Fig 3.3.4,3.3.5).

The consequence of not utilising an assay (such as the flow cytometric assay
developed in this thesis) that enables the concurrent measurement of pig
binding and viability, would be to overestimate plg-R expression on any
'viable' cell type if even small numbers of non-viable cells are present.
Increased pig binding to non-viable cells appears to be a widespread
phenomena and has subsequently been confirmed by Ranson et al (1998) on
several breast carcinoma cell lines including MCF-7, MDA-MB-231 and T47D
cells. Ranson utilised the assay that was developed in this thesis to show the
occurrence of specific pig binding to viable MDA-MB-231 cell. This
independently validates the flow cytometric pig binding assay and shows that

specific pig binding (i.e plg-R expression) does occur on some viable cell type
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The current flow cytometric studies cast a shadow over previous pig binding
data generated using

125

I-plg binding assays considering that pig binding to non

viable cells can not be accounted for using this technique. The question raised
is whether previous observations are valid considering the direct relationship
between cell viability and pig binding (Fig 3.3.4 & 5). If a cell line were
particularly fragile then one would expect that using

125

I-plg binding assays

would yield a less accurate result than a cell line that was more robust due to
the increased proportion of non-viable cells generated during experimental
manipulation. It is clear from the current studies that

125

I-plg binding assays

no longer a satisfactory means of studying pig binding and it is recommended
that all future pig binding studies employ flow cytometry. The differential

expression of plg-Rs on other subpopulations of cells could also be investigate
using the assay described in this thesis - for example, examining plg-R

expression during different stages of the cell cycle. The specific quantitation
plg-Rs by scatchard analysis is currently not possible using flow cytometry
because suitable flow cytometric standards (i.e beads with specific numbers of
lysine binding sites) are unavailable. One improvement to the current flow
cytometric assay would be to synthesise suitable lysine coated beads, with a
defined number of lysine binding sites, which would allow the direct
quantitation of cellular plg-Rs.

No studies have directly examined changes in plg-R expression during
apoptosis. Previous unrelated studies, which utilised morphological

225

examination or PI staining /fluorescence microscopy to detect dead cells,

indicated that pig binding was increased on necrotic cells (Green 1978; Burgos

al 1982; Jenkins et al 1983; Burtin et al 1985). A model system for studying p
binding during CHX-induced apoptosis in U937 cells was developed (Fig 4.3.15). Plg-Rs (i.e. specific pig binding) were found to be dramatically elevated

apoptotic cells (Fig 4.3.6 & 7) along with a large transient increase in cell
uPA (Fig 4.3.8) which indicated that PA could play a role during CHX-induced
apoptosis in U937 cells. The mechanism for the increase in plg-Rs and uPA is

unclear, however it is likely that it does not involve any new protein synthes

(as cells were treated with the protein synthesis inhibitor CHX) suggesting th
intracellular stores of uPA and plg-Rs are externalised during death. The

increase in plg-Rs during apoptosis was not linked to PS exposure (Fig 6.3.2).

The logical outcome for the increase in specific pig binding and uPA expressio
on apoptotic U937 cells is the generation of cell-surface plm. Consequently a
novel flow cytometric PA assay was developed using FITC-aprotinin to detect
plm generation on the surface of specific subpopulations of cells (viable,
apoptotic and late apoptotic/necrotic) (Chapter 5). PA was found to be highly
elevated on apoptotic cells (Fig 5.3.4, 6 & 15) which supports the hypothesis

pig binding and activation play a role in CHX-induced apoptosis in U937 cells.
The importance of both plg-Rs (i.e specific pig binding) and uPA was shown by
the inhibition of PA with TA (Fig 5.3.12) and uPA inhibitors PAI-2 and EGRCMK (Fig 5.3.13). Although the majority of PA appeared to be due to uPA it is
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possible that other proteases, such as tPA could activate pig on apoptotic cells.
Future studies could investigate whether other components of the PA system
(e.g tPA, PAI-2 etc) are modulated during CHX-induced apoptosis or whether
apoptotic proteases (such as the caspases) can generate plm. The flow
cytometric PA assay described in this thesis could be utilised to measure plm

generation on the surface of any cell type or subpopulation of cells. Ranson e

al (1998) have utilised this assay to measure plm generation on the surface of
the breast carcinoma cell line MDA-MB-231.

Analysis of the temporal relationship of plg-R expression to several establish
apoptotic markers (i.e PS exposure, PI uptake and DNA laddering) indicated

that the increase in plg-Rs was a late apoptotic event that was co-incident wi

PI uptake (Fig 6.3.2). This suggested that plg-Rs are likely to play a role in
degradative phase of CHX-induced apoptosis in U937 cells. Further

experimentation indicated that physiological levels of pig were not essential

apoptosis to proceed, but if present, could greatly accelerate both the rate a
level of death (Fig 6.3.3 & 4). Future experiments could be directed toward
examining the temporal variation of other components of the PA system

during CHX-induced apoptosis and also to establish the fate of cell-surface pl

It is possible that cell-surface plm could contribute to the anoikis of dying
Alternatively plm could activate other proteases thereby feeding into the
broader proteolytic network that is prevalent during apoptosis. Another
possibility is that plm could contribute to the dismantling of the cellular
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architecture by directly degrading structural proteins. Clearly the observations

reported in this thesis are only the beginning of an exciting new area of study
involving the PA system.

In summary, this thesis describes the development of novel flow cytometric pig
binding and activation assays which were utilised to analyse pig binding and
activation during cell death. These assays are a valuable technical

advancement and will facilitate the analysis of PA on a diversity of other cell

types and during other cellular processes. Plg-Rs were dramatically elevated on

a variety of non-viable cells including a subpopulation of apoptotic U937 cells
that were generated following CHX treatment. The presence of both plg-Rs (i.e

specific pig binding) and uPA was critical for the high levels of plm formation
on the surface of these cells. Although the function of this plm remains to be

determined it is hypothesised that substrates can be activated or degraded by t
elevated levels of plm on apoptotic cells and that this is responsible for the
accelerated rate at which they die. Without pig these processes were shown to

still occur but at a much reduced rate. Observations also indicated that the ro
of plg-Rs is most likely confined to the degradative phase of apoptosis.

Collectively these data provide strong evidence that the PA system plays a role
in CHX-induced apoptosis in U937 cells and lends support for the important
role of flow cytometry in pig binding and activation studies.
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